IntechOpen was founded by scientists, for scientists, in order to make book publishing accessible around the globe. Over the last two decades, this has driven Open Access (OA) book publishing whilst levelling the playing field for global academics. Through our innovative publishing model and the support of the research community, we have now published over 5,700 Open Access books and are visited online by over three million academics every month. These researchers are increasingly working in broad technology-based subjects, driving multidisciplinary academic endeavours into human health, environment, and technology.
\\n\\n
By listening to our community, and in order to serve these rapidly growing areas which lie at the core of IntechOpen's expertise, we are launching a portfolio of Open Science journals:
All three journals will publish under an Open Access model and embrace Open Science policies to help support the changing needs of academics in these fast-moving research areas. There will be direct links to preprint servers and data repositories, allowing full reproducibility and rapid dissemination of published papers to help accelerate the pace of research. Each journal has renowned Editors in Chief who will work alongside a global Editorial Board, delivering robust single-blind peer review. Supported by our internal editorial teams, this will ensure our authors will receive a quick, user-friendly, and personalised publishing experience.
\\n\\n
"By launching our journals portfolio we are introducing new, dedicated homes for interdisciplinary technology-focused researchers to publish their work, whilst embracing Open Science and creating a unique global home for academics to disseminate their work. We are taking a leap toward Open Science continuing and expanding our fundamental commitment to openly sharing scientific research across the world, making it available for the benefit of all." Dr. Sara Uhac, IntechOpen CEO
\\n\\n
"Our aim is to promote and create better science for a better world by increasing access to information and the latest scientific developments to all scientists, innovators, entrepreneurs and students and give them the opportunity to learn, observe and contribute to knowledge creation. Open Science promotes a swifter path from research to innovation to produce new products and services." Alex Lazinica, IntechOpen founder
\\n\\n
In conclusion, Natalia Reinic Babic, Head of Journal Publishing and Open Science at IntechOpen adds:
\\n\\n
“On behalf of the journal team I’d like to thank all our Editors in Chief, Editorial Boards, internal supporting teams, and our scientific community for their continuous support in making this portfolio a reality - we couldn’t have done it without you! With your support in place, we are confident these journals will become as impactful and successful as our book publishing program and bring us closer to a more open (science) future.”
\\n\\n
We invite you to visit the journals homepage and learn more about the journal’s Editorial Boards, scope and vision as all three journals are now open for submissions.
\\n\\n
Feel free to share this news on social media and help us mark this memorable moment!
After years of being acknowledged as the world's leading publisher of Open Access books, today, we are proud to announce we’ve successfully launched a portfolio of Open Science journals covering rapidly expanding areas of interdisciplinary research.
\n\n\n\n
IntechOpen was founded by scientists, for scientists, in order to make book publishing accessible around the globe. Over the last two decades, this has driven Open Access (OA) book publishing whilst levelling the playing field for global academics. Through our innovative publishing model and the support of the research community, we have now published over 5,700 Open Access books and are visited online by over three million academics every month. These researchers are increasingly working in broad technology-based subjects, driving multidisciplinary academic endeavours into human health, environment, and technology.
\n\n
By listening to our community, and in order to serve these rapidly growing areas which lie at the core of IntechOpen's expertise, we are launching a portfolio of Open Science journals:
All three journals will publish under an Open Access model and embrace Open Science policies to help support the changing needs of academics in these fast-moving research areas. There will be direct links to preprint servers and data repositories, allowing full reproducibility and rapid dissemination of published papers to help accelerate the pace of research. Each journal has renowned Editors in Chief who will work alongside a global Editorial Board, delivering robust single-blind peer review. Supported by our internal editorial teams, this will ensure our authors will receive a quick, user-friendly, and personalised publishing experience.
\n\n
"By launching our journals portfolio we are introducing new, dedicated homes for interdisciplinary technology-focused researchers to publish their work, whilst embracing Open Science and creating a unique global home for academics to disseminate their work. We are taking a leap toward Open Science continuing and expanding our fundamental commitment to openly sharing scientific research across the world, making it available for the benefit of all." Dr. Sara Uhac, IntechOpen CEO
\n\n
"Our aim is to promote and create better science for a better world by increasing access to information and the latest scientific developments to all scientists, innovators, entrepreneurs and students and give them the opportunity to learn, observe and contribute to knowledge creation. Open Science promotes a swifter path from research to innovation to produce new products and services." Alex Lazinica, IntechOpen founder
\n\n
In conclusion, Natalia Reinic Babic, Head of Journal Publishing and Open Science at IntechOpen adds:
\n\n
“On behalf of the journal team I’d like to thank all our Editors in Chief, Editorial Boards, internal supporting teams, and our scientific community for their continuous support in making this portfolio a reality - we couldn’t have done it without you! With your support in place, we are confident these journals will become as impactful and successful as our book publishing program and bring us closer to a more open (science) future.”
\n\n
We invite you to visit the journals homepage and learn more about the journal’s Editorial Boards, scope and vision as all three journals are now open for submissions.
\n\n
Feel free to share this news on social media and help us mark this memorable moment!
\n\n
\n'}],latestNews:[{slug:"intechopen-supports-asapbio-s-new-initiative-publish-your-reviews-20220729",title:"IntechOpen Supports ASAPbio’s New Initiative Publish Your Reviews"},{slug:"webinar-introduction-to-open-science-wednesday-18-may-1-pm-cest-20220518",title:"Webinar: Introduction to Open Science | Wednesday 18 May, 1 PM CEST"},{slug:"step-in-the-right-direction-intechopen-launches-a-portfolio-of-open-science-journals-20220414",title:"Step in the Right Direction: IntechOpen Launches a Portfolio of Open Science Journals"},{slug:"let-s-meet-at-london-book-fair-5-7-april-2022-olympia-london-20220321",title:"Let’s meet at London Book Fair, 5-7 April 2022, Olympia London"},{slug:"50-books-published-as-part-of-intechopen-and-knowledge-unlatched-ku-collaboration-20220316",title:"50 Books published as part of IntechOpen and Knowledge Unlatched (KU) Collaboration"},{slug:"intechopen-joins-the-united-nations-sustainable-development-goals-publishers-compact-20221702",title:"IntechOpen joins the United Nations Sustainable Development Goals Publishers Compact"},{slug:"intechopen-signs-exclusive-representation-agreement-with-lsr-libros-servicios-y-representaciones-s-a-de-c-v-20211123",title:"IntechOpen Signs Exclusive Representation Agreement with LSR Libros Servicios y Representaciones S.A. de C.V"},{slug:"intechopen-expands-partnership-with-research4life-20211110",title:"IntechOpen Expands Partnership with Research4Life"}]},book:{item:{type:"book",id:"5236",leadTitle:null,fullTitle:"High Energy and Short Pulse Lasers",title:"High Energy and Short Pulse Lasers",subtitle:null,reviewType:"peer-reviewed",abstract:"This book gives the readers an introduction to experimental and theoretical knowledge acquired by large-scale laser laboratories that are dealing with extra–high peak power and ultrashort laser pulses for research of terawatt (TW), petawatt (PW), or near-future exawatt (EW) laser interactions, for soft X-ray sources, for acceleration of particles, or for generation of hot dense thermal plasma for the laser fusion. The other part of this book is dealing with the small-scale laser laboratories that are using for its research on commercial sources of laser radiation, nanosecond (ns), picosecond (ps), or femtosecond (fs) laser pulses, either for basic research or for more advanced applications. This book is divided into six main sections dealing with short and ultrashort laser pulses, laser-produced soft X-ray sources, large-scale high-power laser systems, free-electron lasers, fiber-based sources of short optical pulse, and applications of short pulse lasers. In each chapter readers can find fascinating topics related to the high energy and/or short pulse laser technique. Individual chapters should serve the broad spectrum of readers of different expertise, layman, undergraduate and postgraduate students, scientists, and engineers, who may in this book find easily explained fundamentals as well as advanced principles of particular subjects related to these phenomena.",isbn:"978-953-51-2607-2",printIsbn:"978-953-51-2606-5",pdfIsbn:"978-953-51-5078-7",doi:"10.5772/61628",price:139,priceEur:155,priceUsd:179,slug:"high-energy-and-short-pulse-lasers",numberOfPages:424,isOpenForSubmission:!1,isInWos:null,isInBkci:!1,hash:"481d4221e58d2c90fe398be93d898f43",bookSignature:"Richard Viskup",publishedDate:"September 7th 2016",coverURL:"https://cdn.intechopen.com/books/images_new/5236.jpg",numberOfDownloads:37140,numberOfWosCitations:40,numberOfCrossrefCitations:19,numberOfCrossrefCitationsByBook:5,numberOfDimensionsCitations:53,numberOfDimensionsCitationsByBook:7,hasAltmetrics:0,numberOfTotalCitations:112,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"November 18th 2015",dateEndSecondStepPublish:"December 9th 2015",dateEndThirdStepPublish:"March 28th 2016",dateEndFourthStepPublish:"June 26th 2016",dateEndFifthStepPublish:"July 26th 2016",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6,7",editedByType:"Edited by",kuFlag:!1,featuredMarkup:null,editors:[{id:"103742",title:"Dr.",name:"Richard",middleName:null,surname:"Viskup",slug:"richard-viskup",fullName:"Richard Viskup",profilePictureURL:"https://mts.intechopen.com/storage/users/103742/images/7778_n.jpg",biography:"Richard Viskup was born in Bratislava in the Slovak Republic, formerly Czechoslovakia. He received his Master of Science, Doctor in Natural Science, and Doctor of Philosophy in Physics, Plasma Physics, and Laser Physics, respectively, from Comenius University, Bratislava. He obtained his postgraduate Master of Philosophy in Photonics from Strathclyde University, Glasgow, Scotland, and a Doctor of Engineering in Applied Physics from Johannes Kepler University, Linz, Austria.\nDr. Viskup’s research interests include physics, plasma, lasers, material science and analyses, radiation physics, analytical chemistry, spectroscopy, combustion processes, and environmental science, among others.",institutionString:"Johannes Kepler University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"5",totalChapterViews:"0",totalEditedBooks:"4",institution:{name:"Johannes Kepler University of Linz",institutionURL:null,country:{name:"Austria"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"1227",title:"Particle Physics",slug:"particle-physics"}],chapters:[{id:"51849",title:"Generation of High-Intensity Laser Pulses and their Applications",doi:"10.5772/64526",slug:"generation-of-high-intensity-laser-pulses-and-their-applications",totalDownloads:2285,totalCrossrefCites:1,totalDimensionsCites:1,hasAltmetrics:0,abstract:"The progress in the laser technology makes it possible to produce a laser pulse having a peak power of over PW. Focusing such high-power laser pulses enables ones to have unprecedentedly strong laser intensity. The laser intensity over 1019 W/cm2, which is called the relativistic laser intensity, can accelerate electrons almost to the speed of light. The acceleration of charged particles using such a high-power laser pulse has been successfully demonstrated in many experiments. According to the recent calculation using the vector diffraction theory, it is possible, by employing a tight focusing geometry, to produce a femtosecond (fs) laser focal spot to have an intensity of over 1024 W/cm2 in the focal plane. Over this laser intensity, protons can be directly accelerated almost to the speed of light. Such ultrashort and ultrastrong laser intensities will bring ones many opportunities to experimentally study ultrafast physical phenomena we have never met before. This chapter describes how to generate a high-power laser pulse. And, then the focusing characteristics of a femtosecond high-power laser pulse are discussed in the scalar and the vector diffraction limits. Finally, the applications of ultrashort high-power laser are briefly introduced.",signatures:"Tae Moon Jeong and Jongmin Lee",downloadPdfUrl:"/chapter/pdf-download/51849",previewPdfUrl:"/chapter/pdf-preview/51849",authors:[{id:"14353",title:"Prof.",name:"Jongmin",surname:"Lee",slug:"jongmin-lee",fullName:"Jongmin Lee"}],corrections:null},{id:"51704",title:"High-Power Diode-Pumped Short Pulse Lasers Based on Yb:KGW Crystals for Industrial Applications",doi:"10.5772/64571",slug:"high-power-diode-pumped-short-pulse-lasers-based-on-yb-kgw-crystals-for-industrial-applications",totalDownloads:2345,totalCrossrefCites:0,totalDimensionsCites:1,hasAltmetrics:0,abstract:"A diode-pumped, ultrafast Yb:KYW laser system utilizing chirped-pulse amplification (CPA) in a dual-slab regenerative amplifier (RA) with spectral shaping of seeding pulse from a master oscillator (MO) has been developed. A train of compressed pulses with pulse length of 181 fs, repetition rate up to 500 kHz, and average power exceeding 15 W after compression and pulse picker was achieved.",signatures:"Guang-Hoon Kim, Juhee Yang, Byunghak Lee, Bosu Jeong, Sergey\nChizhov, Elena Sall, Vladimir Yashin and Uk Kang",downloadPdfUrl:"/chapter/pdf-download/51704",previewPdfUrl:"/chapter/pdf-preview/51704",authors:[{id:"183797",title:"Dr.",name:"Guang-Hoon",surname:"Kim",slug:"guang-hoon-kim",fullName:"Guang-Hoon Kim"},{id:"187515",title:"Dr.",name:"Juhee",surname:"Yang",slug:"juhee-yang",fullName:"Juhee Yang"},{id:"187517",title:"Mr.",name:"Byunghak",surname:"Lee",slug:"byunghak-lee",fullName:"Byunghak Lee"},{id:"187519",title:"Mr.",name:"Bosu",surname:"Jeong",slug:"bosu-jeong",fullName:"Bosu Jeong"},{id:"187520",title:"MSc.",name:"Sergey",surname:"Chizhov",slug:"sergey-chizhov",fullName:"Sergey Chizhov"},{id:"187521",title:"MSc.",name:"Elena",surname:"Sall",slug:"elena-sall",fullName:"Elena Sall"},{id:"187522",title:"Prof.",name:"Vladimir",surname:"Yashin",slug:"vladimir-yashin",fullName:"Vladimir Yashin"},{id:"187523",title:"Dr.",name:"Uk",surname:"Kang",slug:"uk-kang",fullName:"Uk Kang"}],corrections:null},{id:"51683",title:"Yb:YAG-Pumped, Few-Cycle Optical Parametric Amplifiers",doi:"10.5772/64438",slug:"yb-yag-pumped-few-cycle-optical-parametric-amplifiers",totalDownloads:1738,totalCrossrefCites:1,totalDimensionsCites:3,hasAltmetrics:0,abstract:"In this chapter, the principle, design, and characteristics of high-efficiency, short-pulse-pumped, few-cycle optical parametric chirped-pulse amplification (OPCPA) systems are reviewed. To this end, the feasibility of two techniques to increase the conversion efficiency of few-cycle OPCPA systems is demonstrated and discussed. The techniques result in 2.5 mJ, 7.5 W pulses and correspond to a pump-to-signal conversion efficiency of 30%. The broadband amplified spectrum supports 5.7 fs. Finally, the feasibility of extending the amplified spectrum to a near-single-cycle regime by using the combination of different crystals and phase matching is shown.",signatures:"Hanieh Fattahi",downloadPdfUrl:"/chapter/pdf-download/51683",previewPdfUrl:"/chapter/pdf-preview/51683",authors:[{id:"149557",title:"Dr.",name:"Hanieh",surname:"Fattahi",slug:"hanieh-fattahi",fullName:"Hanieh Fattahi"}],corrections:null},{id:"51539",title:"Brilliance Improvement of a Laser-Produced Soft X-Ray Plasma",doi:"10.5772/64149",slug:"brilliance-improvement-of-a-laser-produced-soft-x-ray-plasma",totalDownloads:1554,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"The brilliance of a laser-produced soft X-ray source is enhanced for gaseous target concepts. In contrast to solid or liquid target materials, these sources are clean and versatile but provide a comparably low conversion efficiency of laser energy into EUV and soft X-ray radiation. The basic idea is to induce supersonic effects in the gas jet, leading to a local increase of the particle density, and thus, to a larger number of possible emitters. Typically, the target gas is expanded into a vacuum environment and the density rapidly drops in all directions. In the present approach, a low pressure helium atmosphere is used to generate shock waves in the supersonic nozzle flow. Passing through these structures, the target gas is recompressed, and the particle density is raised. By focusing the laser beam into such regions, a higher number of gas atoms can be ionized resulting in a brighter and smaller plasma.",signatures:"Tobias Mey",downloadPdfUrl:"/chapter/pdf-download/51539",previewPdfUrl:"/chapter/pdf-preview/51539",authors:[{id:"183471",title:"Dr.",name:"Tobias",surname:"Mey",slug:"tobias-mey",fullName:"Tobias Mey"}],corrections:null},{id:"51317",title:"High-Brightness Solid-State Lasers for Compact Short-Wavelength Sources",doi:"10.5772/64147",slug:"high-brightness-solid-state-lasers-for-compact-short-wavelength-sources",totalDownloads:2363,totalCrossrefCites:1,totalDimensionsCites:2,hasAltmetrics:0,abstract:"Various types of compact short-wavelength sources are emerging in the region from EUV to hard X-ray and further to gamma ray. These high-energy photons are usually accessible in a large-scale facility such as SR or FEL, and the compactness of these new technologies provides new possibilities for broader applications in dedicated laboratories or factories. Laser-produced plasma is used for soft X-ray laser and high average power EUV sources for lithography. Laser Compton short-wavelength sources are now entering into practical applications in medical imaging. The performance of these sources critically depends on the laser driver performance. This chapter describes the recent progress of high-brightness, short-pulse solid-state laser technology in close relation to these new compact short-wavelength sources. Pulsed picosecond thin disc laser progress is reviewed with kW average power specifications. Cryogenic laser is reported for the advantage of higher beam quality in large-pulse energy operation.",signatures:"Akira Endo",downloadPdfUrl:"/chapter/pdf-download/51317",previewPdfUrl:"/chapter/pdf-preview/51317",authors:[{id:"180726",title:"Prof.",name:"Akira",surname:"Endo",slug:"akira-endo",fullName:"Akira Endo"}],corrections:null},{id:"51364",title:"Multiterawatt Hybrid (Solid/Gas) Femtosecond Systems in the Visible",doi:"10.5772/63972",slug:"multiterawatt-hybrid-solid-gas-femtosecond-systems-in-the-visible",totalDownloads:1810,totalCrossrefCites:2,totalDimensionsCites:5,hasAltmetrics:0,abstract:"A novel hybrid (solid/gas) approach to the development of femtosecond high‐intensity laser systems operating in the visible is presented in this chapter. Behind this approach is a combination of a solid‐state front end relying on widespread and highly developed techniques for femtosecond pulse generation in the near infrared with a photochemically driven boosting amplifier operating in the visible spectral range. Historical background of developing photochemically pumped gas lasers on broad bandwidth electronic transitions in molecules and physical principles of their operation are briefly summarized as well. The architecture and the design issues of the hybrid femtosecond systems relying on the amplification of the second harmonic of Ti:sapphire front ends in the photodissociation XeF(C‐A) power‐boosting amplifiers driven by the VUV radiation from electron‐beam‐to‐VUV‐flash converters are described, as well as breakthrough results of proof‐of‐principle experiments demonstrating a high potential of the hybrid approach. Wavelength scaling of laser‐matter interaction is shortly discussed to demonstrate advantages of shorter driver wavelengths for some applications with main emphasis placed on recombination‐pumped soft X‐ray lasers.",signatures:"Leonid D. Mikheev and Valery F. Losev",downloadPdfUrl:"/chapter/pdf-download/51364",previewPdfUrl:"/chapter/pdf-preview/51364",authors:[{id:"183138",title:"Dr.",name:"Leonid",surname:"Mikheev",slug:"leonid-mikheev",fullName:"Leonid Mikheev"},{id:"183140",title:"Prof.",name:"Valery",surname:"Losev",slug:"valery-losev",fullName:"Valery Losev"}],corrections:null},{id:"50854",title:"Nuclear-Induced Plasmas of Gas Mixtures and Nuclear-Pumped Lasers",doi:"10.5772/63823",slug:"nuclear-induced-plasmas-of-gas-mixtures-and-nuclear-pumped-lasers",totalDownloads:1708,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"We briefly describe the basic processes of formation and relaxation of nuclear-induced plasmas of gas mixtures, especially the processes of inverse population creation in nuclear-pumped lasers (NPL). A review of the work to create and research nuclear-pumped lasers is in progress: on transitions of atoms and atomic ions and on molecular transitions. An increased focus is on the gas media, which we also study on WWR-K nuclear reactor and DC-60 ion accelerator. The studies on emission of heteronuclear ionic molecules of inert gases are also reviewed.",signatures:"Mendykhan U. Khasenov",downloadPdfUrl:"/chapter/pdf-download/50854",previewPdfUrl:"/chapter/pdf-preview/50854",authors:[{id:"183205",title:"Dr.",name:"Mendykhan",surname:"Khasenov",slug:"mendykhan-khasenov",fullName:"Mendykhan Khasenov"}],corrections:null},{id:"51599",title:"Undulators for Short Pulse X-Ray Self-Amplified Spontaneous Emission-Free Electron Lasers",doi:"10.5772/64439",slug:"undulators-for-short-pulse-x-ray-self-amplified-spontaneous-emission-free-electron-lasers",totalDownloads:1620,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"We review the synchrotron type radiation sources with focus on undulator and free-electron laser (FEL) schemes, aimed on working in X-ray range and ultra-short time interval. Main FEL schemes, useful for generation of high frequency radiation, extending to X-rays, are presented. High harmonic generation is explored. The advantages and disadvantages of single pass and of multipass designs are discussed. The viable ways to reduce the duration of the pulse, with the goal to generate femtosecond pulses, are indicated. Future developments of X-ray FELs (X-FELs) and the ways to improve the quality of the FEL radiation in this context are discussed.",signatures:"K. Zhukovsky",downloadPdfUrl:"/chapter/pdf-download/51599",previewPdfUrl:"/chapter/pdf-preview/51599",authors:[{id:"183581",title:"Dr.",name:"K.",surname:"Zhukovsky",slug:"k.-zhukovsky",fullName:"K. Zhukovsky"}],corrections:null},{id:"50815",title:"Phase Manipulation of Ultrashort Soft X-Ray Pulses by Reflective Gratings",doi:"10.5772/63416",slug:"phase-manipulation-of-ultrashort-soft-x-ray-pulses-by-reflective-gratings",totalDownloads:1585,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"In this chapter, we discuss the use of reflective diffraction gratings to manipulate the phase of ultrashort pulses in the extreme ultraviolet (XUV) and soft X-ray spectral regions. Gratings may be used to condition the spectral phase of ultrashort pulses, e.g., to compensate for the pulse chirp and compress the pulse, similarly to what is routinely realized for visible and infrared pulses. The chirped pulse amplification technique has been already proposed for soft X-ray free-electron laser radiation; however, it requires the use of a compressor to compensate for the pulse chirp and get closer to the Fourier limit. There are fundamental differences when operating the gratings at wavelengths shorter than ≈40 nm on a broad band: (a) the gratings are operated at grazing incidence; therefore, the optical design has to be consequently tailored to this peculiar geometry; (b) the grating efficiency is definitely lower; therefore, the number of diffractions has to be limited to two. We discuss the different configurations that can be applied to the realization of a grating stretcher/compressor.",signatures:"Fabio Frassetto, Paolo Miotti and Luca Poletto",downloadPdfUrl:"/chapter/pdf-download/50815",previewPdfUrl:"/chapter/pdf-preview/50815",authors:[{id:"4861",title:"Dr.",name:"Luca",surname:"Poletto",slug:"luca-poletto",fullName:"Luca Poletto"},{id:"186618",title:"Dr.",name:"Fabio",surname:"Frassetto",slug:"fabio-frassetto",fullName:"Fabio Frassetto"},{id:"186619",title:"MSc.",name:"Paolo",surname:"Miotti",slug:"paolo-miotti",fullName:"Paolo Miotti"}],corrections:null},{id:"51304",title:"Fiber-Based High-Power Supercontinuum and Frequency Comb Generation",doi:"10.5772/64209",slug:"fiber-based-high-power-supercontinuum-and-frequency-comb-generation",totalDownloads:2340,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"Ultrafast optics has been a rich research field, and picosecond/femtosecond pulsed laser sources seek many applications in both the areas of fundamental research and industrial life. Much attention has been attached to fiber lasers in recent decades as they offering various superiorities over their solid-state counterparts with compact size, low cost, and great stability due to the inherent stability and safety of the waveguide structures as well as high photoelectric conversion efficiency. Fiber-based sources of ultrashort and high-peak/high-average optical pulses have become extremely important for high-precision laser processing while sources whose carrier-envelop offset and repetition rate are stabilized can serve as laser combs with applications covering many research areas, such as precision spectroscopy, optical clock, and optical frequency metrology. For the application as laser combs, four parts as fiber laser, broadband supercontinuum, nonlinear power amplification, and repetition rate stabilization must be concerned. This chapter is intended to give a brief introduction about the achievement of the four technologies mentioned above with different experimental setups, recently developed such as divided-pulse amplification (DPA) in emphasize. Moreover, detailed descriptions of the experimental constructions as well as theoretical analyses about the phenomena they produced are also involved.",signatures:"Qiang Hao, Tingting Liu and Heping Zeng",downloadPdfUrl:"/chapter/pdf-download/51304",previewPdfUrl:"/chapter/pdf-preview/51304",authors:[{id:"14193",title:"Prof.",name:"Heping",surname:"Zeng",slug:"heping-zeng",fullName:"Heping Zeng"},{id:"187050",title:"Dr.",name:"Qiang",surname:"Hao",slug:"qiang-hao",fullName:"Qiang Hao"},{id:"189582",title:"Dr.",name:"Tingting",surname:"Liu",slug:"tingting-liu",fullName:"Tingting Liu"}],corrections:null},{id:"51418",title:"High‐Energy and Short‐Pulse Generation from Passively Mode‐ Locked Ytterbium‐Doped Double‐Clad Fiber Lasers",doi:"10.5772/63900",slug:"high-energy-and-short-pulse-generation-from-passively-mode-locked-ytterbium-doped-double-clad-fiber-",totalDownloads:2332,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"Mode‐locked ytterbium‐doped fiber lasers capable of producing nanosecond‐, picosecond‐ or femtosecond‐level pulses with high energy or power have many advantages for various applications such as material processing and laser surgery. Firstly, in this chapter, the principles and methods used in passively mode‐locked fiber lasers are briefly described. Secondly, mathematical modeling of all normal dispersion ytterbium‐doped fiber lasers for analyzing the pulse generation and propagation has been established and simulated with the generalized nonlinear Schrödinger equation. Thirdly, short pulses generated from passively mode‐locked fiber lasers have been demonstrated with carbon nanotube– deposited D‐shaped fiber as the saturable absorber. Different pulse width can be realized with different parameters of the laser cavity. Finally, the main amplification methods for short laser pulses have been discussed, and a broad prospect for applications of various technologies using short‐pulse fiber lasers is further introduced.",signatures:"Yuzhai Pan",downloadPdfUrl:"/chapter/pdf-download/51418",previewPdfUrl:"/chapter/pdf-preview/51418",authors:[{id:"183493",title:"Dr.",name:"Yuzhai",surname:"Pan",slug:"yuzhai-pan",fullName:"Yuzhai Pan"}],corrections:null},{id:"50866",title:"Effects of Different Laser Pulse Regimes (Nanosecond, Picosecond and Femtosecond) on the Ablation of Materials for Production of Nanoparticles in Liquid Solution",doi:"10.5772/63892",slug:"effects-of-different-laser-pulse-regimes-nanosecond-picosecond-and-femtosecond-on-the-ablation-of-ma",totalDownloads:6119,totalCrossrefCites:11,totalDimensionsCites:36,hasAltmetrics:0,abstract:"Ultra-short laser pulse interaction with materials has received much attention from researchers in micro- and nanomachining, especially for the generation of nanoparticles in liquid environments, because of the straightforward method and direct application for organic solvents. In addition, the colloidal nanoparticles produced by laser ablation have very high purity—they are free from surfactants and reaction products or by-products. In this chapter, nanosecond, picosecond and femtosecond laser pulse durations are compared in laser material processing. Due to the unique properties of the short and ultra-short laser pulse durations in material processing, they are more apparent in the production of precision material processing and generation of nanoparticles in liquid environments.",signatures:"Abubaker Hassan Hamad",downloadPdfUrl:"/chapter/pdf-download/50866",previewPdfUrl:"/chapter/pdf-preview/50866",authors:[{id:"183494",title:"Dr.",name:"Abubaker",surname:"Hamad",slug:"abubaker-hamad",fullName:"Abubaker Hamad"}],corrections:null},{id:"51567",title:"Application of PLD-Fabricated Thick-Film Permanent Magnets",doi:"10.5772/64235",slug:"application-of-pld-fabricated-thick-film-permanent-magnets",totalDownloads:1553,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"Isotropic Nd-Fe-B thick-film magnets have been prepared using a pulsed laser deposition (PLD) method with the control of laser energy density (LED) followed by post-annealing. The characteristics of the method are a high deposition rate up to several tens of microns per hour together with a reliability of magnetic properties due to the good transfer of composition from an Nd-Fe-B target to a film. Several micro-machines comprising the isotropic Nd-Fe-B films such as a miniaturized DC motor and a swimming machine in liquid were demonstrated. Furthermore, the deposition of isotropic Nd (or Pr)-Fe-B thick-film magnets on a Si or glass substrate was carried out to apply the films to various micro-electro-mechanical-systems (MEMS). We also introduced the preparation of isotropic Sm-Co, Fe-Pt, and nano-composite Nd-Fe-B+α-Fe film magnets synthesized using the PLD.",signatures:"Masaki Nakano, Takeshi Yanai and Hirotoshi Fukunaga",downloadPdfUrl:"/chapter/pdf-download/51567",previewPdfUrl:"/chapter/pdf-preview/51567",authors:[{id:"182170",title:"Prof.",name:"Masaki",surname:"Nakano",slug:"masaki-nakano",fullName:"Masaki Nakano"}],corrections:null},{id:"51658",title:"Obtaining a Thin and Flexible Dental Film of Hydroxyapatite",doi:"10.5772/63955",slug:"obtaining-a-thin-and-flexible-dental-film-of-hydroxyapatite",totalDownloads:1287,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"The deposition of hydroxyapatite thin films has become a topic of interest in medical applications. This dental film applied on the surface of the tooth may act as a highly resistant and flexible artificial enamel, protecting teeth and removing tooth sensitivity. Other possibilities include whitening and coating enamel-deficient structures. We obtained this flexible film of hydroxyapatite using laser ablation. The plasma plumes were generated by an Nd:YAG nanosecond laser in a vacuum chamber. We used the pulsed laser deposition (PLD) technique and conducted investigations using optical emission spectroscopy (OES), laser-induced breakdown spectroscopy (LIBS), and Raman spectroscopy. Initially, a thin film of HA was deposited on a soluble substrate and heated, followed by immersion into pure water to dissolve the substrates. The originality of our approach consists in the fact that the flexible HA film can be obtained in pure state, because it grows without a substrate, using just a base and lateral supports between, on which it will grow vertically. In order to verify the compatibility and the “stickiness” of HA on the teeth, we chose to grow the film between the roots of a tooth. In this case, besides the film, we also obtained HA microfibers. We tried to bind the film on an extracted tooth. A protocol must be established in order to allow the bonding of the film to the surface of the tooth, knowing that contaminants such as saliva or sulcular fluid increase bonding strength to enamel or dentin. We realized an efficient bonding as HA absorbs protein, the mineral also participates in this ionic exchange, and we strengthened the tooth structure. The main purpose of our research is to rebuild the dentine layer or enamel and close the dental channels. Our experiments led to the creation of an HA foil that has the role of protecting teeth against cariogenic bacteria and could even have cosmetic effects by teeth whitening. This dental plaster acts as an artificial HA enamel, very resistant and flexible, protecting the tooth and eliminating dental sensitivity. Being very thin, it is invisible once applied on teeth and can be observed only by examination under a strong light.",signatures:"Lucia Marin Biolan, Andrei Bedros Agop and Doriana Forna",downloadPdfUrl:"/chapter/pdf-download/51658",previewPdfUrl:"/chapter/pdf-preview/51658",authors:[{id:"183803",title:"Dr.",name:"Lucia",surname:"Marin-Biolan",slug:"lucia-marin-biolan",fullName:"Lucia Marin-Biolan"}],corrections:null},{id:"51363",title:"High‐Energy Nanosecond Laser Pulses for Synthesis of Better Bone Implants",doi:"10.5772/63770",slug:"high-energy-nanosecond-laser-pulses-for-synthesis-of-better-bone-implants",totalDownloads:1959,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"The main objective of this chapter is to introduce high‐energy nanosecond laser pulse treatment for enhancing the surface bioactivity of titanium for bone and tissue implant fabrication. Improvement to the implant performance could immensely benefit the human patient. Bioactivity enhancement of materials is currently an essential challenge in implant engineering. Laser micro/nano surface texturing of materials offers a simple, accurate, and precise method to increase the biocompatibility of materials in one single step. In this chapter, the effects of laser power, scanning parameters, and frequency on surface structure and topographic properties are studied. Through bioactivity assessment of treated titanium substrates, it was found that an increase in power and frequency increases the bioactivity of titanium, while a decrease in scanning speed of laser could lead to an increase in the cell adhesion ability of titanium.",signatures:"Amirkianoosh Kiani and Mitra Radmanesh",downloadPdfUrl:"/chapter/pdf-download/51363",previewPdfUrl:"/chapter/pdf-preview/51363",authors:[{id:"183144",title:"Dr.",name:"Amirkianoosh",surname:"Kiani",slug:"amirkianoosh-kiani",fullName:"Amirkianoosh Kiani"},{id:"183413",title:"Ms.",name:"Mitra",surname:"Radmanesh",slug:"mitra-radmanesh",fullName:"Mitra Radmanesh"}],corrections:null},{id:"51630",title:"Excimer Laser and Femtosecond Laser in Ophthalmology",doi:"10.5772/64238",slug:"excimer-laser-and-femtosecond-laser-in-ophthalmology",totalDownloads:2359,totalCrossrefCites:1,totalDimensionsCites:3,hasAltmetrics:0,abstract:"Laser technology is used in many basic and clinical disciplines and specialties, and it has played an important role in promoting the development of ophthalmology, especially corneal refractive surgery. We provide an overview of the evolution of laser technology for use in refractive and other ophthalmologic surgeries, mainly focusing on two types of lasers and their applications. First, we discuss the characteristics of the excimer laser and its application in corneal refractive surgery treating ametropia (e.g., photorefractive keratectomy (PRK), laser epithelial keratomileusis (LASEK), epipolis laser in situ keratomileusis (Epi-LASIK), and transepithelial photorefractive keratectomy (Trans-PRK) and presbyopia surgery). Second, we discuss the characteristics of the femtosecond laser and its application in corneal refractive surgery (e.g., femtosecond laser in situ keratomileusis (FS-LASIK), insertion of intracorneal ring segments, small-incision lenticule extraction (SMILE), and femtosecond lenticule extraction (FLEx)) and other ophthalmologic surgeries (e.g., penetrating keratoplasty (PKP), deep anterior lamellar keratoplasty, Descemet’s stripping endothelial keratoplasty (DSEK), and cataract surgery). The patients studied received many benefits from the excimer laser and femtosecond laser technologies and were satisfied with their clinical outcomes.",signatures:"Liang Hu, Yiqing Huang and Meng Lin",downloadPdfUrl:"/chapter/pdf-download/51630",previewPdfUrl:"/chapter/pdf-preview/51630",authors:[{id:"183882",title:"Prof.",name:"Liang",surname:"Hu",slug:"liang-hu",fullName:"Liang Hu"},{id:"188684",title:"Dr.",name:"Yiqing",surname:"Huang",slug:"yiqing-huang",fullName:"Yiqing Huang"},{id:"188686",title:"Dr.",name:"Meng",surname:"Lin",slug:"meng-lin",fullName:"Meng Lin"}],corrections:null},{id:"51123",title:"Diode Laser‐Based Sensors for Extreme Harsh Environment Data Acquisition",doi:"10.5772/63971",slug:"diode-laser-based-sensors-for-extreme-harsh-environment-data-acquisition",totalDownloads:2185,totalCrossrefCites:2,totalDimensionsCites:2,hasAltmetrics:0,abstract:"The world has witnessed several step changes in living standards, productivity, growth, and innovation. We are currently witnessing a convergence of intelligent devices, intelligent networks, and intelligent decision making. Obtaining long‐term accurate, in situ, and real time data from the machines is necessary for enabling the industrial Internet. This relies heavily on sensor systems. Development of robust sensors that can operate reliably in extreme environments will make it possible to gather data from previously inaccessible locations in the equipment. This will enable machine operators to monitor and optimize the performance of their machines. Diode laser‐based diagnostics technology has found applications in a variety of areas and a versatile range of operating conditions. It has proven to be a strong and reliable technique for remote measurements of concentrations and temperatures in harsh environments. Some of the major challenges for implementation of these sensors in real world are machine vibrations, window clogging, cooling, etc. In this chapter, the authors discuss about the application details and specific technologies suitable for the applications. Few case studies are considered, and the theoretical approach, algorithm development, and experimental validation are also discussed.",signatures:"Chayan Mitra and Rachit Sharma",downloadPdfUrl:"/chapter/pdf-download/51123",previewPdfUrl:"/chapter/pdf-preview/51123",authors:[{id:"181669",title:"Mr.",name:"Chayan",surname:"Mitra",slug:"chayan-mitra",fullName:"Chayan Mitra"},{id:"189160",title:"Dr.",name:"Rachit",surname:"Sharma",slug:"rachit-sharma",fullName:"Rachit Sharma"}],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},subseries:null,tags:null},relatedBooks:[{type:"book",id:"7377",title:"Diesel and Gasoline Engines",subtitle:null,isOpenForSubmission:!1,hash:"dab9fe312a28dd603ac4b21628070d59",slug:"diesel-and-gasoline-engines",bookSignature:"Richard Viskup",coverURL:"https://cdn.intechopen.com/books/images_new/7377.jpg",editedByType:"Edited by",editors:[{id:"103742",title:"Dr.",name:"Richard",surname:"Viskup",slug:"richard-viskup",fullName:"Richard Viskup"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10178",title:"Environmental Emissions",subtitle:null,isOpenForSubmission:!1,hash:"febf21ec717bfe20ae25a9dab9b5d438",slug:"environmental-emissions",bookSignature:"Richard Viskup",coverURL:"https://cdn.intechopen.com/books/images_new/10178.jpg",editedByType:"Edited by",editors:[{id:"103742",title:"Dr.",name:"Richard",surname:"Viskup",slug:"richard-viskup",fullName:"Richard Viskup"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8813",title:"Introduction to Diesel Emissions",subtitle:null,isOpenForSubmission:!1,hash:"693a8757f50c6f257cca62961cba76c2",slug:"introduction-to-diesel-emissions",bookSignature:"Richard Viskup",coverURL:"https://cdn.intechopen.com/books/images_new/8813.jpg",editedByType:"Edited by",editors:[{id:"103742",title:"Dr.",name:"Richard",surname:"Viskup",slug:"richard-viskup",fullName:"Richard Viskup"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8628",title:"Synchrotron Radiation",subtitle:"Useful and Interesting Applications",isOpenForSubmission:!1,hash:"5bbb65395b91d370fc0f3652e9fbc359",slug:"synchrotron-radiation-useful-and-interesting-applications",bookSignature:"Daisy Joseph",coverURL:"https://cdn.intechopen.com/books/images_new/8628.jpg",editedByType:"Edited by",editors:[{id:"187281",title:"Dr.",name:"Daisy",surname:"Joseph",slug:"daisy-joseph",fullName:"Daisy Joseph"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2270",title:"Fourier Transform",subtitle:"Materials Analysis",isOpenForSubmission:!1,hash:"5e094b066da527193e878e160b4772af",slug:"fourier-transform-materials-analysis",bookSignature:"Salih Mohammed Salih",coverURL:"https://cdn.intechopen.com/books/images_new/2270.jpg",editedByType:"Edited by",editors:[{id:"111691",title:"Dr.Ing.",name:"Salih",surname:"Salih",slug:"salih-salih",fullName:"Salih Salih"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"79356",slug:"corrigendum-the-ghanaian-flora-as-a-potential-source-of-anthelmintic-and-anti-schistosomal-agents",title:"Corrigendum: The Ghanaian Flora as a Potential Source of Anthelmintic and Anti-Schistosomal Agents",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/76505.pdf\r\n",downloadPdfUrl:"/chapter/pdf-download/76505",previewPdfUrl:"/chapter/pdf-preview/76505",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/76505",risUrl:"/chapter/ris/76505",chapter:{id:"76353",slug:"the-ghanaian-flora-as-a-potential-source-of-anthelmintic-and-anti-schistosomal-agents",signatures:"Evelyn Asante-Kwatia, Abraham Yeboah Mensah, Lord Gyimah and Arnold Donkor Forkuo",dateSubmitted:"February 24th 2021",dateReviewed:"March 25th 2021",datePrePublished:"April 20th 2021",datePublished:"May 11th 2022",book:{id:"10356",title:"Natural Medicinal Plants",subtitle:null,fullTitle:"Natural Medicinal Plants",slug:"natural-medicinal-plants",publishedDate:"May 11th 2022",bookSignature:"Hany A. El-Shemy",coverURL:"https://cdn.intechopen.com/books/images_new/10356.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"54719",title:"Prof.",name:"Hany",middleName:null,surname:"El-Shemy",slug:"hany-el-shemy",fullName:"Hany El-Shemy"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"217045",title:"Dr.",name:"Arnold Forkuo",middleName:null,surname:"Donkor",fullName:"Arnold Forkuo Donkor",slug:"arnold-forkuo-donkor",email:"forkuo3@gmail.com",position:null,institution:{name:"Kwame Nkrumah University of Science and Technology",institutionURL:null,country:{name:"Ghana"}}},{id:"303360",title:"Dr.",name:"Evelyn",middleName:null,surname:"Asante-Kwatia",fullName:"Evelyn Asante-Kwatia",slug:"evelyn-asante-kwatia",email:"emireku@yahoo.com",position:null,institution:null},{id:"309974",title:"Prof.",name:"Abraham Yeboah",middleName:null,surname:"Mensah",fullName:"Abraham Yeboah Mensah",slug:"abraham-yeboah-mensah",email:"aymensah@yahoo.com",position:null,institution:{name:"Kwame Nkrumah University of Science and Technology",institutionURL:null,country:{name:"Ghana"}}},{id:"347910",title:"Mr.",name:"Lord",middleName:null,surname:"Gyimah",fullName:"Lord Gyimah",slug:"lord-gyimah",email:"lordgyimah36@gmail.com",position:null,institution:{name:"Kwame Nkrumah University of Science and Technology",institutionURL:null,country:{name:"Ghana"}}}]}},chapter:{id:"76353",slug:"the-ghanaian-flora-as-a-potential-source-of-anthelmintic-and-anti-schistosomal-agents",signatures:"Evelyn Asante-Kwatia, Abraham Yeboah Mensah, Lord Gyimah and Arnold Donkor Forkuo",dateSubmitted:"February 24th 2021",dateReviewed:"March 25th 2021",datePrePublished:"April 20th 2021",datePublished:"May 11th 2022",book:{id:"10356",title:"Natural Medicinal Plants",subtitle:null,fullTitle:"Natural Medicinal Plants",slug:"natural-medicinal-plants",publishedDate:"May 11th 2022",bookSignature:"Hany A. El-Shemy",coverURL:"https://cdn.intechopen.com/books/images_new/10356.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"54719",title:"Prof.",name:"Hany",middleName:null,surname:"El-Shemy",slug:"hany-el-shemy",fullName:"Hany El-Shemy"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"217045",title:"Dr.",name:"Arnold Forkuo",middleName:null,surname:"Donkor",fullName:"Arnold Forkuo Donkor",slug:"arnold-forkuo-donkor",email:"forkuo3@gmail.com",position:null,institution:{name:"Kwame Nkrumah University of Science and Technology",institutionURL:null,country:{name:"Ghana"}}},{id:"303360",title:"Dr.",name:"Evelyn",middleName:null,surname:"Asante-Kwatia",fullName:"Evelyn Asante-Kwatia",slug:"evelyn-asante-kwatia",email:"emireku@yahoo.com",position:null,institution:null},{id:"309974",title:"Prof.",name:"Abraham Yeboah",middleName:null,surname:"Mensah",fullName:"Abraham Yeboah Mensah",slug:"abraham-yeboah-mensah",email:"aymensah@yahoo.com",position:null,institution:{name:"Kwame Nkrumah University of Science and Technology",institutionURL:null,country:{name:"Ghana"}}},{id:"347910",title:"Mr.",name:"Lord",middleName:null,surname:"Gyimah",fullName:"Lord Gyimah",slug:"lord-gyimah",email:"lordgyimah36@gmail.com",position:null,institution:{name:"Kwame Nkrumah University of Science and Technology",institutionURL:null,country:{name:"Ghana"}}}]},book:{id:"10356",title:"Natural Medicinal Plants",subtitle:null,fullTitle:"Natural Medicinal Plants",slug:"natural-medicinal-plants",publishedDate:"May 11th 2022",bookSignature:"Hany A. El-Shemy",coverURL:"https://cdn.intechopen.com/books/images_new/10356.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"54719",title:"Prof.",name:"Hany",middleName:null,surname:"El-Shemy",slug:"hany-el-shemy",fullName:"Hany El-Shemy"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"11729",leadTitle:null,title:"Circumcision - Advances and New Perspectives",subtitle:null,reviewType:"peer-reviewed",abstract:"
\r\n\tMale circumcision is a procedure that has been practiced since the dawn of human culture more than six thousand years ago. It is performed for both medical and non-medical reasons. Despite being a simple procedure, it may lead to a myriad of minor and even crippling complications, if not done properly, such as iatrogenic injury of the glans or the urethra. Several techniques have been used to perform circumcision including the classic open technique, clamp technique, and laser /electrocautery technique with various safety outcomes. Overtime time, there has been an ongoing debate over the pros and cons of cultural circumcision with a significant dichotomy between the opinions of the experts in the field.
\r\n
\r\n\tThe main purpose of this book will aim to present a comprehensive overview of the historic background of circumcision in males and the debate over female circumcision. It is intended to be an addition to a description of the different procedural techniques of circumcision highlighting their potential complications.
",isbn:"978-1-80355-907-0",printIsbn:"978-1-80355-906-3",pdfIsbn:"978-1-80355-908-7",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,isSalesforceBook:!1,isNomenclature:!1,hash:"d4761c03b5694edec9f7fc48092549ce",bookSignature:"Dr. Ahmad Zaghal and Dr. Ali El Safadi",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/11729.jpg",keywords:"History Of Circumcision, Male Circumcision, Female Circumcision, Indications, Contraindications, Peri-Procedural Preparation, Analgesia, Clamp, Meatal Stenosis, Iatrogenic Injury, Adhesions, Buried Penis",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:null,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"February 25th 2022",dateEndSecondStepPublish:"April 29th 2022",dateEndThirdStepPublish:"June 28th 2022",dateEndFourthStepPublish:"September 16th 2022",dateEndFifthStepPublish:"November 15th 2022",dateConfirmationOfParticipation:null,remainingDaysToSecondStep:"4 months",secondStepPassed:!0,areRegistrationsClosed:!0,currentStepOfPublishingProcess:4,editedByType:null,kuFlag:!1,biosketch:"Pediatric surgeon and clinical educator, member of Royal College of Surgeons of England, European Pediatric Surgeon’s Association, British Association of Pediatric Endoscopic Surgeons, American College of Surgeons, International Society for Pediatric Wound Care.",coeditorOneBiosketch:"Obstetrics and Gynecology trainee and clinical researcher.",coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"240621",title:"Dr.",name:"Ahmad",middleName:null,surname:"Zaghal",slug:"ahmad-zaghal",fullName:"Ahmad Zaghal",profilePictureURL:"https://mts.intechopen.com/storage/users/240621/images/system/240621.jpg",biography:"Ahmad Zaghal, MD, MSc (Clin Ed), FACS, FEBPS, FHEA, graduated from the general surgery-residency program at The American University of Beirut-Medical Center (AUBMC), Lebanon, in 2012. He then completed a two-year fellowship in Pediatric Surgery at the University of Iowa-Hospitals and Clinics, USA. Then he joined Chelsea and Westminster Hospital, UK, for another year of fellowship in pediatric surgery. Dr. Zaghal is board certified by the European Board of Pediatric Surgery.\nDr. Zaghal has been a pediatric surgeon and assistant professor of surgery at AUBMC since 2017. He has special interests in minimally invasive and neonatal surgery, and medical education. He is a fellow of the Higher Education Academy. Dr. Zaghal has published several articles in peer-reviewed journals and authored several chapters in general and pediatric surgery.",institutionString:"American University of Beirut",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"2",totalChapterViews:"0",totalEditedBooks:"2",institution:{name:"American University of Beirut",institutionURL:null,country:{name:"Lebanon"}}}],coeditorOne:{id:"450673",title:"Dr.",name:"Ali",middleName:null,surname:"El Safadi",slug:"ali-el-safadi",fullName:"Ali El Safadi",profilePictureURL:"https://intech-files.s3.amazonaws.com/a043Y00000rTNkyQAG/Co1_Profile_Picture__c%202021-12-20%2012%3A56%3A08.218",biography:null,institutionString:"American University of Beirut Medical Center",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"American University of Beirut Medical Center",institutionURL:null,country:{name:"Lebanon"}}},coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"16",title:"Medicine",slug:"medicine"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"184402",firstName:"Romina",lastName:"Rovan",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/184402/images/4747_n.jpg",email:"romina.r@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"10352",title:"Abdominal Surgery",subtitle:"A Brief Overview",isOpenForSubmission:!1,hash:"0d1d92b2286b03cf2fd8d88368d9d9cb",slug:"abdominal-surgery-a-brief-overview",bookSignature:"Ahmad Zaghal and Arwa El Rifai",coverURL:"https://cdn.intechopen.com/books/images_new/10352.jpg",editedByType:"Edited by",editors:[{id:"240621",title:"Dr.",name:"Ahmad",surname:"Zaghal",slug:"ahmad-zaghal",fullName:"Ahmad Zaghal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7985",title:"Circumcision and the Community",subtitle:null,isOpenForSubmission:!1,hash:"023cc135aeeae6d2ea8cfc01ab3f4dc7",slug:"circumcision-and-the-community",bookSignature:"Ahmad Zaghal and Nishat Rahman",coverURL:"https://cdn.intechopen.com/books/images_new/7985.jpg",editedByType:"Edited by",editors:[{id:"240621",title:"Dr.",name:"Ahmad",surname:"Zaghal",slug:"ahmad-zaghal",fullName:"Ahmad Zaghal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6550",title:"Cohort Studies in Health Sciences",subtitle:null,isOpenForSubmission:!1,hash:"01df5aba4fff1a84b37a2fdafa809660",slug:"cohort-studies-in-health-sciences",bookSignature:"R. Mauricio Barría",coverURL:"https://cdn.intechopen.com/books/images_new/6550.jpg",editedByType:"Edited by",editors:[{id:"88861",title:"Dr.",name:"R. Mauricio",surname:"Barría",slug:"r.-mauricio-barria",fullName:"R. Mauricio Barría"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9500",title:"Recent Advances in Bone Tumours and Osteoarthritis",subtitle:null,isOpenForSubmission:!1,hash:"ea4ec0d6ee01b88e264178886e3210ed",slug:"recent-advances-in-bone-tumours-and-osteoarthritis",bookSignature:"Hiran Amarasekera",coverURL:"https://cdn.intechopen.com/books/images_new/9500.jpg",editedByType:"Edited by",editors:[{id:"67634",title:"Dr.",name:"Hiran",surname:"Amarasekera",slug:"hiran-amarasekera",fullName:"Hiran Amarasekera"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2270",title:"Fourier Transform",subtitle:"Materials Analysis",isOpenForSubmission:!1,hash:"5e094b066da527193e878e160b4772af",slug:"fourier-transform-materials-analysis",bookSignature:"Salih Mohammed Salih",coverURL:"https://cdn.intechopen.com/books/images_new/2270.jpg",editedByType:"Edited by",editors:[{id:"111691",title:"Dr.Ing.",name:"Salih",surname:"Salih",slug:"salih-salih",fullName:"Salih Salih"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"75427",title:"Proprioception Impairment and Treatment Approaches in Pediatrics",doi:"10.5772/intechopen.96382",slug:"proprioception-impairment-and-treatment-approaches-in-pediatrics",body:'
1. Introduction
It is important to learn about the 7 senses. We all are familiar with the five senses and the other 2 senses are the Vestibular sense of balance, movement and Proprioception body position sense. By integrating, or combining all the information we get from our senses, we can ‘make sense’ of the world around us and successfully move through and interact in our world [1].
Proprioception is a continuous loop of feedback between sensory receptors throughout your body and your nervous system. Proprioception, also called kinesthesia, is the body’s ability to sense its location, movements, and actions. Children who are clumsy, uncoordinated, and sensory seeking are often experiencing proprioceptive dysfunction. The following are common signs of proprioceptive dysfunction:
Sensory Seeking (pushes, writes too hard, plays rough, bangs or shakes feet while sitting, chews, bites, and likes tight clothes)
Poor Motor Planning/Control and Body Awareness (difficulty going up and down stairs, bumps into people and objects frequently, difficulty riding a bike)
Poor Postural Control (slumps, unable to stand on one foot, needs to rest head on desk while working)
These children often self-regulate by engaging in behaviors that provide proprioceptive input such as toe walking, crashing, running or flapping. Heavy work or tasks that involve heavy resistance and input to the muscles and joints is essential to regulating proprioception [2].
Children that have difficulty sensing or processing proprioception often try to self-regulate by engaging in activities and/or behaviors that provide intense or frequent proprioceptive input [3].
Sensory Processing/Sensory Integration is when our different sensory systems work together to process different sensations from our body and/or environment. So, we are able to identify and give meaning to the different sensations we experience to accomplish daily activities and move in a coordinated manner. Sensory Processing Disorder is the inability to receive and efficiently use sensory information. Difficulty in processing sensory information interferes in our daily activities and impacts our functional ability to perform different tasks [4].
Benefits of sensory integration therapy may include: [5]
Modulation of sensory systems
Self-regulations
Improved function in school, home and community
Improved independence with activities of daily living (ADL)
Maximized functional ability to perform daily and recreational activities
Enhanced motor planning ability
Active involvement and exploration of environments
Efficient organization of sensory information
Assessment and intervention should explicitly focus on links among self-regulation, social participation, skills and perceived competence to address parents’ expectations [6].
Interventions are proposed that relate to children’s participation in contexts in which they live, learn, and play as well as the support of parents in the occupation of parenting [7].
Parents usually understand their child better than anyone else. They play an important role during the intervention and throughout their life time. I hope this chapter would enhance then to understand and give a clear picture of the child who have difficulty with proprioception dysfunction. The concept of this chapter comes from a body of work developed by A. Jean Ayres, PhD, OTR. This theory has been further developed and refined by the research of Dr. Ayres, and other occupational and physical therapists.
2. Proprioception impairment and treatment approaches in pediatrics
2.1 Proprioception
Proprioception refers to the sense of relative position and movement of the limbs and body.The mechanoreceptors embedded in the joint muscle, tendon and skin provides the proprioceptive information [8].
For good control of the muscle and voluntary movement proprioception is required. In pediatric conditions like CP, autism, Downs syndrome and development disorders it is always associated with proprioceptive deficits and hence the movement control is affected [9].
Proprioception provides ability to move. if there is any deficit in proprioception, our body movements would become slower, difficult and require more effort to perform a movement.
Processing of proprioception occurs:
Proprioception always integrates with tactile and vestibular system [10].
Sherrington has the first studies on these topics in 1906, he has been established that muscle spindles are a major source of proprioceptive feedback to the central nervous system and appear to mediate the conscious perception of movement and limb position for the proprioceptive information [11].
The development steps:
1 Month
The newborn will interpret some of his body sensations and respond with built in reflex movement respond to
Gravity and movement
Muscle and joint
sensation
Sound
Smell & taste
Touch
2 & 3 Months
Eyes and neck motor functions
Grasping
Raising up
4 to 6 Months
Arms & hands movements
Airplane position
Recognizes the moving and loved to be moved
6 to 8 Months
Locomotion
Spatial perception
Finger and eyes
Motor planning
Babbling
9 to 1 Months
Play
Standing up
Words
2 Years
Localization of touch
Moving
Mapping the body
Climbing
Self-hound
3rd to 7th Year
By 5 years the child becomes mature sensorimotor being.
The important age of development of sensory integration after birth is from 1st month to 7 years. Sensory stimulation, motor activity and exposure to environment during the early childhood have a great influence on the neurons and major role in the development of sensory and motor processes [12, 13].
2.2 Role of sensation
Sensations play a vital role in giving sensory input and information to the CNS. Every sensation is a type of information from the nervous system to produce a response and control the body and mind to the given information with a good amount of sensation or the sensory input is necessary for the development of the nervous system (Figures 1–5) [2, 14].
Figure 1.
Exteroceptors.
Figure 2.
Proprioceptors.
Figure 3.
Functions of propriocetion.
Figure 4.
Things to be consider.
Figure 5.
For parents.
3. The process of sensory integration
Proprioception sense which is provoked by getting the information from contraction and stretching of the muscles, pulling and compression of the joints between bones.
The sensation from one’s own body which occurs during movement both during static and dynamic and which always sends information to the brain about position is the proprioceptive sense [8].
Proprioception is the unconscious awareness of the body in space or at resting position. The somatosensory system plays a major role in the sensory integration.
The motor execution depends on somatosensory feedback.
Important for body balance and praxis
Important for reticular activating system.
Important for the development of muscle tone.
Proprioception helps us to move. When proprioception is affected the child finds it difficult to perform the normal movement. The child finds it difficult to walk, clumsier, slower and must give more effort to perform the normal movement [15].
Any deficit or problem in the proprioception will lead to sensory integration dysfunction.
Causes,
Hereditary factors
Developmental disabilities
Chemical factors
Due to lack of awareness about the neurological deficit, the parents will not be able to identify the problems or the difficulties faced by the children. They will not be able to analyze the learning and the behavioral problems are due to the sensory issue.
Sometimes lack of opportunities to play and explore and sometimes lack of interaction with the environment can also lead to these types of sensory seeking or sensory deficit in children.
It is always the responsibilities of the parents to give the child the required “sensory diet”. Sensory diet is the required amount of sensory input that the child can gain from interacting with the surrounding and peer groups through playing etc. and explore new ideas and techniques to play and enjoy.
3.1 Functions
The modulating influence of proprioception over the senses appears to occur at the level of cerebellum, thalamus and somatosensory cortex [16].
4. Proprioceptive dysfunction
Sensory seeking
Poor motor planning/Control and body awareness
Poor posture control
Balance affected
Uncoordinated movement
Clumsiness.
The deficit associated with proprioceptive system.
The under reactivity to typical sensory stimuli:
Hypo responsivity to proprioceptive input
Usually exhibit hypo responsivity to touch
Always seeks proprioceptive input to regulate or maintain state of arousal
Both over responsivity and under responsivity. Both extremes may occur in the same children [2].
Gravitational in severity, Vestibular proprioceptive disorders
Proprioceptive sensitivity.
4.1 Sensory diet
“The daily total of sensorimotor experience needed by a person to adaptively interact with the environment”.
Sensory diet is for the self-regulation. The importance of the proprioceptive system in to give a person with information on how far to reach, how much pressure, where we are in space, to learn about body schema. It involves movement, compression and stretching at a joint.
Ayres conceptualized SPD as a disorder of body scheme in which children misperceive their immediate space and their surrounding space. She believed that therapy based on a “sensory integration approach” would normalize the spatial perceptions from multiple sensory systems and contribute to successful participation in daily life activities [17, 18].
Several authors have reported on the motor control difficulties related to poor proprioceptive processing among children with ASD, including decreased postural control and motor planning, overreliance on proprioception, difficulty matching proprioception with vision during reach, decreased organization of space, and poor motor anticipation [19, 20].
5. How to give proprioceptive input
Proprioceptive input can be given in two different ways one is calming and other is excitatory.
Calming activities is usually given to child who is over aroused.
Excitatory proprioception inputs are given to under arouse and the excitatory input should increase arousal state of the child.
It is important to assess the child’s current state of arousal state of the child.
It is important to assess the child’s current state of arousal.
Proprioception always woks along with the vestibular system which has a great influence and effect on the child behavior of the child.
Heavy work activities activate proprioceptive receptors
A big ball pit, bean bag, rolling up with blankets and pillows, jumping on bed
Trampoline jumps gives a great proprioceptive input
Staircase walking with a ball. Ask the kids to climb up & down the stairs holding the ball for about 10 minutes 5 times followed by 1 minute rest 2 sets a day for 2 weeks.
Figure 7.
Balance board activities. Ask the kid to step on the balance board 8–10 minutes first with support and then without support then to reaching activity twice a day 2–3 weeks.
Figure 8.
Passing the ball. Ask the kid to pass the ball by kicking 10–15 minutes twice a day for 2–3 weeks.
Scooter board. Ask the kid to go for prone lying and using the hand pushing backwards to propel forward. 10–15 minutes twice daily 3–4 weeks.
Figure 11.
Swiss ball activities. Ask the kid to sit on the swiss ball & then bouncing followed by reaching activities 8–10 minutes twice daily 2–3 weeks.
The points to consider for giving proprioceptive input
The purpose is to decide whether the activity to be given should stimulate an under responsive or sensory seeking.
Secondly to identify the trigger points and suitable time to engage the child. We should identify when the child will get distracted.
We should observe the child and analyses when she/he reach the calm alert state. This will help us to identify how long and how often activities should be given.
Activities which can be done with parents at home can be taught to parents and the activities can be scheduled. Some activities like wall pushes, squeeze object, jumping etc.
Therapy based exercise.
Using a SI unit with various textures and different king of swings and mirrors to provide a visual feedback and the child can receive a maximum amount of proprioception input from the environment or the therapy room where it is well prepared for the child to receive the inputs.
The parents should try to analyses the behavior and the adaptive response that the child reacts or any changes which takes place before and after the therapy.
More often the sensory issues are mistaken for behavioral issue. The children always struggle with proprioceptive difficulties either hyperactive or decreased arousal level to perform their daily living activities.
First and foremost, the patient should analyses and whether the child avoid the proprioception inputs or seeing for proprioceptive input.
The parents should analyze and understand. If the child avoids the proprioceptive inputs
Always the child will be lethargic
Always tries to sit in a place
Condition like autism the child will not have eye contact or social interaction
The child will avoid physical activities
Lack of coordination
Inability to perform sports activities, climbing ladder and ropes
Develops poor body posture
If the child seeks proprioceptive input
The child always jumps and runs around
Always on the move
Aggressiveness
Biting, kicking, hitting, pushing
Always wants to chew and bite objects
A prolonged and multidimensional care is needed for the children [15].
There should always be an interaction between teacher, parent and therapist.
Sensory activities like deep breathing exercise with vital support. Sensory supports can be given with weighted blanked [21].
Assessment plays a major role in the development of the child integration. It is important to be aware of the assessment and evaluation required for the correct diagnosis for the child.
Therapist plays a major role to diagnose and to give the sensory integration Intervention.
Identification of sensory integrative deficit
Documentation of the level of function of the child
Appraisal / reappraisal changes based on the outcomes
Perform an informal assessment then with formal assessment the sensory integration and praxis tests “gold standard” for evaluating sensory integration and praxis functions.
SIPT is a standardized assessment tool with normative data for age limit 4–0 to 8–11 of age.
Some of the clinical outcome measures
OTA- Watertown clinical assessment which helps us to observe and examine sensory modulation and sensory discrimination.
Sensory profile (Dunn, 1994, 1999) Screens for SI dysfunction by assessing sensory responsiveness.
Sensory Integration Inventory (Rev. ed) (Reisman and Hansches, 1992) this screens for SI dysfunction.
7. Conclusions
Several studies have found evidence that children with sensory processing disorder can gain more insight into their development by assessing and providing an exact intervention at their right age and time. I hope this chapter would help out the parents to analyze the difficulties the children go through and guide them in the right path.
Acknowledgments
First of all, I praise the Almighty, who is above all for his glorious presence in me and for his blessings to complete this chapter.
I would like to convey my sincere thanks to Chancellor Dr.A.C.SHANMUGAM, B.A., B.L., President Er.A.C.S.ARUNKUMAR, B.Tech, M.B.A, Secretary Thiru.A.Ravikumar M.B.A and Vice chancellor prof.Dr.S.Geetha Lakshmi for giving me an opportunity to access the splendid resources in our university Dr.M.G.R Educational & Research Institute University.
I would like to express my sincere gratitude to the principal Dr.C.V.SENTHIL NATHAN M.P.T(Geriatrics), PGDDR, M.I.A.P, MHCPC, MISCP, for his constant support and guidance. Dr.M.G.R Educational & Research Institute University.
Finally, I would like to express my heartfelt thanks to my parents for their blessings and my beloved husband Dr.N.KAVIRAJA B.P.T, DBDT, M.I.A.P,MRCI,MD(ACU) and My son K.JISHNURAJ for their support &friends who have given many moments to cherish and treasure.
Conflict of interest
Nil.
\n',keywords:"proprioceptive dysfunction, sensory integration, gravitational insecurity, postural insecurity, modulation",chapterPDFUrl:"https://cdn.intechopen.com/pdfs/75427.pdf",chapterXML:"https://mts.intechopen.com/source/xml/75427.xml",downloadPdfUrl:"/chapter/pdf-download/75427",previewPdfUrl:"/chapter/pdf-preview/75427",totalDownloads:412,totalViews:0,totalCrossrefCites:0,totalDimensionsCites:0,totalAltmetricsMentions:0,introChapter:null,impactScore:0,impactScorePercentile:44,impactScoreQuartile:2,hasAltmetrics:0,dateSubmitted:"September 23rd 2020",dateReviewed:"February 3rd 2021",datePrePublished:"March 9th 2021",datePublished:"June 23rd 2021",dateFinished:"February 25th 2021",readingETA:"0",abstract:"In children problems like trauma and injuries are quite obvious. Other problems related to sensory system dysfunction are identified at the later stages of the child due to lack of awareness of the sensory integration problems which is not obvious. Some children have behavioral problems and some are poor at the school which is related to each other finally cause trouble to perform their daily routine. Early identification and intervention play a major role in improving the ability and development of the proprioceptive senses. Hence this chapter will introduce the new aspect of proprioception sense and its dysfunction. It would enhance you to identify the problems and understand the challenges that the child come across due to increase or decrease in proprioceptive input. We will be able to help them to overcome these challenges and frame a treatment strategy and help them to lead a successful life.",reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/75427",risUrl:"/chapter/ris/75427",book:{id:"10554",slug:"proprioception"},signatures:"Kamatchi Kaviraja",authors:[{id:"332439",title:"Dr.",name:"Kaviraja",middleName:null,surname:"Kamatchi",fullName:"Kaviraja Kamatchi",slug:"kaviraja-kamatchi",email:"kamatchi.physio@drmgrdu.ac.in",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Dr. M.G.R. Educational and Research Institute",institutionURL:null,country:{name:"India"}}}],sections:[{id:"sec_1",title:"1. Introduction",level:"1"},{id:"sec_2",title:"2. Proprioception impairment and treatment approaches in pediatrics",level:"1"},{id:"sec_2_2",title:"2.1 Proprioception",level:"2"},{id:"sec_3_2",title:"2.2 Role of sensation",level:"2"},{id:"sec_5",title:"3. The process of sensory integration",level:"1"},{id:"sec_5_2",title:"3.1 Functions",level:"2"},{id:"sec_7",title:"4. Proprioceptive dysfunction",level:"1"},{id:"sec_7_2",title:"4.1 Sensory diet",level:"2"},{id:"sec_9",title:"5. How to give proprioceptive input",level:"1"},{id:"sec_10",title:"6. Oral activities",level:"1"},{id:"sec_11",title:"7. Conclusions",level:"1"},{id:"sec_12",title:"Acknowledgments",level:"1"},{id:"sec_15",title:"Conflict of interest",level:"1"}],chapterReferences:[{id:"B1",body:'Importance of Sensory Integration [Internet]. Vol. 501, Pathways. 2013. p. 2445. Available from: https://pathways.org/watch/importance-of-sensory-integration/#:∼:text=Puttingtogether information from all,and interact in our world'},{id:"B2",body:'Blanche EI, Reinoso G, Chang MC, Bodison S. Proprioceptive processing difficulties among children with autism spectrum disorders and developmental disabilities. American Journal of Occupational Therapy. 2012 Sep 1;66(5):621–4. DOI: 10.5014/ajot.2012.004234'},{id:"B3",body:'Hansen A. What is Proprioception and Why is it Important? [Internet]. sonoran sun pediatric therapy. 2017. Available from: https://sonoransunpediatrictherapy.com/2017/11/16/what-is-proprioception-and-why-is-it-important/#:∼:text=To put it simply%2C proprioception, attend and focus%2C and speech'},{id:"B4",body:'What is Sensory Integration and Why is it Important in a Child’s Development? [Internet]. Arizona Orthopedic Physical Therapy. 2013. Available from: https://azopt.net/sensory-integration/'},{id:"B5",body:'Sensory Integration Therapy [Internet]. American Academy of Pediatrics. 2012. Available from: https://www.healthychildren.org/English/health-issues/conditions/developmental-disabilities/Pages/Sensory-Integration-Therapy.aspx'},{id:"B6",body:'Cohn ES, Kramer J, Schub JA, May-Benson T. Parents’ explanatory models and hopes for outcomes of occupational therapy using a sensory integration approach. American Journal of Occupational Therapy. 2014 Jul 1;68(4):454–62. DOI: 10.5014/ajot.2014.010843'},{id:"B7",body:'Cohn E, Miller LJ, Tickle-Degnen L. Parental hopes for therapy outcomes: Children with sensory modulation disorders. American Journal of Occupational Therapy. 2000 Jan 1;54(1):36–43. DOI: 10.5014/ajot.54.1.36'},{id:"B8",body:'Buderath P, Gärtner K, Frings M, Christiansen H, Schoch B, Konczak J, Gizewski ER, Hebebrand J, Timmann D. Postural and gait performance in children with attention deficit/hyperactivity disorder. Gait & posture. 2009 Feb 1;29(2):249–54. DOI: 10.1016/j.gaitpost.2008.08.016'},{id:"B9",body:'Holst-Wolf JM, Yeh I, Konczak J. Development of proprioceptive acuity in typically developing children: normative data on forearm position sense. Frontiers in human neuroscience. 2016 Aug 29;10:436. DOI: 10.3389/fnhum.2016.00436'},{id:"B10",body:'Roley SS, Blanche EI, Schaaf RC. Understanding the nature of sensory integration with diverse populations. Pro-Ed; 2001'},{id:"B11",body:'Sherrington C. The Integrative Action of the Nervous System. The Journal of Nervous and Mental Disease. 1907 Dec 1;34(12):801–2'},{id:"B12",body:'Ayres AJ, Robbins J. Sensory integration and the child: Understanding hidden sensory challenges. Western Psychological Services; 2005'},{id:"B13",body:'Tugay N, Tugay BU. Proprioception : The Forgotten Sixth Sense. Proprioception after Arthroplast. 2015;(June)'},{id:"B14",body:'Proprioceptive [Internet]. Middle Town Centre for Autism - Sensory Processing Resources. Available from: https://sensory-processing.middletownautism.com/sensory-strategies/strategies-according-to-sense/proprioceptive/#1'},{id:"B15",body:'Montgomery P, Richter E. Effect of sensory integrative therapy on the neuromotor development of retarded children. Physical Therapy. 1977 Jul 1;57(7):799–806. DOI: 10.1093/ptj/57.7.799'},{id:"B16",body:'Should I Discipline My Child’s Sensory Seeking Behavior? [Internet]. Brain Balance. Available from: https://blog.brainbalancecenters.com/should-i-discipline-my-childs-sensory-seeking-behavior'},{id:"B17",body:'Ayres AJ. Development of the body scheme in children. The American journal of occupational therapy: official publication of the American Occupational Therapy Association. 1961 May 1;15:99–102'},{id:"B18",body:'Ayres AJ. Sensorimotor foundations of academic ability. Perceptual and learning disabilities in children. 1975;2:301–58'},{id:"B19",body:'Weimer AK, Schatz AM, Lincoln A, Ballantyne AO, Trauner DA. “Motor” impairment in Asperger syndrome: evidence for a deficit in proprioception. Journal of Developmental & Behavioral Pediatrics. 2001 Apr 1;22(2):92–101. DOI: 10.1097/00004703-200104000-00002'},{id:"B20",body:'Schmitz C, Martineau J, Barthélémy C, Assaiante C. Motor control and children with autism: deficit of anticipatory function?. Neuroscience letters. 2003 Sep 4;348(1):17–20. DOI: 10.1016/S0304-3940(03)00644-X'},{id:"B21",body:'Christy E. Yee O. Sensory Diet Chart. 1995;1–2'}],footnotes:[],contributors:[{corresp:"yes",contributorFullName:"Kamatchi Kaviraja",address:"kamatchi.physio@drmgrdu.ac.in",affiliation:'
Faculty of Physiotherapy, Dr. M.G.R Educational and Research Institute, Velappanchavadi, Chennai, Tamil Nadu, India
'}],corrections:null},book:{id:"10554",type:"book",title:"Proprioception",subtitle:null,fullTitle:"Proprioception",slug:"proprioception",publishedDate:"June 23rd 2021",bookSignature:"José A. Vega and Juan Cobo",coverURL:"https://cdn.intechopen.com/books/images_new/10554.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",isbn:"978-1-83968-070-0",printIsbn:"978-1-83968-069-4",pdfIsbn:"978-1-83968-074-8",reviewType:"peer-reviewed",numberOfWosCitations:2,isAvailableForWebshopOrdering:!0,editors:[{id:"59892",title:"Prof.",name:"José A.",middleName:null,surname:"Vega",slug:"jose-a.-vega",fullName:"José A. Vega"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:{id:"100648",title:"Dr.",name:"Juan",middleName:null,surname:"Cobo",slug:"juan-cobo",fullName:"Juan Cobo"},coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"213"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"75762",type:"chapter",title:"Structural and Biological Basis for Proprioception",slug:"structural-and-biological-basis-for-proprioception",totalDownloads:532,totalCrossrefCites:1,signatures:"José A. Vega and Juan Cobo",reviewType:"peer-reviewed",authors:[{id:"59892",title:"Prof.",name:"José A.",middleName:null,surname:"Vega",fullName:"José A. Vega",slug:"jose-a.-vega"},{id:"100648",title:"Dr.",name:"Juan",middleName:null,surname:"Cobo",fullName:"Juan Cobo",slug:"juan-cobo"}]},{id:"75009",type:"chapter",title:"Proprioception and Clinical Correlation",slug:"proprioception-and-clinical-correlation",totalDownloads:530,totalCrossrefCites:0,signatures:"Pinar Gelener, Gözde İyigün and Ramadan Özmanevra",reviewType:"peer-reviewed",authors:[{id:"234748",title:"Dr.",name:"Pinar",middleName:null,surname:"Gelener",fullName:"Pinar Gelener",slug:"pinar-gelener"},{id:"342237",title:"Associate Prof.",name:"Ramadan",middleName:null,surname:"Özmanevra",fullName:"Ramadan Özmanevra",slug:"ramadan-ozmanevra"},{id:"342238",title:"Associate Prof.",name:"Gözde",middleName:null,surname:"Iyigün",fullName:"Gözde Iyigün",slug:"gozde-iyigun"}]},{id:"74729",type:"chapter",title:"Recording of Proprioceptive Muscle Reflexes in the Lower Extremity",slug:"recording-of-proprioceptive-muscle-reflexes-in-the-lower-extremity",totalDownloads:336,totalCrossrefCites:0,signatures:"Juhani Partanen, Urho Sompa and Miguel Muñoz-Ruiz",reviewType:"peer-reviewed",authors:[{id:"215350",title:"Dr.",name:"Juhani",middleName:null,surname:"Partanen",fullName:"Juhani Partanen",slug:"juhani-partanen"},{id:"343231",title:"Dr.",name:"Urho",middleName:null,surname:"Sompa",fullName:"Urho Sompa",slug:"urho-sompa"},{id:"343232",title:"Dr.",name:"Miguel",middleName:"Angel",surname:"Muñoz-Ruiz",fullName:"Miguel Muñoz-Ruiz",slug:"miguel-munoz-ruiz"}]},{id:"74257",type:"chapter",title:"The Knee Proprioception as Patient-Dependent Outcome Measures within Surgical and Non-Surgical Interventions",slug:"the-knee-proprioception-as-patient-dependent-outcome-measures-within-surgical-and-non-surgical-inter",totalDownloads:402,totalCrossrefCites:0,signatures:"Wangdo Kim",reviewType:"peer-reviewed",authors:[{id:"216754",title:"Ph.D.",name:"Wangdo",middleName:null,surname:"Kim",fullName:"Wangdo Kim",slug:"wangdo-kim"}]},{id:"76398",type:"chapter",title:"Proprioceptors in Cephalic Muscles",slug:"proprioceptors-in-cephalic-muscles",totalDownloads:308,totalCrossrefCites:0,signatures:"Juan L. Cobo, Sonsoles Junquera, José Martín-Cruces, Antonio Solé-Magdalena, Olivia García-Suárez and Teresa Cobo",reviewType:"peer-reviewed",authors:[{id:"270071",title:"Prof.",name:"Juan L.",middleName:null,surname:"Cobo",fullName:"Juan L. Cobo",slug:"juan-l.-cobo"}]},{id:"75427",type:"chapter",title:"Proprioception Impairment and Treatment Approaches in Pediatrics",slug:"proprioception-impairment-and-treatment-approaches-in-pediatrics",totalDownloads:412,totalCrossrefCites:0,signatures:"Kamatchi Kaviraja",reviewType:"peer-reviewed",authors:[{id:"332439",title:"Dr.",name:"Kaviraja",middleName:null,surname:"Kamatchi",fullName:"Kaviraja Kamatchi",slug:"kaviraja-kamatchi"}]},{id:"74677",type:"chapter",title:"Proprioceptive Perception: An Emergence of the Interaction of Body and Language",slug:"proprioceptive-perception-an-emergence-of-the-interaction-of-body-and-language",totalDownloads:367,totalCrossrefCites:0,signatures:"Alejandra Vasquez-Rosati and Carmen Cordero-Homad",reviewType:"peer-reviewed",authors:[{id:"331407",title:"Ph.D.",name:"Alejandra",middleName:null,surname:"Vasquez-Rosati",fullName:"Alejandra Vasquez-Rosati",slug:"alejandra-vasquez-rosati"},{id:"333809",title:"Prof.",name:"Carmen",middleName:null,surname:"Cordero",fullName:"Carmen Cordero",slug:"carmen-cordero"}]},{id:"75834",type:"chapter",title:"Nomophobia Kids and Proprioception",slug:"nomophobia-kids-and-proprioception",totalDownloads:332,totalCrossrefCites:0,signatures:"Giridharan Vaishnavi",reviewType:"peer-reviewed",authors:[{id:"333944",title:"Dr.",name:"Giridharan",middleName:null,surname:"Vaishnavi",fullName:"Giridharan Vaishnavi",slug:"giridharan-vaishnavi"}]},{id:"75326",type:"chapter",title:"Proprioception in Immersive Virtual Reality",slug:"proprioception-in-immersive-virtual-reality",totalDownloads:355,totalCrossrefCites:0,signatures:"Alexander Vladimirovich Zakharov, Alexander Vladimirovich Kolsanov, Elena Viktorovna Khivintseva, Vasiliy Fedorovich Pyatin and Alexander Vladimirovich Yashkov",reviewType:"peer-reviewed",authors:[{id:"314711",title:"M.D.",name:"Alexander Vladimirovich",middleName:null,surname:"Zakharov",fullName:"Alexander Vladimirovich Zakharov",slug:"alexander-vladimirovich-zakharov"},{id:"314712",title:"Dr.",name:"Elena Viktorovna",middleName:null,surname:"Khivintseva",fullName:"Elena Viktorovna Khivintseva",slug:"elena-viktorovna-khivintseva"},{id:"346435",title:"Prof.",name:"Alexander Vladimirovich",middleName:null,surname:"Kolsanov",fullName:"Alexander Vladimirovich Kolsanov",slug:"alexander-vladimirovich-kolsanov"},{id:"346465",title:"Prof.",name:"Alexander Vladimirovich",middleName:null,surname:"Yashkov",fullName:"Alexander Vladimirovich Yashkov",slug:"alexander-vladimirovich-yashkov"},{id:"346496",title:"Prof.",name:"Vasiliy Fedorovich",middleName:null,surname:"Pyatin",fullName:"Vasiliy Fedorovich Pyatin",slug:"vasiliy-fedorovich-pyatin"}]}]},relatedBooks:[{type:"book",id:"6907",title:"Feed Your Mind",subtitle:"How Does Nutrition Modulate Brain Function throughout Life?",isOpenForSubmission:!1,hash:"91a663d09b6d6e80db3a69fca11e5b68",slug:"feed-your-mind-how-does-nutrition-modulate-brain-function-throughout-life-",bookSignature:"Clémentine Bosch-Bouju, Sophie Layé and Véronique Pallet",coverURL:"https://cdn.intechopen.com/books/images_new/6907.jpg",editedByType:"Edited by",editors:[{id:"265901",title:"Dr.",name:"Clémentine",surname:"Bosch-Bouju",slug:"clementine-bosch-bouju",fullName:"Clémentine Bosch-Bouju"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"69232",title:"Introductory Chapter: Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?",slug:"introductory-chapter-feed-your-mind-how-does-nutrition-modulate-brain-function-throughout-life-",signatures:"Clémentine Bosch-Bouju",authors:[{id:"265901",title:"Dr.",name:"Clémentine",middleName:null,surname:"Bosch-Bouju",fullName:"Clémentine Bosch-Bouju",slug:"clementine-bosch-bouju"}]},{id:"68423",title:"Polyunsaturated Fatty Acid Metabolism in the Brain and Brain Cells",slug:"polyunsaturated-fatty-acid-metabolism-in-the-brain-and-brain-cells",signatures:"Corinne Joffre",authors:[{id:"281107",title:"Dr.",name:"Corinne",middleName:null,surname:"Joffre",fullName:"Corinne Joffre",slug:"corinne-joffre"}]},{id:"68362",title:"Carbohydrates and the Brain: Roles and Impact",slug:"carbohydrates-and-the-brain-roles-and-impact",signatures:"Xavier Fioramonti and Luc Pénicaud",authors:[{id:"281112",title:"Ph.D.",name:"Xavier",middleName:null,surname:"Fioramonti",fullName:"Xavier Fioramonti",slug:"xavier-fioramonti"},{id:"281113",title:"Dr.",name:"Luc",middleName:null,surname:"Pénicaud",fullName:"Luc Pénicaud",slug:"luc-penicaud"}]},{id:"66223",title:"Dietary Impact on Neuronal Autophagy Control and Brain Health",slug:"dietary-impact-on-neuronal-autophagy-control-and-brain-health",signatures:"Claudia Ntsapi, Andre du Toit and Ben Loos",authors:[{id:"148642",title:"Dr.",name:"Ben",middleName:null,surname:"Loos",fullName:"Ben Loos",slug:"ben-loos"},{id:"187297",title:"Mrs.",name:"Claudia",middleName:null,surname:"Ntsapi",fullName:"Claudia Ntsapi",slug:"claudia-ntsapi"},{id:"295702",title:"Dr.",name:"Andre",middleName:null,surname:"du Toit",fullName:"Andre du Toit",slug:"andre-du-toit"}]},{id:"65073",title:"Enteral Feeding: Brain-Visceral Interactions in the Processing of Nutrients",slug:"enteral-feeding-brain-visceral-interactions-in-the-processing-of-nutrients",signatures:"María Angeles Zafra Palma, Javier Mahía, María J. Simón, Filomena Molina and Amadeo Puerto",authors:[{id:"202078",title:"Dr.",name:"Javier",middleName:null,surname:"Mahía",fullName:"Javier Mahía",slug:"javier-mahia"},{id:"202079",title:"Dr.",name:"Amadeo",middleName:null,surname:"Puerto",fullName:"Amadeo Puerto",slug:"amadeo-puerto"},{id:"272834",title:"Dr.",name:"María Ángeles",middleName:null,surname:"Zafra Palma",fullName:"María Ángeles Zafra Palma",slug:"maria-angeles-zafra-palma"},{id:"284925",title:"Dr.",name:"María J.",middleName:null,surname:"Simón",fullName:"María J. Simón",slug:"maria-j.-simon"},{id:"284926",title:"Dr.",name:"Filomena",middleName:null,surname:"Molina",fullName:"Filomena Molina",slug:"filomena-molina"}]}]}],publishedBooks:[{type:"book",id:"6808",title:"Autonomic Nervous System",subtitle:null,isOpenForSubmission:!1,hash:"d95e7c43f124d1a6e39b88862a917fc1",slug:"autonomic-nervous-system",bookSignature:"Pavol Svorc",coverURL:"https://cdn.intechopen.com/books/images_new/6808.jpg",editedByType:"Edited by",editors:[{id:"169212",title:"Prof.",name:"Pavol",surname:"Svorc",slug:"pavol-svorc",fullName:"Pavol Svorc"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6899",title:"Chronobiology",subtitle:"The Science of Biological Time Structure",isOpenForSubmission:!1,hash:"521dfb38a216470da6f8f7d02469832c",slug:"chronobiology-the-science-of-biological-time-structure",bookSignature:"Pavol Svorc",coverURL:"https://cdn.intechopen.com/books/images_new/6899.jpg",editedByType:"Edited by",editors:[{id:"169212",title:"Prof.",name:"Pavol",surname:"Svorc",slug:"pavol-svorc",fullName:"Pavol Svorc"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6991",title:"Neurons",subtitle:"Dendrites and Axons",isOpenForSubmission:!1,hash:"696489f55e1077935f47087fa3829b5f",slug:"neurons-dendrites-and-axons",bookSignature:"Gonzalo Emiliano Aranda Abreu and María Elena Hernández Aguilar",coverURL:"https://cdn.intechopen.com/books/images_new/6991.jpg",editedByType:"Edited by",editors:[{id:"72314",title:"Dr.",name:"Gonzalo Emiliano",surname:"Aranda Abreu",slug:"gonzalo-emiliano-aranda-abreu",fullName:"Gonzalo Emiliano Aranda Abreu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9347",title:"Neuroimaging",subtitle:"Neurobiology, Multimodal and Network Applications",isOpenForSubmission:!1,hash:"a3479e76c6ac538aac76409c9efb7e41",slug:"neuroimaging-neurobiology-multimodal-and-network-applications",bookSignature:"Yongxia Zhou",coverURL:"https://cdn.intechopen.com/books/images_new/9347.jpg",editedByType:"Edited by",editors:[{id:"259308",title:"Dr.",name:"Yongxia",surname:"Zhou",slug:"yongxia-zhou",fullName:"Yongxia Zhou"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10554",title:"Proprioception",subtitle:null,isOpenForSubmission:!1,hash:"e104e615fbd94caa987df3a8d8b3fb8b",slug:"proprioception",bookSignature:"José A. Vega and Juan Cobo",coverURL:"https://cdn.intechopen.com/books/images_new/10554.jpg",editedByType:"Edited by",editors:[{id:"59892",title:"Prof.",name:"José A.",surname:"Vega",slug:"jose-a.-vega",fullName:"José A. Vega"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],publishedBooksByAuthor:[{type:"book",id:"10554",title:"Proprioception",subtitle:null,isOpenForSubmission:!1,hash:"e104e615fbd94caa987df3a8d8b3fb8b",slug:"proprioception",bookSignature:"José A. Vega and Juan Cobo",coverURL:"https://cdn.intechopen.com/books/images_new/10554.jpg",editedByType:"Edited by",editors:[{id:"59892",title:"Prof.",name:"José A.",surname:"Vega",slug:"jose-a.-vega",fullName:"José A. Vega"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},onlineFirst:{chapter:{type:"chapter",id:"81569",title:"Impact of Interferon Alpha/Beta in the Management of Chronic Myeloproliferative Disorders",doi:"10.5772/intechopen.104501",slug:"impact-of-interferon-alpha-beta-in-the-management-of-chronic-myeloproliferative-disorders",body:'
1. Introduction
Chronic myeloproliferative disorders are a group of clonal diseases of the stem cell. It is a group of several diseases with some common features. They derive from a multipotential hematopoietic stem cell. A clone of neoplastic cells in all these neoplams is characterized by a lower proliferative activity than that of acute myeloproliferative diseases. In each of these diseases, leukocytosis, thrombocythemia, and polyglobulia may appear at some stage, depending on the diagnosis [1, 2].
The research on interferon has been going on since the 1950s [3]. Then, the attention was paid to its influence on the immune system. It has been noted that it can exert an antiproliferative effect by stimulating cells of the immune system [4]. In 1987, a publication by Ludwig et al. was published, which reported the effectiveness of interferon alpha in the treatment of chronic myeloproliferative disorders [5].
More and more new studies have been showing the effectiveness of interferon alpha in reducing the number of platelets, reducing the need for phlebotomies in patients with polycythemia vera and also in reducing the number of leukocytes. Moreover, interferon reduced the symptoms of myeloproliferative disorders such as redness and itching of the skin. Additionally, it turned out to be effective in reducing the size of the spleen.
Further studies on the assessment of remission using molecular-level response assessments indicate that the interferon action in chronic myeloproliferation diseases targets cells from the mutant clone with no effect on normal bone marrow cells [6].
Over the years, interferon alpha-2a and interferon alpha-2b have been introduced into the treatment of chronic myeloproliferation, followed by their pegylated forms. The introduction of pegylated forms allowed for a reduction in the number of side effects and less frequent administration of the drug to patients. In recent years, monopegylated interferon alpha-2b has been used to further increase the interval between drug administrations while maintaining its antiproliferative efficacy.
The exact mechanism of action of interferon alpha in the treatment of chronic myeloproliferative disease is still not fully understood, but it has an impact on JAK2 (Janus Kinase) signal transducers and activates the STAT signal pathway (Janus Kinase/SignalTransducer and Activator of Transcription).
Interferon alpha binds to IFNAR1 and IFNAR2c, which are type I interferon receptors. Interferon alpha has an impact on JAK2(Janus Kinase) signal transducers and activates the STAT signal pathway. The disturbances in this signaling pathway are observed in chronic myeloproliferative disorders [7].
Interferon inhibits the JAK-STAT signaling pathway by directly inhibiting the action of thrombopoietin in this pathway [8].
So far, three driver mutations have been described in the course of chronic myeloproliferative diseases that affect the functioning of the JAK-STAT pathway.
JAK2 kinase and JAK1, JAK3, and TYK2 kinases belong to the family of non-receptor tyrosine kinases. They are involved in the intracellular signal transduction of the JAK-STAT pathway. It is a system of intracellular proteins used by growth factors and cytokines to express genes that regulate cell activation, proliferation, and differentiation. The mechanism of JAK activation is based on the autophosphorylation of tyrosine residues that occurs after ligand binds to the receptor. JAK2 kinase transmits signals from the hematopoietic cytokine receptors of the myeloid lineage (erythropoietin, granulocyte-colony stimulating factor thrombopoietin, and lymphoid lineage [9].
A somatic G/T point mutation in exon 14 of the JAK2 kinase gene converts valine to phenylalanine at position 617 (V617F) in the JAK2 pseudokinase domain, which allows constitutive, ligand-independent activation of the receptor to trigger a proliferative signal [10].
Mutation of the MPL gene, which encodes the receptor for thrombopoietin, increases the sensitivity of magekaryocytes to the action of thrombopoietin, which stimulates their proliferation [11].
Malfunction of calreticulin as a result of mutation of the CARL gene leads to the activation of the MPL-JAK/STAT signaling pathway, which is independent of the ligand, as calreticulin is responsible, for the proper formation of the MPL receptor. Consequently, there is a clonal proliferation of hematopoietic stem cells [12].
Below, we provide an overview of some clinical studies on the efficacy of interferon in chronic myeloproliferative disorders.
2. Chronic myeloproliferative disorders
2.1 Polycythemia vera
Polycythemia vera (PV) is characterized by an increase in the number of erythrocytes in the peripheral blood.
Polycythemia vera is caused by a clonal mutation in the multipotential hematopoietic stem cell of the bone marrow. The mutation leads to an uncontrolled proliferation of the mutated cell clone, independent of erythropoietin and other regulatory factors. As the mutation takes place at an early stage of hematopoiesis, an increase of the number of erythrocytes as well as of leukocytes and platelets is observed in the peripheral blood. The cause of proliferation in PV independent from external factors is a mutation in the Janus 2 (JAK2) tyrosine kinase gene. The V617F point mutation in the JAK2 gene is responsible for about 96% mutation, and in the remaining cases the mutation arises in exon 12. Both mutations lead to constitutive activation of the JAK-STAT signaling pathway [13].
As a result of the uncontrolled proliferation, blood viscosity increases, which generates symptoms such as headaches and dizziness, visual disturbances, or erythromelalgia. As the number of all hematopoietic cells, including the granulocytes ones, increases, the difficult to control symptoms of their hyperdegranulation may appear, among which gastric ulcer or skin itching is often observed. During the disease progression, the spleen and liver become enlarged.
The most common complication of the disease is episodes of thrombosis, especially arterial one. During the course of the disease, it can also evolve into myelofibrosis or acute myeloid leukemia.
The treatment of PV is aimed at preventing thromboembolic complications, relieving the general symptoms, the appearance of hepatosplenomegaly as well as preventing its progression.
Each patient should receive an antiplatelet drug chronically, and usually acetylsalicylic acid is the choice. Most often, the treatment is started with phlebotomy in order to rapidly lower the hematocrit level. If cytoreductive therapy is necessary, the drugs of first choice are hydroxycarbamide and interferon [2].
However, the research on the mechanism of the action of interferons is still ongoing. In vitro studies with CD34+ cells from peripheral blood of patients diagnosed with polycythemia vera showed that interferon inhibits clonal changed cells selectively. It was found that interferon alpha-2b and pegylated interferon alpha-2a reduce the percentage of cells with JAK2 V617F mutation by about 40%. Pegylated interferon alpha-2a works by activating mitogen-activated protein kinase P38. It affects CD34+ cells of patients with polycythemia vera by increasing the rate of their apoptosis [6].
A case of a patient with PV with a confirmed chromosomal translocation t(6;8) treated with interferon alpha-2b, which resulted in a reduction of the clone with translocation by 50% from the baseline value, was also described [14].
In 2019, the results of a phase II multicenter study were published, which aimed at assessing the effectiveness of recombinant pegylated interferon alpha-2a in cases of refractory to previously hydroxycarbamide therapy. The study included 65 patients with essential thrombocythemia (ET) and 50 patients with polycythemia vera. All patients had previously been treated with hydroxycarbamide and showed resistance to this drug or its intolerance.
The assessment of the response was performed after 12 months of treatment. Overall response rate to interferon was higher in patients diagnosed with ET than in patients with polycythemia vera. In essential thrombocythemia, the percentage of achieved complete remissions was 43 and 26% of partial remissions. The remission rate in ET patients was higher if calreticulin CALR gene mutation was present. Patients with polycythemia vera achieved complete remission in 22% of cases and partial remission in 38% of cases.
Treatment-related side effects that follow to discontinuation of treatment were reported in almost 14% of patients [15].
The duration of response to treatment with pegylated interferon alpha-2a and the assessment of its safety in long-term use in patients with chronic myeloproliferative disorders was the goal of a phase II of the single-center study. Forty-three adult patients with polycythemia vera and 40 patients with essential thrombocythemia were enrolled in the study. The complete hematological response was defined as a decrease in hemoglobin concentration below 15.0 g/l, without phlebotomies, a resolution of splenomegaly, and no thrombotic episodes in the case of PV, and for essential thrombocythemia—a decrease platelet count below 440,000/μl and two other conditions as above. The assessment of the hematological response was performed every 3–6 months. The median follow-up was 83 months.
The hematological response was obtained in 80% of cases for the entire group. In patients with polycythemia vera, 77% of patients achieved a complete response (CR) while 7% a partial response (PR). The duration of response averaged 65 months for CR and 35 months for PR. In the group of patients diagnosed with essential thrombocythemia, CR was achieved in 73% and PR in 3%. The durance of CR was 58 months and PR was 25 months.
The molecular response for the entire group was achieved in 63% of cases.
The overall analysis showed that the duration of hematological remission and its achievement with pegylated interferon alpha-2a treatment is not affected neither by baseline disease characteristics nor JAK2 allele burden and disease molecular status. There was also no effect on age, sex, or the presence of splenomegaly.
During the course of the study, 22% of patients discontinued the treatment, because of toxicity. Toxicity was the greatest at the beginning of treatment. The starting dose was 450 μg per week and was gradually tapered off.
Thus, on the basis of the above observations, the researchers established that pegylated interferon alpha-2a may give long-term hematological and molecular remissions [16].
The assessment of pegylated interferon alpha-2a in group of patients diagnosed with polycythemia vera only was performed. The evaluation was carried out on a group of 27 patients. Interferon decreased the JAK2 V617F allele burden in 89% of cases. In three patients who were JAK2 homozygous at baseline, after the interferon alpha-2a treatment wild-type of JAK2 reappeared. The reduction of the JAK2 allele burden was estimated from 49% to an average 27%, and additional in one patient the mutant JAK2 allele was not detectable after treatment. It can therefore be postulated that the action of pegylated interferon alpha-2a is directed to cells of the polycythemia vera clone [17].
In 2005, the results of treatment by pegylated interferon alpha-2b of 21 patients diagnosed with polycythemia vera and 21 patients diagnosed with essential thrombocythemia were published. In the case of polycythemia vera in 14 patients, PRV-1 gene mutation was initially detected. In 36% of cases, PRV-1 expression normalized after treatment with pegylated interferon alpha-2b. For the entire group of 42 patients, the remission assessment showed that complete remission was achieved in 69% cases after 6 months of treatment. However, only in 19 patients remission was still maintained 2 years after the start of the study. Pegylated interferon alpha-2b was equally effective in patients with PV and ET. The use and the type of prior therapy did not affect the achievement of remission [18].
Another study with enrolled only PV patients included 136 patients. They were divided into two arms. One group received interferon alpha-2b and the other group received hydroxycarbamide. Interferon dosage was administered in 3 million units three times a week for 2 years and then 5 million units two times a week. Hydroxycarbamide was administered at a dose between 15 and 20 mg/kg/day.
In the group of patients treated with interferon, a significantly lower percentage of patients developed erythromelalgia (9.4%) and distal parasthesia (14%) compared with the group treated with hydroxycarbamide, for whom these percentages were respectively: 29 and 37.5%. Interferon alpha-2b was found to be more effective in inducing a molecular response, which was achieved in 54.7% of cases, in comparison with hydroxycarbamide—19.4% of cases, despite the fact that the percentage of achieved general hematological responses did not differ between the groups and amounted about 70%. The 5-year progression free period in the interferon group was achieved in a higher percentage (66%) than in the hydroxycarbamide group (46.7%) [19].
The most recent form of interferon approved by the European Medicines Agency (EMA) for the treatment of patients is ropeginterferon. It is human recombinant interferon alpha-2b. Ropeginterferon is a monopegylated form of interferon alpha-2b. Ropeginterferon is conjugated with a two-arm methoxypolyethylene glycol (mPEG).
Thanks to these changes to the structure of the molecule, it was possible to achieve a significant increase in its half-life. Ropeginterferon can be administered subcutaneously to patients every 14 days. The clinical trials conducted so far have assessed the ropeginterferon dose from 50 micrograms to a maximum dose of 500 microgams administered as standard every 2 weeks. The possible dose change in case of side effects includes not only the reduction of the drug dose itself, but also the extension of the interval between doses. The extension of the dosing interval up to 4 weeks was assessed.
Ropeginterforn was approved in 2019 by the EMA for the use in patients diagnosed with polycythemia vera without splenomegaly, as monotherapy.
Ropeginterferon, like the previous forms of interferons used in treatment, is contraindicated in patients with severe mental disorders, such as severe depression. It is also a contraindication in patients with noncompensatory standard treatment of disorders of the thyroid gland as well as severe forms of autoimmune diseases. The safety profile of ropeginterferon is similar to that of other forms of alpha interferons. The most common side effects are flu-like symptoms [20].
Ropeginterferon has been shown to exhibit in vitro activity against JAK2-mutant cells. The activity of ropeginterferon against JAK2-positive cells is similar to that of other forms of interferons used actually for standard therapy. Ropeginterferon has an inhibitory effect on erythroid progenitor cells with a mutant JAK2 gene. At the same time, it has almost no effect on progenitor cells without the mutated allele (JAK2-wile-type) and normal CD34+ cells. A gradual decrease of JAK2-positive cells was observed in patients with PV during ropeginterferon treatment. The examination was performed after 6 and 12 months of treatment. In comparison, the reduction in the percentage of JAK2 positive cells in patients treated with hydroxycarbamide was significantly lower.
These results may suggest that ropeginterferon may cause elimination of the mutant clone, but further prospective clinical trials are needed to confirm this theory. The evaluation was performed on a group of patients enrolled in the PROUD-PV study who were treated in France [21].
In 2017, a multicenter study was opened in Italy. The study was of the second phase. In total, 127 patients with polycythemia vera were included in the study. All patients enrolled on the study had low-risk PV. The clinical trial consisted of two arms. Patients received phlebotomies and low-dose aspirin in one arm and ropeginterferon in the other arm. The aim of the study was to achieve a hematocrit of 45% or lower without any evidence of disease progression. Ropeginterferon was administered every 2 weeks at a constant dose of 100 μg.
The response to the treatment was assessed after 12 months. The reduction of hematocrit to the assumed level was achieved in significantly higher percentage of patients in the ropeginterferon group than of patients who received only phlebotomies and aspirin. In addition, none of the patients treated with ropeginterferon experienced disease progression during the course of the study, while among those treated with phlebotomies, 8% of patients progressed.
Grade 4 or 5 adverse events were not observed in patients treated with ropeginterferon, and the incidence of remaining adverse event (AE) was small and comparable in both arms. The most common side effects in the ropeginterferon group were flu-like symptoms and neutropenia; however, the third-grade neutropenia was the most common (8% of cases) [22].
One of the most important clinical studies on the use of ropeginterferon was the PROUD-PV study and its continuation: the CONTINUATION-PV study. These were three-phase, multicenter studies. The aim of the study was to compare the effectiveness of ropeginterferon in relation to hydroxycarbamide. The study included adult patients diagnosed with polycythemia vera treated with hydroxycarbamide for less than 3 years and no cytoreductive treatment at all. In total, 257 patients received this treatment. The patients were divided into two groups: those receiving ropeginterferon or the other being given hydroxycarbamide.
During the PROUD-study, drug doses were increased until the hematocrit was achieved below 45% without the use of phlebotomies, and the normalization of the number of leukocytes and platelets was reached.
The PROUD-PV study lasted 12 months. After this time, the patients continued the treatment under the CONTINUATION-PV study for further 36 months. After the final analysis performed in the 12th month at the end of PROUD study, it was found that the hematological response rates did not differ between the ropeginterferon and hydroxycarbamide treatment groups. These were consecutively 43% in the ropeginterferon arm and 46% in the control arm.
However, after analyzing the CONTINUATION- PV study, it turned out that after 36 months of treatment, the rates of hematological responses begin to prevail in the group of patients receiving ropeginterferon, 53% versus 38% in the control group. Thus, from the above data, it can be seen that the response rate to ropeginterferon increases with the duration of treatment [23].
Another analysis of patients participating in the PROUD and CONTINUATION studies was based on the assessment of treatment results after 24 months, dividing patients into two groups according to age (under and over 60 years).
The initial comparison of both groups of patients showed that older patients had a more aggressive course of the disease. Patients over 60 years of age had a higher percentage of cells with a mutant JAK2 allele. They experienced both general symptoms and some complications, such as thrombosis, more frequently. Both patients under 60 years of age and over 60 years of age in the ropeginterferon arm had a higher rate of molecular response, namely 77.1 and 58.7% compared with the HU remission: 33.3 and 36.1%, respectively. Significantly higher reductions in the JAK2 allele were observed in both groups of patients after ropeginterferon treatment: it was 54.8% for younger patients and 35.1% for elderly patients. For comparison, this difference in the group of patients treated with HU was 4.5 and 18.4%, respectively.
What is more, the age did not affect the frequency of ropeginterferon side effects. In addition, the incidence of adverse ropeginterferon disorders was similar to that observed in the hydroxycarbamide group [24].
2.2 Essential thrombocythemia
Essential thrombocythemia is a clonal growth of multipotential stem cells in the bone marrow. The consequence of this is increased proliferation of megakaryocytes in the bone marrow and an increase in the number of platelets in the peripheral blood. The level of platelets above 450,000/μl is considered a diagnostic criterion.
Essential thrombocythemia may progress over time to a more aggressive form of myeloproliferation, i.e., myelofibrosis. The disease can also evolve into acute myeloid leukemia or myelodysplastic syndrome, both with very poor prognosis. Thromboembolic complications are serious, and they concern over 20% of patients. Thrombosis occurs in the artery and venous area. Moreover, in patients with a very high platelet count, above 1,000,000/μl, bleeding may occur as a result of secondary von Willebrand syndrome [1, 2].
The treatment of ET is primarily aimed to prevent thrombotic complications.
In low-risk patients, only acetylsalicylic acid is used. In cases of high-risk patients, hydroxycarbamide is the first-line drug for most patients. Anagrelide and interferon are commonly used as second-line drugs.
Due to the possible effects of hydroxycarbamide of cytogenetic changes in the bone marrow cells after long-lasting usage, some experts recommend the use of interferon in younger patients in the first line. Interferon is also used as the drug of choice in patients planning a pregnancy [25].
The efficacy of pegylated interferon alpha-2a was assessed on the basis of the group of 39 patients with essential thrombocythemia and 40 patients with polycythemia vera.
Of the overall group, 81% of patients were previously treated prior to the study entry. The patients received pegylated interferon alpha-2a in a dose of 90 μg once a week. The dose of 450 μg was associated with a high percentage of intolerance.
In patients with essential thrombocythemia, the complete remission was achieved in 76%, while the overall hematological response rate brought 81%. Moreover, the molecular remission was achieved in 38%, in 14% of cases, JAK2 transcript became not detectable.
Patients diagnosed with polycythemia vera achieved 70% complete hematological remission and 80% general hematological response to treatment. JAK2 transcript was undetectable in 6% of patients. Molecular remission was achieved in 54% of cases.
Pegylated interferon alpha-2a at the dose of 90 μg per week was very well tolerated. In total, 20% of patients experienced a grade of 3 or 4 of adverse reaction, which was neutropenia. In addition, an increase in liver function tests was observed. Grade 4 of AE was not observed among patients who started the treatment with 90 μg/week while grade 3 neutropenia was an adverse event in only 7% of cases [26].
The effect of interferon alpha-2b treatment in patients with ET and PV was investigated. The study was prospective. Some of the results concerning the group of patients with polycythemia vera are presented in the subsection on polycythemia vera. In total, 123 patients with diagnosed essential thrombocythemia participated in the study. All of them received interferon alpha-2b. The patients were divided into two groups depending on the presence of the JAK2 V617F mutation. The enrolled patients were between 18 and 65 years of age. The treatment they received was, sequentially, interferon alpha-2b in the dose of 3 million units three times a week for the first 2 years, after which time the dose was changed into a maintenance dose, which amounted to 5 million units two times a week.
The analysis showed that the patients with the JAK2 V617F mutation present in a higher percentage achieved an overall hematological response as well as a complete hematological response. The overall hematological response was achieved in 83% of patients with JAK2 mutation, and the complete hematological remission was achieved in 23 cases. In the group of ET patients without the JAK2 V617F mutation, overall hematological response was achieved in 61.4%, while the complete hematological remission was achieved in 12 patients. The 5-year progression-free survival was obtained in 75.9% in the JAKV617F group and only in 47.6% without the mutation.
A significant proportion of patients experienced mild side effects. Grade 3 and 4 of adverse events were severe, most of them being a fever. The isolated cases of elevated liver tests and nausea have also been reported [19].
Pegylated interferon alpha-2b in patients with essential thrombocythemia who were previously treated with hydroxycarbamide, anagrelide, and other forms of interferon alpha, however, due to the lack of efficacy or toxicity, the patients required a change of treatment, was assessed. Pegylated interferon alpha-2b turned out to be effective in these cases. It led to the complete hematological remission in 91% of patients after 2 months of therapy, and in 100% of patients after 4 months. However, merely 11 patients participated in the study. Also only two patients required treatment discontinuation due to the side effects such as depression and general fatigue grade 3 [27].
2.2.1 Pregnancy
In case of pregnant patients, interferon is currently considered the only safe cytoreductive drug. Over the years, several analyses of the results of interferon treatment during pregnancy have been carried out.
The assessment of 34 pregnancies in 23 women diagnosed with ET was performed retrospectively. All the pregnancies included in the analysis were of high risk. This high risk was associated with a high platelet count above 1,500,000/μl, a history of thrombotic episode, severe microcirculation disorders, or a history of major hemorrhage.
It turned out that the use of interferon allowed the birth of an alive child in 73.5% of cases. There was no difference in efficacy between the basic and pegylated forms of interferon alpha. In pregnancies without interferon treatment, the percentage of live births was only 60%. Moreover, it was not found if the presence of the JAK2 V617F mutation had any influence on the course of pregnancy [28].
An analysis of the course of pregnancy in patients with ET was assessed in Italy. Data from 17 centers were taken into account. Data from 122 pregnancies were collected from 92 women. In patients diagnosed with essential thrombocythemia, the risk of the spontaneous loss of pregnancy is about 2.5 times higher than among the general population. In the contrary to the study quoted above, it was found that the presence of the JAK2 mutation increases the risk of pregnancy loss. The proportion of live births in patients exposed to interferon during pregnancy was 95%, compared with 71.6% in the group of patients not treated with interferon.
The multivariate analysis also showed that the use of acetylsalicylic acid during pregnancy had no effect on the live birth rate of patients with ET [29].
Whatever its form, interferon is the drug of first choice in pregnancy. Hydroxycarbamide and anagrelide should be withdrawn for about 6 months, and at least for 3 months, before the planned conception. Experts recommend the use of interferon in high-risk pregnancies [30]. A Japanese analysis of 10 consecutive pregnancies in ET patients showed 100% live births in patients who received interferon [31].
2.3 Myelofibrosis
In myelofibrosis (MF), monoclonal megakaryocytes produce cytokines that stimulate the proliferation of normal, non-neoplastic fibroblasts and stimulate angiogenesis. The consequence of this is the gradual fibrosis of the bone marrow, impaired hematopoiesis in the bone marrow, and the formation of extramedullary location mainly in the sites of fetal hematopoiesis, i.e., in the spleen and the liver.
The production of various cytokines by neoplastic megakaryocytes leads to the proliferation of normal, noncancerous fibroblasts as well as to increased angiogenesis.
Progressive bone marrow fibrosis leads to worsening anemia and thrombocytopenia. On the other hand, the production of proinflammatory cytokines by megakaryoblasts leads to the general symptoms such as weight loss, fever, joint pain, night sweats, and consequently, progressive worsening of general condition.
The prognosis for myelofibrosis is poor. In about 20% of patients, myelofibrosis evolves into acute myeloid leukemia with poor prognosis.
Currently, the only effective method of treatment that gives a chance to prolong the life is allogeneic bone marrow transplantation. However, this method is only available to younger patients.
The goal of treatment of patients who have not been qualified for allotranspalntation is to reduce the symptoms and to improve the patient’s quality of life. In case of leukocytosis cytoreducing drugs, such as hydroxycarbamide, melphalan, or cladribine can be used. They cause a reduction in the number of leukocytes and may, to some extent, inhibit splenomegaly. Interferon alpha has been used successfully for the treatment of myelofibrosis for many years. The results of its effectiveness will be presented below [2].
Currently, the JAK2 inhibitor ruxolitinib is approved for the treatment of myelofibrosis with enlarged spleen in intermediate and high-risk patients. Ruxolitinib reduces the size of the spleen, reduces general symptoms, and improves the quality of life; however, it does not prolong the overall survival of patients [32].
In 2015, the results of a retrospective study were published to compare the histological parameters of the bone marrow before and after interferon treatment. Twelve patients diagnosed with primary myelofibrosis as well as post-PV MF and post-ET MF were enrolled in the study. Patients were treated with pegylated recombinant interferon alpha-2a or recombinant interferon alpha-2b in standard doses. The time of treatment was from 1 to 10 years. Some patients had previously been treated with hydroxycarbamide or anagrelide. In all cases, karyotype was normal. The prognostic factor of Dynamic International Prognostic Scoring System (DIPSS) was assessed at the beginning as well as during the treatment.
Bone marrow cellularity decreased in cases with increased bone marrow cellularity before the treatment. After the interferon treatment, a reduction in the degree of bone marrow fibrosis was found. The parameters, such as the density of naked nuclei and the density of megakaryocytes in the bone marrow, also improved.
It proves that if the JAK2 V617F mutation had been present, DIPSS was decreased after interferon treatment. This relationship was not observed in patients without the JAK2 V617F mutation. The improvement in peripheral blood morphological parameters and the overall clinical improvement correlated with the improvement in the assessed histological parameters of the bone marrow.
Before the initiation of interferon, seven patients had splenomegaly. During the treatment with interferon, the complete resolution of splenomegaly was achieved in 17% of patients (two cases), and its size decreased in 25% (three cases). A good clinical response was achieved in 83% during interferon therapy. There was no significant difference in response between the two types of interferon used [33].
A prospective study was also conducted in patients with low and intermediate-1 risk group myelofibrosis. Seventeen patients were enrolled. Patients received interferon alpha-2b (0.5–3 milion units/three times a week) or pegylated interferon alpha-2a (45–90 μg/week). The duration of therapy was on average 3.3 years.
Most of the patients responded to the treatment. Partial remission was found in seven patients and complete remission in two patients. Moreover, in four cases, the disease was stabilized and in one case the clinical improvement was achieved. Three patients did not respond to treatment at all and progressed to myelofibrosis. Additionally, the assessment in reducing spleen size was performed. At baseline, 15 patients have splenomegaly, nine of them achieved the compete regression of spleen size [34].
However, the efficacy of interferon in the treatment of myelofibrosis appears to be limited only to a less advanced form, when the bone marrow still has an adequate percentage of normal hemopoiesis and the marrow stroma is not significantly fibrotic. In more advanced stages, interferon was not shown to have any significant effect on the regression of the fibrosis process [35].
In 2020, the results of the COMBI study were published. That was a two-phase, multicenter, single-arm study that investigated the efficacy and safety of the combination of ruxolitinib and pegylated interferon alpha. Thirty-two patients with PV and 18 patients with primary and secondary myelofibrosis participated in the study. The patients were at age 18 and older. Remission was achieved in 44% of myelofibrosis cases, including 28% (5 patients) of complete remission. In patients with PV, the results were slightly worse: 31% of remissions, including 9% of complete remissions. Patients received pegylated interferon alpha-2a (45 μg/week) or pegylated interferon alpha-2b (35 μg/week) in low doses and ruxolitinib in doses of 5–20 mg twice a day.
For the entire group of patients (with PV and MF), the initial JAK2 allele burden was 47% at baseline, and after 2 years of treatment with interferon and ruxolitinib, it decreased to 12%.
The treatment toxicity was low. The highest incidence of side effects occurred at initiation of therapy. It was mostly anemia and thrombocytopenia.
The observations from the COMBI study show that, for the combination of interferon in lower doses with ruxolitinib, it may be effective and well tolerated even in the group of patients who had intolerance to interferon used as the only drug in higher doses. The combined treatment improved the bone marrow in terms of fibrosis and its cellularity. It also allowed to improve the value of peripheral blood counts [36].
It is currently known that some of the additional mutations are associated with a worse prognosis in patients with myelorpoliferation, including patients with myelofibrosis. Some of these mutations have been identified as high-risk molecular mutations. These are ASXL1, EZH2, IDH1/2, or SRSF2. Earlier studies have shown their association with a more aggressive course of the disease, worse prognosis, and shorter survival of patients, as well as a poorer response to treatment. Due to their importance, they have been included in the diagnostic criteria of myelofibrosis [37].
It is also known that the presence of driver mutations, i.e., JAK2, CALR, and MPL or triple negativity, may affect the course of myeloproliferation, including the incidence of thromboembolic complications.
The assessment of the influence of driver mutations and a panel of selected additional mutations on the effectiveness of interferon treatment in patients with myelofibrosis was performed on a group of 30 patients. Only the patients with low- and intermediate-1-risk were enrolled in the study. The treatment with pegylated interferon alpha-2a or interferon alpha-2b resulted in a complete remission in two patients and partial remission in nine patients. The disease progressed in three cases. One patient relapsed and four died. The remaining patients achieved a clinical improvement or disease stabilization. In the studied group, it was not found if the effectiveness of interferon treatment was influenced by the lack of driver mutations. Among the group of four patients with additional mutations, two died and one had disease progression. It was a mutation of ASXL1 and SRSF2. The treatment with interferon in patients without additional molecular mutations in the early stages of the disease may prevent further progression of the disease [38].
The side effects of interferon in the group of patients with myelofibrosis are similar to those occurring after the treatment of other chronic myeloproliferative diseases. The most frequently described are hematological toxicity- anemia and thrombocytopenia, less often is the appearance of leukopenia. Hematological toxicity usually resolves with dose reduction or extension of the dose interval. The most frequently nonhematological toxicity was fatigue, muscle pain, weakness, and depression symptoms. All symptoms are usually mild and do not exceed grade 2 [38].
However, the use of interferon in the treatment of myelofibrosis has not been recommended as a standard therapy. Interferon is still being evaluated in clinical trials, or it is used in selected patients as a nonstandard therapy in this diagnosis.
2.4 Mastocytosis
Mastocytosis is characterized by an excessive proliferation of abnormal mast cells and their accumulation in various organs.
The basis for the development of mastocytosis is ligand-independent activation of the KIT receptor, resulting from mutations in the KIT proto-oncogene. The KIT receptor is a trans membrane receptor with tyrosine kinase’s activity. Its activation stimulates the proliferation of mast cells. That excessive numbers of mast cells infiltrate tissues and organs and release mediators such as histamine, interleukine-6, tryptase, heparin, and others, which are responsible for the appearance of symptoms typical of mastocytosis. In addition, the infiltration of tissues for mast cells itself causes damage to the affected organs.
The prognosis of mastocytosis depends on the type of the disease. In the case of cutaneous mastocytosis (CM), in the majority of cases prognosis is good and the disease does not shorten the patient’s life, but in aggressive systemic mastocytosis (ASM), the average follow-up is about 40 months. Mast cell leukemia has a poor prognosis with a median follow-up of approximately 1 year.
Systemic mastocytosis usually requires the implementation of cytoreductive therapy. The first line of therapy is interferon alone or its combination with corticosteroids. In aggressive systemic mastocytosis, the first line in addition to interferon 2-CdA can be used. An effective drug turned out to be midostaurin in the case of the present KIT mutation. In patients without the KIT D816V mutation, treatment with imatinib may be effective. In the case of mast cell leukemia, multidrug chemotherapy is most often required, as in acute leukemias, followed by bone marrow transplantation [39].
Systemic mastocytosis requiring treatment is a rare disease, this is why the studies available in the literature evaluating various therapies concern mostly small groups of patients.
In 2002, the French authors presented their experiences on the use of interferon in patients with systemic mastocytosis. They included 20 patients. The patients received interferon alpha-2b in gradually increased doses.
The patients were assessed after 6 months. In cases in which bone marrow was infiltrated for mast cells at baseline, it still remained infiltrated after 6 months of treatment.
However, the responses were obtained in terms of symptoms related to mast cell degranulation. Partial remission was achieved in 35% of patients and minor remission in 30%. It concerns mainly skin lesions and vascular congestion. Moreover, the assessment of the histamine level in the plasma revealed a decrease of it in patients who previously presented symptoms related to the degranulation of mast cells, such as gastrointestinal disorders and flushing.
A high percentage of side effects were found during treatment. They concerned 35% of patients. Depression and cytopenia were most frequent ones [40].
Another analysis was a report of five patients with systemic mastocytosis treated with interferon and prednisolone. All patients received interferon alpha-2b in a dose of 3 million units three times a week and four patients additionally received prednisolone. Four patients responded to interferon treatment at varying degrees. One patient, who at baseline had bone marrow involvement by mast cells in above 10%, progressed to mast cell leukemia. In two patients, the symptoms C resolved completely and in one of them they partially disappeared. In one case, stabilizing disease was achieved [41].
In 2009, a retrospective analysis of patients treated with cytoreductive therapy due to mastocytosis was published. The authors collected data from 108 patients treated at the Mayo Clinic. This analysis allowed for the comparison of the efficacy of four drugs used in systemic mastocytosis. There were interferon alpha alone or in the combination with prednisone—among 40 patients, hydroxycarbamide—among 26 ones, imatinib—among 22 persons, and 2-chlorodeoxyadenosine (2-CdA)—among 22 patients.
After dividing the patients into three additional groups on the basis of the type of mastocytosis—indolent systemic mastocytosis, aggressive systemic mastocytosis, and systemic mastocytosis associated with another clonal hematological nonmast cell lineage disease (SM-AHNMD)—the effectiveness of each of type of therapy was assessed.
The highest response rates in indolent and aggressive mastocytosis were achieved with interferon treatment. They were 60% of the responses in both groups, and in the SM-AHNMD group of patients, the percentage was also one of the highest and amounted to 45%. The second most effective drug was 2-CdA. The response rates were 56% for indolent MS, 50% for aggressive MS, and 55% for SM-AHNMD. The patients treated with imatinib achieved response in 14, 50, and 9% by following groups, respectively. In contrast, patients with indolent and aggressive systemic mastocytosis did not respond to hydroxycarbamide treatment at all. The response rate in both groups was 0%. However, patients with MS associated with another clonal hematological nonmast cell lineage disease achieved 21% response to hydroxycarbamide. Additionally, it was found that only interferon relieved symptoms caused by the release of inflammatory mediators by mast cells.
The additional analysis showed no influence of the TET 2 mutation on the response to treatment [42].
In the literature, there are also single cases of mastocytosis presenting trials of nonstandard treatment. That is description of a patient with systemic mastocytosis with mast cell bone marrow involvement. Mutation of c-kit Asp816Val was present. Patient progressed despite treatment with dasatinib and 2-chlorodeoxyadenosine. The patient developed symptoms related to the degranulation of mast cells and increased ascites.
The patient was treated with pranlukast, which is an anti-leukotriene receptor antagonist due to an asthma episode. The rate of ascites growth decreased significantly after one administration. The patient required paracentesis every 10 days and not every 3 days, as before starting to take the drug. After 15 days of treatment with pranlukast, the patient received interferon alpha, which resulted in complete regression of ascites, resolution of pancytopenia, and complete disappearance of the c-kit mutation clone. The infiltration of mast cells in the bone marrow significantly decreased [43].
Interferon alpha was also effective in a patient with systemic mastocytosis associated with myelodysplastic syndrome with the c-kit D816V mutation, which was refractory to imatinib treatment [44].
Interferon alpha also proved to be effective in the treatment of osteoporotic lesions appearing in the course of mastocytosis.
The series of 10 cases with resolved mastocytosis and osteoporosis-related fractures was presented in 2011. The patients received interferon alpha in a dose of 1.5 million units three times a week as well as pamindronic acid. The patients were treated for an average of 60 months. For the first 2 years, pamindronate was given at a dose of 1 mg/kg every month, and then every 3 months.
During the course of the study, no patient had a new-bone fracture. The level of alkaline phosphatase decreased by 25% in relation to the value before treatment and tryptase by 34%. Bone density increased during treated with interferon and pamindronate. The increase was on average 12% in the spine bones and 1.9% in the hip bones. At the same time, there was no increase in the density of the hip bone and a minimal increase in the density of the spine in patients treated with pamindronate alone.
The results of this observation suggest that it is beneficial to add low doses of interferon alpha to pamindronate treatment in terms of bone density increase [45].
That experiences show that interferon used in systemic mastocytosis significantly improves the quality of life of patients by inhibiting the symptoms caused by degranulation of mast cells. They prevent bone fractures and, in some patients, they cause remission of bone marrow infiltration by mast cells.
2.5 Chronic neutrophilic leukemia
Chronic neutrophilic leukemia (CNL) is a very rare disease. It is characterized by the clonal proliferation of mature neutrophils.
The diagnostic criteria proposed by the World Health Organization (WHO) comprise leukocyte counts above 25,000/μl (including more than 80% of rod and segmented neutrophils in the bone marrow blast cells count below 5%), normal neutrophils maturation, and an increase of neutrophilopoiesis. Also the presence of the CSF3R gene mutation is required.
Physical examination often shows enlargement of the liver and spleen, moreover, patients complain on weight loss and weakness [1].
The prognosis varies. The average survival time for patients with CNL is less than 2 years.
Only few descriptions of chronic neutrophilic leukemia are available in the literature, and these are mostly single case reports.
Because it is an extremely rare disease, there are no established and generally accepted treatment standards. In most cases, patients are given hydroxycarbamide or interferon. Patients who are eligible for a bone marrow transplant may benefit from this treatment. Bone marrow allotransplantation remains the only method that gives a chance for a significant extension of life.
The German authors presented a series of 14 cases of chronic neutrophilic leukemia. The group of patients consisted of eight women and six men. The average age was 64.7 years. From the entire group of patients, longer survival was achieved only in three cases. One of these patients was treated with interferon alpha and achieved hematological remission, the other underwent bone marrow allotransplantation from a family donor, and the third one was treated with hydroxycarbamide and transfusions as needed. The follow-up period of the patient after allogeneic matched related donor transplantation (allo-MRD) was 73 months, and for the patient after interferon treatment it was 41 months.
The remaining patients died within 2 years of diagnosis. Six patients, the largest group, died due to intracranial bleeding, three patients died because of leukemia cell tissue infiltration, one patient because of the disease transformation into leukemia, and one patient because of pneumonia [46].
It can be seen from these experiences that treatment with interferon alpha can significantly extend the survival time of patients.
The case of a 40-year-old woman diagnosed with chronic neutrophilic leukemia is presented by Yassin and coauthors. Initially, the patient had almost 41,000 leukocytes in the peripheral blood. In a physical examination, splenomegaly and hepatomegaly were not present. Patient received pegylated interferon alpha-2a. The initially dose was 50 μg once a week for the first 2 weeks, then the dose was increased to 135 μg weekly for 6 weeks, and then the dose interval was extended to another 2 weeks. As a result of the treatment, the general condition of the patient improved and the parameters of peripheral blood counts were normalized [47].
Another case report presented in the literature describes a 41-year-old woman diagnosed with CNL accompanied by focal segmental glomerulosclerosis (FSGS). The patient had increasing leukocytosis for several months. On the admission to the hospital, leukocytosis was 94,000/μl. Moreover, the number of platelets in the morphology exceeded 1,000,000/μl. More than a year earlier, the patient had splenectomy due to splenomegaly and spleen infraction.
Additionally, JAK2 V617F mutation was found. Some authors suggest that the presence of JAK2 mutation may be associated with longer survival in CNL.
The patient received hydroxycarbamide for 3 months and reduction in the number of leukocytes was achieved. After this time, interferon alpha-2b was added to hydroxycarbamide. As a result, focal segmental glomerulosclerosis disappeared and the renal tests improved [48].
Another case of chronic neutrophilic leukemia with a JAK2 gene mutation concerns a 53-year-old man. The patient’s baseline leukocytosis was 33,500/μl, including the neutrophil count of 29,700/μl. The patient also had splenomegaly.
The treatment with interferon alpha-2b at a dose of 3 million units every other day was started. After a month of treatment, the number of leukocytes was reduced to less than 10,000/μl. Then the patient was treated chronically with interferon alpha-2b in doses of 3 million units every 2 weeks. As a result of the therapy, the number of leukocytes remains between 8 and 10,000/μl. The patient remains in general good condition [49].
A series of two CNL cases are also shown. The first patient was a 70-year-old woman with stable leukocytosis of about 35,000/μl and the remaining morphology parameters in normal range. The patient was only observed for 5 years until hepasplenomegaly progressed rapidly. Then, interferon alpha-2b was included. Due to the treatment, the rapid regression of hepatosplenomegaly was achieved.
The second case is a 68-year-old woman with baseline leukocytosis of almost 14,000/μl. In this case, the treatment with hydroxycarbamide was started immediately. However, no improvement was achieved. After 6 weeks of HU treatment, interferon alpha-2b 3 million units 3 times a week was implemented and leukocytosis decreased. Due to the interferon treatment, the disease stabilized for a long time. Because the patient experienced an adverse reaction, a severe flu-like syndrome, interferon was discontinued. After interferon withdrawal, the disease progressed gradually and the treatment attempts by busulfan and 6-mercaptopurine were unsuccessful. Therefore, interferon was readministered and the disease went into remission. Interferon treatment was continued at a reduced dose. The disease regression was achieved again.
Additionally, the patient showed an improvement in the function of granulocytes in terms of phagocytosis and an improvement in neutral killer (NK) cell function after treatment with interferon [50].
The above examples show that interferon alpha is effective in the treatment of chronic neutrophilic leukemia. The side effects are rare and can be managed with dose reductions. Moreover, in these cases, interferon is also effective in a reduced dose. Disease remission or regression can be achieved without typical of CNL complications, such as intracranial bleeding.
2.6 Another
Interferon has been used in the past to treat chronic myeloid leukemia. The treatment with tyrosine kinase inhibitors is now a standard practice. However, in a small number of patients, they are ineffective or exhibit unmanageable toxicity. Therefore, the attempts are underway to use interferon in combination with TKI in lower doses, which is to ensure the enhancement of the antiproliferative effect while reducing the toxicity.
There are ongoing attempts to use ropeginterferon in patients diagnosed with chronic myeloid leukemia, in whom treatment with imatinib alone has not led to deep molecular response (DMR). The first phase study was conducted in a small group of patients with chronic myeloid leukemia. The patients in first chronic phase treated with imatinib who did not achieve DMR, but in complete hematologic remission and complete cytogenetic remission, were included in the study. Patients have been treated with imatinib for at least 18 months. Twelve patients were enrolled in the study, and they completed the study according to the protocol. These patients received additional ropeginterferon to imatinib and four achieved DMR. Low toxicity was observed during the treatment. Among the hematological toxicities, neutropenia was the most common. There was no nonhematological toxicity with a degree higher than 1/2 during the treatment. Moreover, it has been found that better effects and fewer side effects are obtained when ropeginterferon is administered for a longer time, but in lower doses. The comparison of the effectiveness of interferon in chronic myeloproliferative disorders based on selected articles is presented in Table 1 [51].
Interferon alpha appears to be an effective and safe drug in the most type of chronic myeloproliferative disorders. Nowadays, all forms of its using have similar effectiveness. Interferon alpha can be effective even in cases of resistance for first-line treatment. Trial research is currently underway to combine it with some new drugs, such as ruxolitinib, and to add it to the already well-established therapy, it is a promising option for patients with refractory disease.
From time to time, new forms of interferon, such as ropeginterferon, are introduced, which gives hope for better effectiveness, better safety profile, and greater comfort in its use for patients who have to be treated for many years. In the case of the use of interferons alpha in the treatment of chronic myeloproliferative diseases, there are still opportunities to extend its use and to study its combination with newly introduced drugs.
\n',keywords:"chronic myeloproliferative disorders, polycythemia vera, essential thrombocythemia, myelofibrosis, ropeginterferon, pegylated interferon alpha",chapterPDFUrl:"https://cdn.intechopen.com/pdfs/81569.pdf",chapterXML:"https://mts.intechopen.com/source/xml/81569.xml",downloadPdfUrl:"/chapter/pdf-download/81569",previewPdfUrl:"/chapter/pdf-preview/81569",totalDownloads:19,totalViews:0,totalCrossrefCites:0,dateSubmitted:"January 30th 2022",dateReviewed:"March 14th 2022",datePrePublished:"April 29th 2022",datePublished:null,dateFinished:"April 29th 2022",readingETA:"0",abstract:"It has been noted that interferon can exert an antiproliferative effect by stimulating cells of the immune system. Interferon has been shown to be effective in the treatment of chronic myeloproliferative neoplasms. Over the years, interferon alpha-2a and interferon alpha-2b have been introduced into the treatment of chronic myeloproliferation, followed by their pegylated forms. Studies have been showing the effectiveness of interferon alpha in reducing the number of platelets in essential thrombocythemia, reducing the need for phlebotomies in patients with polycythemia vera and also in reducing the number of leukocytes. Additionally, it turned out to be effective in reducing the size of the spleen. Interferon has also been shown to be effective in inducing long-term molecular remissions. The introduction of new forms of interferon such as ropeginterferon and the combination of interferon alpha with newly introduced drugs from other groups causes that interferon remains an important drug in the field of chronic myeloproliferative disorders. The chapter presents the results of clinical trials and the experiences of various centers in its usage for mieloproliferative neoplasms.",reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/81569",risUrl:"/chapter/ris/81569",signatures:"Anna Prochwicz and Dorota Krochmalczyk",book:{id:"11275",type:"book",title:"Interferon - Immune Metabolism",subtitle:null,fullTitle:"Interferon - Immune Metabolism",slug:null,publishedDate:null,bookSignature:"Prof. Hridayesh Prakash",coverURL:"https://cdn.intechopen.com/books/images_new/11275.jpg",licenceType:"CC BY 3.0",editedByType:null,isbn:"978-1-80355-886-8",printIsbn:"978-1-80355-885-1",pdfIsbn:"978-1-80355-887-5",isAvailableForWebshopOrdering:!0,editors:[{id:"287184",title:"Prof.",name:"Hridayesh",middleName:null,surname:"Prakash",slug:"hridayesh-prakash",fullName:"Hridayesh Prakash"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:null,sections:[{id:"sec_1",title:"1. Introduction",level:"1"},{id:"sec_2",title:"2. Chronic myeloproliferative disorders",level:"1"},{id:"sec_2_2",title:"2.1 Polycythemia vera",level:"2"},{id:"sec_2_3",title:"2.1.1 Ropeginterferon (monopegylated interferon alfa-2b)",level:"3"},{id:"sec_4_2",title:"2.2 Essential thrombocythemia",level:"2"},{id:"sec_4_3",title:"2.2.1 Pregnancy",level:"3"},{id:"sec_6_2",title:"2.3 Myelofibrosis",level:"2"},{id:"sec_7_2",title:"2.4 Mastocytosis",level:"2"},{id:"sec_8_2",title:"2.5 Chronic neutrophilic leukemia",level:"2"},{id:"sec_9_2",title:"2.6 Another",level:"2"},{id:"sec_11",title:"3. Conclusions",level:"1"}],chapterReferences:[{id:"B1",body:'Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405. DOI: 10.1182/blood-2016-03-643544'},{id:"B2",body:'Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology. American Society of Hematology. Education Program. 2003:200-224. DOI: 10.1182/asheducation-2003.1.200'},{id:"B3",body:'Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proceedings of the Royal Society of London—Series B: Biological Sciences. 1957;147:258-267. DOI: 10.1098/rspb.1957.0048'},{id:"B4",body:'Hasselbalch HC, Holmström MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: Minimal residual disease and cure? Seminars in Immunopathology. 2019;41:5-19. DOI: 10.1007/s00281-018-0700-2'},{id:"B5",body:'Ludwig H, Linkesch W, Gisslinger H, et al. Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunology, Immunotherapy. 1987;25:266-273. DOI: 10.1007/BF00199157'},{id:"B6",body:'Lu M, Zhang W, Li Y, et al. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Experimental Hematology. 2010;38:472-480. DOI: 10.1016/j.exphem.2010.03.005'},{id:"B7",body:'Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008;22:1990-1998. DOI: 10.1038/leu.2008.280'},{id:"B8",body:'Wang Q , Miyakawa Y, Fox N, Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood. 2000;96:2093-2099'},{id:"B9",body:'Waters MJ, Brooks AJ. JAK2 activation by growth hormone and other cytokines. The Biochemical Journal. 2015;466:1-11. DOI: 10.1042/BJ20141293'},{id:"B10",body:'Brooks AJ, Dai W, O’Mara ML, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science. 2014;344:1249783. DOI: 10.1126/science.1249783'},{id:"B11",body:'Chaligné R, Tonetti C, Besancenot R, et al. New mutations of MPL in primitive myelofibrosis: Only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008;22:1557-1566. DOI: 10.1038/leu.2008.137'},{id:"B12",body:'Chachoua I, Pecquet C, El-Khoury M, et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2016;127:1325-1335. DOI: 10.1182/blood-2015-11-681932'},{id:"B13",body:'Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. The New England Journal of Medicine. 2005;352:1779-1790. DOI: 10.1056/NEJMoa051113'},{id:"B14",body:'Hino M, Futami E, Okuno S, et al. Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Annals of Hematology. 1993;66:161-162. DOI: 10.1007/BF01697629'},{id:"B15",body:'Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134:1498-1509. DOI: 10.1182/blood.2019000428'},{id:"B16",body:'Masarova L, Patel KP, Newberry KJ, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. The Lancet Haematology. 2017;4:e165-e175. DOI: 10.1016/S2352-3026(17)30030-3'},{id:"B17",body:'Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108:2037-2040. DOI: 10.1182/blood-2006-03-009860'},{id:"B18",body:'Samuelsson J, Hasselbalch H, Bruserud O, et al. Nordic study Group for Myeloproliferative Disorders. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: Feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006;106:2397-2405. DOI: 10.1002/cncr.21900'},{id:"B19",body:'Huang BT, Zeng QC, Zhao WH, et al. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leukemia Research. 2014;38:1177-1183. DOI: 10.1016/j.leukres.2014.06.019'},{id:"B20",body:'European Medicines Agency. Besremi Assessment Report. European Medicines Agency Website. Amsterdam, Netherlands: European Medicines Agency; 2020. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/besremi'},{id:"B21",body:'Verger E, Soret-Dulphy J, Maslah N, et al. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer Journal. 2018;8:94. DOI: 10.1038/s41408-018-0133-0'},{id:"B22",body:'Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (low-PV study): A multicentre, randomised phase 2 trial. The Lancet Haematology. 2021;8:e175-e184. DOI: 10.1016/S2352-3026(20)30373-2'},{id:"B23",body:'Gisslinger H, Klade C, Georgiev P, et al. PROUD-PV study group. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study. The Lancet Haematology. 2020;7:e196-e208. DOI: 10.1016/S2352-3026(19)30236-4'},{id:"B24",body:'Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b: Efficacy and safety in different age groups. Hema. 2020;4:e485. DOI: 10.1097/HS9.0000000000000485'},{id:"B25",body:'Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: When, which agent, and how? Blood. 2014;124:3529-3537. DOI: 10.1182/blood-2014-05-577635'},{id:"B26",body:'Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. Journal of Clinical Oncology. 2009;27:5418-5524. DOI: 10.1200/JCO.2009.23.6075'},{id:"B27",body:'Alvarado Y, Cortes J, Verstovsek S, et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemotherapy and Pharmacology. 2003;51:81-86. DOI: 10.1007/s00280-002-0533-4'},{id:"B28",body:'Schrickel L, Heidel FH, Sadjadian P, et al. German study group MPN, GSG-MPN. Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: Outcome and safety. Journal of Cancer Research and Clinical Oncology. 2021;147:1481-1491. DOI: 10.1007/s00432-020-03430-4'},{id:"B29",body:'Melillo L, Tieghi A, Candoni A, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. American Journal of Hematology. 2009;84:636-640. DOI: 10.1002/ajh.21504'},{id:"B30",body:'Harrison CN, Bareford D, Butt N, et al. British Committee for Standards in Haematology. Guideline for investigation and management of adults and children presenting with a thrombocytosis. British Journal of Haematology. 2010;149:352-375. DOI: 10.1111/j.1365-2141.2010.08122.x'},{id:"B31",body:'Edahiro Y, Yasuda H, Gotoh A, et al. Interferon therapy for pregnant patients with essential thrombocythemia in Japan. International Journal of Hematology. 2021;113:106-111. DOI: 10.1007/s12185-020-03001-w'},{id:"B32",body:'Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30:1701-1707. DOI: 10.1038/leu.2016.148'},{id:"B33",body:'Pizzi M, Silver RT, Barel A, Orazi A. Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Modern Pathology. 2015;28:1315-1323. DOI: 10.1038/modpathol.2015.93'},{id:"B34",body:'Silver RT, Vandris K, Goldman JJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: A preliminary report. Blood. 2011;117:6669-6672. DOI: 10.1182/blood-2010-11-320069'},{id:"B35",body:'Bachleitner-Hofmann T, Gisslinger H. The role of interferon-alpha in the treatment of idiopathic myelofibrosis. Annals of Hematology. 1999;78:533-538. DOI: 10.1007/s002770050554'},{id:"B36",body:'Sørensen AL, Mikkelsen SU, Knudsen TA, et al. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: A phase II study. Haematologica. 2020;105:2262-2272. DOI: 10.3324/haematol.2019.235648'},{id:"B37",body:'Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861-1869. DOI: 10.1038/leu.2013.119'},{id:"B38",body:'Silver RT, Barel AC, Lascu E, et al. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. Cancer. 2017;123:2680-2687. DOI: 10.1002/cncr.30679'},{id:"B39",body:'Pardanani A. Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management. American Journal of Hematology. 2021;96:508-525. DOI: 10.1002/ajh.26118'},{id:"B40",body:'Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: Results of a multicentre phase II trial on 20 patients. British Journal of Haematology. 2002;119:1090-1097. DOI: 10.1046/j.1365-2141.2002.03944.x'},{id:"B41",body:'Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature. Leukemia Research. 2004;28:249-257. DOI: 10.1016/s0145-2126(03)00259-5'},{id:"B42",body:'Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. American Journal of Hematology. 2009;84:790-794. DOI: 10.1002/ajh.21561'},{id:"B43",body:'Mizuno I, Tominaga R, Gomyo H, et al. Systemic mastocytosis with refractory ascites successfully treated with interferon-α and a leukotriene receptor antagonist. Japanese. 2019;60:1555-1559. DOI: 10.11406/rinketsu.60.1555'},{id:"B44",body:'Yoshida C, Takeuchi M, Tsuchiyama J, Sadahira Y. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha. Internal Medicine. 2009;48:1973-1978. DOI: 10.2169/internalmedicine.48.2294'},{id:"B45",body:'Laroche M, Livideanu C, Paul C, Cantagrel A. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. The American Journal of Medicine. 2011;124:776-778. DOI: 10.1016/j.amjmed.2011.02.038'},{id:"B46",body:'Böhm J, Schaefer HE. Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease. Journal of Clinical Pathology. 2002;55:862-864. DOI: 10.1136/jcp.55.11.862'},{id:"B47",body:'Yassin MA, Kohla S, Al-Sabbagh A, et al. A case of chronic neutrophilic leukemia successfully treated with pegylated interferon alpha-2a. Clinical Medicine Insights: Case Reports. 2015;8:33-36. DOI: 10.4137/CCRep.S22820'},{id:"B48",body:'Wang R, Tong H, Wang H, et al. Nephrotic syndrome related to chronic neutrophilic leukemia. Internal Medicine. 2014;53:2505-2509. DOI: 10.2169/internalmedicine.53.2162'},{id:"B49",body:'Zhang X, Pan J, Guo J. Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon α-2b. Acta Haematologica. 2013;130:44-46. DOI: 10.1159/000345851'},{id:"B50",body:'Meyer S, Feremans W, Cantiniaux B, et al. Successful alpha-2b-interferon therapy for chronic neutrophilic leukemia. American Journal of Hematology. 1993;43:307-309. DOI: 10.1002/ajh.2830430416'},{id:"B51",body:'Heibl S, Buxhofer-Ausch V, Schmidt S, et al. A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1. Hematological Oncology. 2020;38:792-798. DOI: 10.1002/hon.2786'}],footnotes:[],contributors:[{corresp:"yes",contributorFullName:"Anna Prochwicz",address:"annaprochwicz@interia.pl",affiliation:'
Department of Hematology, Specialized Hospital, Poland
Department of Hematology, Jagiellonian University Medical College, Poland
'}],corrections:null},book:{id:"11275",type:"book",title:"Interferon - Immune Metabolism",subtitle:null,fullTitle:"Interferon - Immune Metabolism",slug:null,publishedDate:null,bookSignature:"Prof. Hridayesh Prakash",coverURL:"https://cdn.intechopen.com/books/images_new/11275.jpg",licenceType:"CC BY 3.0",editedByType:null,isbn:"978-1-80355-886-8",printIsbn:"978-1-80355-885-1",pdfIsbn:"978-1-80355-887-5",isAvailableForWebshopOrdering:!0,editors:[{id:"287184",title:"Prof.",name:"Hridayesh",middleName:null,surname:"Prakash",slug:"hridayesh-prakash",fullName:"Hridayesh Prakash"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},profile:{item:{id:"207140",title:"Dr.",name:"Elisa",middleName:null,surname:"García-Vences",email:"edna.garcia@anahuac.mx",fullName:"Elisa García-Vences",slug:"elisa-garcia-vences",position:null,biography:"Dr. Elisa García-Vences earned her Masters and Doctoral degrees\nat Universidad Nacional Autonoma de Mexico. She conducted\nher postdoctoral training at the Instituto Nacional de Psiquiatría\n(INP). Dr. García was an associate researcher at INP and Instituto Nacional de Genómica. Currently, she is a professor, senior\nresearcher, and coordinator of the Master Program on Medical\nSciences at Universidad Anáhuac México. As a researcher, she is a\nmember of the National Research System and Secretary of the Research and Bioethics Committee of the Health Sciences Research Center at Universidad Anáhuac. Dr.\nGarcía has collaborated in 15 original articles on spinal cord injury, being the first\nauthor in two of them. Dr. García has participated in three book chapters as author\nand co-author.",institutionString:"Centro de Investigación en Ciencias de la Salud (CICSA)",profilePictureURL:"https://mts.intechopen.com/storage/users/207140/images/10955_n.jpg",totalCites:0,totalChapterViews:"0",outsideEditionCount:0,totalAuthoredChapters:"5",totalEditedBooks:"0",personalWebsiteURL:null,twitterURL:null,linkedinURL:null,institution:{name:"Universidad Anáhuac",institutionURL:null,country:{name:"Mexico"}}},booksEdited:[],chaptersAuthored:[{id:"59170",title:"Pharmacological and Nonpharmacological Therapeutic Strategies Based on the Pathophysiology of Acute and Chronic Spinal Cord Injury",slug:"pharmacological-and-nonpharmacological-therapeutic-strategies-based-on-the-pathophysiology-of-acute-",abstract:"Spinal cord injury (SCI) induces a series of anatomic and physiological disorders which have severe repercussions on neural function. SCI is classified chronologically into an acute (primary and secondary phase) and a chronic phase. The primary phase results directly from the initial trauma and is comprised of disturbances in neural tissue (mainly axons), blood vessels, and spinal shock. Secondary injury results from a series of time-dependent pathophysiological changes, beginning in the first minutes after SCI and lasting days and weeks. This phase is characterized by biochemical and immunological alterations in the injury site and periphery, leading to neuronal over-excitation, apoptosis, and axonal demyelination. In chronic stages, the pathophysiology consists of disturbances in fiber organization, oligodendrocyte apoptosis, fibroglial scar formation, and cyst formation, leading to parenchymal alterations such as syringomyelia and hydromyelia hindering the possibility for functional basal axonal regeneration. This chapter will review a wide range of pharmacological and nonpharmacological therapeutic strategies in preclinical and clinical phases, each targeting different pathological mechanisms of SCI in acute and chronic stages of SCI; taking into account limitations, advances, scope, and new trends. The chapter focuses on the general aspects of SCI pathophysiology, pharmacological and nonpharmacological treatments acute and chronic stages of SCI.",signatures:"Elisa Garcia, Roxana Rodríguez-Barrera, Jose Mondragón-Caso,\nHoracio Carvajal and Antonio Ibarra",authors:[{id:"72488",title:"Dr.",name:"José Juan Antonio",surname:"Ibarra Arias",fullName:"José Juan Antonio Ibarra Arias",slug:"jose-juan-antonio-ibarra-arias",email:"jose.ibarra@anahuac.mx"},{id:"207140",title:"Dr.",name:"Elisa",surname:"García-Vences",fullName:"Elisa García-Vences",slug:"elisa-garcia-vences",email:"edna.garcia@anahuac.mx"},{id:"207141",title:"Dr.",name:"Roxana",surname:"Rodriguez-Barrera",fullName:"Roxana Rodriguez-Barrera",slug:"roxana-rodriguez-barrera",email:"haydeeroba@hotmail.com"},{id:"217342",title:"Mr.",name:"Horacio",surname:"Carvajal",fullName:"Horacio Carvajal",slug:"horacio-carvajal",email:"carvajalhor2@gmail.com"},{id:"217343",title:"Mr.",name:"José",surname:"Mondragón-Caso",fullName:"José Mondragón-Caso",slug:"jose-mondragon-caso",email:"josarmandomc@gmail.com"}],book:{id:"6069",title:"Essentials of Spinal Cord Injury Medicine",slug:"essentials-of-spinal-cord-injury-medicine",productType:{id:"1",title:"Edited Volume"}}},{id:"66029",title:"Transplantation or Transference of Cultured Cells as a Treatment for Spinal Cord Injury",slug:"transplantation-or-transference-of-cultured-cells-as-a-treatment-for-spinal-cord-injury",abstract:"Spinal cord injury (SCI) involves damage to the spinal cord causing both structural and functional changes, which can lead to temporary or permanent alterations. Even though there have been many advances in its treatment, the results of clinical trials suggest that the current therapies are not sufficiently effective. Recently, there has been a lot of interest in regulating this harmful environment by transplanting cultured cells and boosting their antiinflammatory cytokines and growth factors production. Several types of cells have been studied for SCI therapy including, Schwann cells (SC’s), olfactory ensheathing cells (OECs), choroid plexus epithelial cells (CPECs), and immune cells (ICs) (lymphocytes, dendritic cells and alternative macrophage and microglia phenotypes). These treatments have shown to be promising and in this chapter, we will review the general aspects of transplanting these cells for SCI therapy as well as the neuroprotective and regenerative responses that different types of cells have reached in different SCI models. The mesenchymal stem cells (MSC) are one of the most well studied cell types; however, they were not included in this section because they will be reviewed in another chapter of this book.",signatures:"Roxana Rodríguez-Barrera, Karla Soria-Zavala, Julián García-Sánchez, Lisset Karina Navarro-Torres, Estefanía de la Cruz Castillo and Elisa García-Vences",authors:[{id:"207140",title:"Dr.",name:"Elisa",surname:"García-Vences",fullName:"Elisa García-Vences",slug:"elisa-garcia-vences",email:"edna.garcia@anahuac.mx"},{id:"280102",title:"Dr.",name:"Roxana",surname:"Rodríguez-Barrera",fullName:"Roxana Rodríguez-Barrera",slug:"roxana-rodriguez-barrera",email:"roxana.rodriguezb@anahuac.mx"},{id:"280109",title:"MSc.",name:"Karla",surname:"Soria-Zavala",fullName:"Karla Soria-Zavala",slug:"karla-soria-zavala",email:"kasz11@hotmail.com"},{id:"280110",title:"BSc.",name:"Julián",surname:"García-Sánchez",fullName:"Julián García-Sánchez",slug:"julian-garcia-sanchez",email:"juliangarcia011@gmail.com"},{id:"280112",title:"MSc.",name:"Estefanía",surname:"de la Cruz Castillo",fullName:"Estefanía de la Cruz Castillo",slug:"estefania-de-la-cruz-castillo",email:"eecc_92@hotmail.com"},{id:"291737",title:"Dr.",name:"Lisset Karina",surname:"Navarro-Torres",fullName:"Lisset Karina Navarro-Torres",slug:"lisset-karina-navarro-torres",email:"lisset_navarro@outlook.com"}],book:{id:"7879",title:"Spinal Cord Injury Therapy",slug:"spinal-cord-injury-therapy",productType:{id:"1",title:"Edited Volume"}}},{id:"72303",title:"Beyond the Quality of Life in Bowel Dysfunction after Spinal Cord Injury: Approaches to the Consequences in Motility, Immune System, and Microbiome",slug:"beyond-the-quality-of-life-in-bowel-dysfunction-after-spinal-cord-injury-approaches-to-the-consequen",abstract:"Spinal cord injury (SCI) is a harmful event that involves several repercussions on sensory and motor function that affects the quality of life (QoL) of patients. After SCI, many damage mechanisms are activated that impact on both autonomous extrinsic and intrinsic innervation toward the gut, and these changes modify the gut motility causing bowel dysfunction (BD), an entity that affects 40% of patients with SCI, being the second comorbidity after loss of mobility with no recognized cure. The severity of complications is ruled by the level and severity of injury, having a worse prognosis with an injury that is the most proximal to the brain. In the last 5 years, some experiments have tried to elucidate the consequences of dysbiosis in the gut and aggregated proinflammatory processes. The goal of this chapter is to establish the importance of bacterial composition and immune system repercussions in bowel dysfunction after SCI and how could it give rise to new therapies.",signatures:"Estefanía de la Cruz-Castillo and Elisa García-Vences",authors:[{id:"207140",title:"Dr.",name:"Elisa",surname:"García-Vences",fullName:"Elisa García-Vences",slug:"elisa-garcia-vences",email:"edna.garcia@anahuac.mx"},{id:"280112",title:"MSc.",name:"Estefanía",surname:"de la Cruz Castillo",fullName:"Estefanía de la Cruz Castillo",slug:"estefania-de-la-cruz-castillo",email:"eecc_92@hotmail.com"}],book:{id:"9800",title:"Paraplegia",slug:"paraplegia",productType:{id:"1",title:"Edited Volume"}}},{id:"72439",title:"Rehabilitation Therapies in Spinal Cord Injury Patients",slug:"rehabilitation-therapies-in-spinal-cord-injury-patients",abstract:"Spinal cord injury (SCI) represents a neurological life-changing condition that causes devastating physical, social, psychological, and economic consequences in the injured patient. It is due to traumatic causes that affect the motor and sensory functions, limiting daily life activities. Since rehabilitation is a fundamental process of recovery, this chapter will review diverse approaches in rehabilitation to restore or improve patients’ capability. In the first section, functionality and quality of life tools will be discussed. Subsequently, rehabilitation strategies and their adoption will be explained. Ultimately, rehabilitation goals, according to the level of injury, will be reviewed.",signatures:"Brenda Rodríguez-Mendoza, Paola A. Santiago-Tovar, Marco A. Guerrero-Godinez and Elisa García-Vences",authors:[{id:"207140",title:"Dr.",name:"Elisa",surname:"García-Vences",fullName:"Elisa García-Vences",slug:"elisa-garcia-vences",email:"edna.garcia@anahuac.mx"},{id:"320580",title:"Dr.",name:"Brenda",surname:"Rodríguez-Mendoza",fullName:"Brenda Rodríguez-Mendoza",slug:"brenda-rodriguez-mendoza",email:"brenda_evan@hotmail.com"},{id:"320581",title:"Dr.",name:"Paola A.",surname:"Santiago-Tovar",fullName:"Paola A. Santiago-Tovar",slug:"paola-a.-santiago-tovar",email:"pao_stgo18@hotmail.com"},{id:"320642",title:"Dr.",name:"Marco A.",surname:"Guerrero- Godinez",fullName:"Marco A. Guerrero- Godinez",slug:"marco-a.-guerrero-godinez",email:"rehabilitacion_marcoguerrero@hotmail.com"}],book:{id:"9800",title:"Paraplegia",slug:"paraplegia",productType:{id:"1",title:"Edited Volume"}}},{id:"72664",title:"Cytokines in Scar Glial Formation after an Acute and Chronic Spinal Cord Injury",slug:"cytokines-in-scar-glial-formation-after-an-acute-and-chronic-spinal-cord-injury",abstract:"The inflammatory response after a spinal cord injury (SCI) is a secondary mechanism of damage, this involves alterations at the local and systemic level, and it is mediated by cytokine participation that takes part actively. The excessive inflammatory response causes an autoreactive response that targets against components of the nervous tissue; this response lengthens the inflammatory process initiated during the acute phase. The participation of immune cells in acute phases is characterized by the arrival of neutrophils, macrophages, and microglia, as well as T lymphocytes, which express their peaks on different days post-injury (1st, 3rd, and 11th respectively). The chronic phase of the injury begins 14 days after it occurred, reaching its highest point at 60 days, and can still be detected the following 180 days. One of the outcomes of the inflammatory process and cytokine synthesis is the generation of glial scar. In this chapter, we will review the different cytokine mechanisms involved in the formation of glial scar in acute and chronic phases, as well as the modulating treatments of glial scar.",signatures:"Roxana Rodrígez-Barrera, Adrián Flores-Romero, Julián García-Sánchez, Lisset Karina Navarro-Torres, Marcela Garibay-López and Elisa García-Vences",authors:[{id:"207140",title:"Dr.",name:"Elisa",surname:"García-Vences",fullName:"Elisa García-Vences",slug:"elisa-garcia-vences",email:"edna.garcia@anahuac.mx"},{id:"280102",title:"Dr.",name:"Roxana",surname:"Rodríguez-Barrera",fullName:"Roxana Rodríguez-Barrera",slug:"roxana-rodriguez-barrera",email:"roxana.rodriguezb@anahuac.mx"},{id:"280110",title:"BSc.",name:"Julián",surname:"García-Sánchez",fullName:"Julián García-Sánchez",slug:"julian-garcia-sanchez",email:"juliangarcia011@gmail.com"},{id:"291737",title:"Dr.",name:"Lisset Karina",surname:"Navarro-Torres",fullName:"Lisset Karina Navarro-Torres",slug:"lisset-karina-navarro-torres",email:"lisset_navarro@outlook.com"},{id:"303310",title:"MSc.",name:"Adrián",surname:"Flores- Romero",fullName:"Adrián Flores- Romero",slug:"adrian-flores-romero",email:"adrianmvz22@gmail.com"},{id:"303311",title:"BSc.",name:"Marcela",surname:"Garibay Lopéz",fullName:"Marcela Garibay Lopéz",slug:"marcela-garibay-lopez",email:"garibay_marcela@hotmail.com"}],book:{id:"7853",title:"Cytokines",slug:"cytokines",productType:{id:"1",title:"Edited Volume"}}}],collaborators:[{id:"40227",title:"Associate Prof.",name:"Haruo",surname:"Shimazaki",slug:"haruo-shimazaki",fullName:"Haruo Shimazaki",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/40227/images/2906_n.jpg",biography:null,institutionString:null,institution:{name:"Jichi Medical University",institutionURL:null,country:{name:"Japan"}}},{id:"59261",title:"Prof.",name:"Michel",surname:"Salzet",slug:"michel-salzet",fullName:"Michel Salzet",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Miniaturisation pour la Synthèse, l'Analyse et la Protéomique",institutionURL:null,country:{name:"France"}}},{id:"61272",title:"Prof.",name:"Isabelle",surname:"Fournier",slug:"isabelle-fournier",fullName:"Isabelle Fournier",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Miniaturisation pour la Synthèse, l'Analyse et la Protéomique",institutionURL:null,country:{name:"France"}}},{id:"179731",title:"Dr.",name:"Mokhtar",surname:"Arazpour",slug:"mokhtar-arazpour",fullName:"Mokhtar Arazpour",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/179731/images/system/179731.jpg",biography:'Dr. Mokhtar Arazpour is an associate professor in the Department of Orthotics and Prosthetics, University of Social Welfare and Rehabilitation Sciences (USWR), Tehran, Iran, where he also obtained his BS, MSc, and Ph.D. in Orthotics and Prosthetics. The title of his Ph.D. thesis is \\"Design, Construction, and Evaluation of the New Powered Gait Orthosis for Walking in Spinal Cord Injury Patients.\\" Dr. Arazpour’s research interests include lower-limb orthotics, osteoarthritis of knee and hand joints, design and construction of new lower limb orthosis, and walking analysis.',institutionString:"University of Social Welfare and Rehabilitation Sciences",institution:{name:"University of Social Welfare and Rehabilitation Sciences",institutionURL:null,country:{name:"Iran"}}},{id:"206315",title:"Dr.",name:"Guive",surname:"Sharifi",slug:"guive-sharifi",fullName:"Guive Sharifi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Social Welfare and Rehabilitation Sciences",institutionURL:null,country:{name:"Iran"}}},{id:"206337",title:"Prof.",name:"Dasa",surname:"Cizkova",slug:"dasa-cizkova",fullName:"Dasa Cizkova",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"213561",title:"Dr.",name:"Mohammad Ebrahim",surname:"Mousavi",slug:"mohammad-ebrahim-mousavi",fullName:"Mohammad Ebrahim Mousavi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Social Welfare and Rehabilitation Sciences",institutionURL:null,country:{name:"Iran"}}},{id:"219858",title:"Dr.",name:"Jusal",surname:"Quanico",slug:"jusal-quanico",fullName:"Jusal Quanico",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Lille 1 University",institutionURL:null,country:{name:"France"}}},{id:"219879",title:"MSc.",name:"Adriana-Natalia",surname:"Murgoci",slug:"adriana-natalia-murgoci",fullName:"Adriana-Natalia Murgoci",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Lille 1 University",institutionURL:null,country:{name:"France"}}},{id:"220066",title:"Dr.",name:"Lenka",surname:"Kresakova",slug:"lenka-kresakova",fullName:"Lenka Kresakova",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Veterinary Medicine in Košice",institutionURL:null,country:{name:"Slovakia"}}}]},generic:{page:{slug:"open-access-funding-funders-list",title:"List of Funders by Country",intro:"
If your research is financed through any of the below-mentioned funders, please consult their Open Access policies or grant ‘terms and conditions’ to explore ways to cover your publication costs (also accessible by clicking on the link in their title).
\n\n
IMPORTANT: You must be a member or grantee of the listed funders in order to apply for their Open Access publication funds. Do not attempt to contact the funders if this is not the case.
",metaTitle:"List of Funders by Country",metaDescription:"If your research is financed through any of the below-mentioned funders, please consult their Open Access policies or grant ‘terms and conditions’ to explore ways to cover your publication costs (also accessible by clicking on the link in their title).",metaKeywords:null,canonicalURL:"/page/open-access-funding-funders-list",contentRaw:'[{"type":"htmlEditorComponent","content":"
UK Research and Innovation (former Research Councils UK (RCUK) - including AHRC, BBSRC, ESRC, EPSRC, MRC, NERC, STFC.) Processing charges for books/book chapters can be covered through RCUK block grants which are allocated to most universities in the UK, which then handle the OA publication funding requests. It is at the discretion of the university whether it will approve the request.)
UK Research and Innovation (former Research Councils UK (RCUK) - including AHRC, BBSRC, ESRC, EPSRC, MRC, NERC, STFC.) Processing charges for books/book chapters can be covered through RCUK block grants which are allocated to most universities in the UK, which then handle the OA publication funding requests. It is at the discretion of the university whether it will approve the request.)
Wellcome Trust (Funding available only to Wellcome-funded researchers/grantees)
\n
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{},profiles:[{id:"396",title:"Dr.",name:"Vedran",middleName:null,surname:"Kordic",slug:"vedran-kordic",fullName:"Vedran Kordic",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/396/images/7281_n.png",biography:"After obtaining his Master's degree in Mechanical Engineering he continued his education at the Vienna University of Technology where he obtained his PhD degree in 2004. He worked as a researcher at the Automation and Control Institute, Faculty of Electrical Engineering, Vienna University of Technology until 2008. His studies in robotics lead him not only to a PhD degree but also inspired him to co-found and build the International Journal of Advanced Robotic Systems - world's first Open Access journal in the field of robotics.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"441",title:"Ph.D.",name:"Jaekyu",middleName:null,surname:"Park",slug:"jaekyu-park",fullName:"Jaekyu Park",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/441/images/1881_n.jpg",biography:null,institutionString:null,institution:{name:"LG Corporation (South Korea)",country:{name:"Korea, South"}}},{id:"465",title:"Dr.",name:"Christian",middleName:null,surname:"Martens",slug:"christian-martens",fullName:"Christian Martens",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Rheinmetall (Germany)",country:{name:"Germany"}}},{id:"479",title:"Dr.",name:"Valentina",middleName:null,surname:"Colla",slug:"valentina-colla",fullName:"Valentina Colla",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/479/images/358_n.jpg",biography:null,institutionString:null,institution:{name:"Sant'Anna School of Advanced Studies",country:{name:"Italy"}}},{id:"494",title:"PhD",name:"Loris",middleName:null,surname:"Nanni",slug:"loris-nanni",fullName:"Loris Nanni",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/494/images/system/494.jpg",biography:"Loris Nanni received his Master Degree cum laude on June-2002 from the University of Bologna, and the April 26th 2006 he received his Ph.D. in Computer Engineering at DEIS, University of Bologna. On September, 29th 2006 he has won a post PhD fellowship from the university of Bologna (from October 2006 to October 2008), at the competitive examination he was ranked first in the industrial engineering area. He extensively served as referee for several international journals. He is author/coauthor of more than 100 research papers. He has been involved in some projects supported by MURST and European Community. His research interests include pattern recognition, bioinformatics, and biometric systems (fingerprint classification and recognition, signature verification, face recognition).",institutionString:null,institution:null},{id:"496",title:"Dr.",name:"Carlos",middleName:null,surname:"Leon",slug:"carlos-leon",fullName:"Carlos Leon",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Seville",country:{name:"Spain"}}},{id:"512",title:"Dr.",name:"Dayang",middleName:null,surname:"Jawawi",slug:"dayang-jawawi",fullName:"Dayang Jawawi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Technology Malaysia",country:{name:"Malaysia"}}},{id:"528",title:"Dr.",name:"Kresimir",middleName:null,surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/528/images/system/528.jpg",biography:"K. Delac received his B.Sc.E.E. degree in 2003 and is currentlypursuing a Ph.D. degree at the University of Zagreb, Faculty of Electrical Engineering andComputing. His current research interests are digital image analysis, pattern recognition andbiometrics.",institutionString:null,institution:{name:"University of Zagreb",country:{name:"Croatia"}}},{id:"557",title:"Dr.",name:"Andon",middleName:"Venelinov",surname:"Topalov",slug:"andon-topalov",fullName:"Andon Topalov",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/557/images/1927_n.jpg",biography:"Dr. Andon V. Topalov received the MSc degree in Control Engineering from the Faculty of Information Systems, Technologies, and Automation at Moscow State University of Civil Engineering (MGGU) in 1979. He then received his PhD degree in Control Engineering from the Department of Automation and Remote Control at Moscow State Mining University (MGSU), Moscow, in 1984. From 1985 to 1986, he was a Research Fellow in the Research Institute for Electronic Equipment, ZZU AD, Plovdiv, Bulgaria. In 1986, he joined the Department of Control Systems, Technical University of Sofia at the Plovdiv campus, where he is presently a Full Professor. He has held long-term visiting Professor/Scholar positions at various institutions in South Korea, Turkey, Mexico, Greece, Belgium, UK, and Germany. And he has coauthored one book and authored or coauthored more than 80 research papers in conference proceedings and journals. His current research interests are in the fields of intelligent control and robotics.",institutionString:null,institution:{name:"Technical University of Sofia",country:{name:"Bulgaria"}}},{id:"585",title:"Prof.",name:"Munir",middleName:null,surname:"Merdan",slug:"munir-merdan",fullName:"Munir Merdan",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/585/images/system/585.jpg",biography:"Munir Merdan received the M.Sc. degree in mechanical engineering from the Technical University of Sarajevo, Bosnia and Herzegovina, in 2001, and the Ph.D. degree in electrical engineering from the Vienna University of Technology, Vienna, Austria, in 2009.Since 2005, he has been at the Automation and Control Institute, Vienna University of Technology, where he is currently a Senior Researcher. His research interests include the application of agent technology for achieving agile control in the manufacturing environment.",institutionString:null,institution:null},{id:"605",title:"Prof",name:"Dil",middleName:null,surname:"Hussain",slug:"dil-hussain",fullName:"Dil Hussain",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/605/images/system/605.jpg",biography:"Dr. Dil Muhammad Akbar Hussain is a professor of Electronics Engineering & Computer Science at the Department of Energy Technology, Aalborg University Denmark. Professor Akbar has a Master degree in Digital Electronics from Govt. College University, Lahore Pakistan and a P-hD degree in Control Engineering from the School of Engineering and Applied Sciences, University of Sussex United Kingdom. Aalborg University has Two Satellite Campuses, one in Copenhagen (Aalborg University Copenhagen) and the other in Esbjerg (Aalborg University Esbjerg).\n· He is a member of prestigious IEEE (Institute of Electrical and Electronics Engineers), and IAENG (International Association of Engineers) organizations. \n· He is the chief Editor of the Journal of Software Engineering.\n· He is the member of the Editorial Board of International Journal of Computer Science and Software Technology (IJCSST) and International Journal of Computer Engineering and Information Technology. \n· He is also the Editor of Communication in Computer and Information Science CCIS-20 by Springer.\n· Reviewer For Many Conferences\nHe is the lead person in making collaboration agreements between Aalborg University and many universities of Pakistan, for which the MOU’s (Memorandum of Understanding) have been signed.\nProfessor Akbar is working in Academia since 1990, he started his career as a Lab demonstrator/TA at the University of Sussex. After finishing his P. hD degree in 1992, he served in the Industry as a Scientific Officer and continued his academic career as a visiting scholar for a number of educational institutions. In 1996 he joined National University of Science & Technology Pakistan (NUST) as an Associate Professor; NUST is one of the top few universities in Pakistan. In 1999 he joined an International Company Lineo Inc, Canada as Manager Compiler Group, where he headed the group for developing Compiler Tool Chain and Porting of Operating Systems for the BLACKfin processor. The processor development was a joint venture by Intel and Analog Devices. In 2002 Lineo Inc., was taken over by another company, so he joined Aalborg University Denmark as an Assistant Professor.\nProfessor Akbar has truly a multi-disciplined career and he continued his legacy and making progress in many areas of his interests both in teaching and research. He has contributed in stochastic estimation of control area especially, in the Multiple Target Tracking and Interactive Multiple Model (IMM) research, Ball & Beam Control Problem, Robotics, Levitation Control. He has contributed in developing Algorithms for Fingerprint Matching, Computer Vision and Face Recognition. He has been supervising Pattern Recognition, Formal Languages and Distributed Processing projects for several years. He has reviewed many books on Management, Computer Science. Currently, he is an active and permanent reviewer for many international conferences and symposia and the program committee member for many international conferences.\nIn teaching he has taught the core computer science subjects like, Digital Design, Real Time Embedded System Programming, Operating Systems, Software Engineering, Data Structures, Databases, Compiler Construction. In the Engineering side, Digital Signal Processing, Computer Architecture, Electronics Devices, Digital Filtering and Engineering Management.\nApart from his Academic Interest and activities he loves sport especially, Cricket, Football, Snooker and Squash. He plays cricket for Esbjerg city in the second division team as an opener wicket keeper batsman. He is a very good player of squash but has not played squash since his arrival in Denmark.",institutionString:null,institution:null},{id:"611",title:"Prof.",name:"T",middleName:null,surname:"Nagarajan",slug:"t-nagarajan",fullName:"T Nagarajan",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universiti Teknologi Petronas",country:{name:"Malaysia"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:13389},{group:"region",caption:"Middle and South America",value:2,count:11661},{group:"region",caption:"Africa",value:3,count:4168},{group:"region",caption:"Asia",value:4,count:22334},{group:"region",caption:"Australia and Oceania",value:5,count:2019},{group:"region",caption:"Europe",value:6,count:33642}],offset:12,limit:12,total:135277},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"-dateEndThirdStepPublish",topicId:"12"},books:[{type:"book",id:"11668",title:"Mercury Pollution",subtitle:null,isOpenForSubmission:!0,hash:"0bd111f57835089cad4a9741326dbab7",slug:null,bookSignature:"Dr. Ahmed Abdelhafez and Dr. Mohamed Abbas",coverURL:"https://cdn.intechopen.com/books/images_new/11668.jpg",editedByType:null,editors:[{id:"196849",title:"Dr.",name:"Ahmed",surname:"Abdelhafez",slug:"ahmed-abdelhafez",fullName:"Ahmed Abdelhafez"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12223",title:"Sustainable Management of Natural Resources",subtitle:null,isOpenForSubmission:!0,hash:"1881a08bbd8f5dc1102c5cb7c635bc35",slug:null,bookSignature:"Dr. Mohd Nazip Suratman and Dr. Engku Azlin Rahayu Engku Ariff",coverURL:"https://cdn.intechopen.com/books/images_new/12223.jpg",editedByType:null,editors:[{id:"144417",title:"Dr.",name:"Mohd Nazip",surname:"Suratman",slug:"mohd-nazip-suratman",fullName:"Mohd Nazip Suratman"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11650",title:"Aquifers - New Insights",subtitle:null,isOpenForSubmission:!0,hash:"27c1a2a053cb1d83de903c5b969bc3a2",slug:null,bookSignature:"Dr. Abhay Soni and Dr. Prabhat Jain",coverURL:"https://cdn.intechopen.com/books/images_new/11650.jpg",editedByType:null,editors:[{id:"271093",title:"Dr.",name:"Abhay",surname:"Soni",slug:"abhay-soni",fullName:"Abhay Soni"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12222",title:"Advances and Challenges in Microplastics",subtitle:null,isOpenForSubmission:!0,hash:"a36734a551e0997d2255f6ce99eff818",slug:null,bookSignature:"Prof. El-Sayed Salama",coverURL:"https://cdn.intechopen.com/books/images_new/12222.jpg",editedByType:null,editors:[{id:"347657",title:"Prof.",name:"El-Sayed",surname:"Salama",slug:"el-sayed-salama",fullName:"El-Sayed Salama"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10845",title:"Marine Ecosystems - Biodiversity, Ecosystem Services and Human Impacts",subtitle:null,isOpenForSubmission:!0,hash:"727e7eb3d4ba529ec5eb4f150e078523",slug:null,bookSignature:"Dr. Ana M.M. Marta Gonçalves",coverURL:"https://cdn.intechopen.com/books/images_new/10845.jpg",editedByType:null,editors:[{id:"320124",title:"Dr.",name:"Ana M.M.",surname:"Gonçalves",slug:"ana-m.m.-goncalves",fullName:"Ana M.M. Gonçalves"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12180",title:"Wetlands",subtitle:null,isOpenForSubmission:!0,hash:"8957c5c2baaed32223f911a6d4aa5a03",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12180.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12221",title:"Air Pollution",subtitle:null,isOpenForSubmission:!0,hash:"439a018ee0c4960560cb798601f2a372",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12221.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12130",title:"Sustainable Built Environment",subtitle:null,isOpenForSubmission:!0,hash:"ed1dbae71b967e06efb049208f0c1068",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12130.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12131",title:"Climate Change and Fires",subtitle:null,isOpenForSubmission:!0,hash:"ea0858f07a3e87aaf9e5eaa75b4b44bd",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/12131.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:24},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:7},{group:"topic",caption:"Business, Management and Economics",value:7,count:4},{group:"topic",caption:"Chemistry",value:8,count:16},{group:"topic",caption:"Computer and Information Science",value:9,count:18},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:8},{group:"topic",caption:"Engineering",value:11,count:39},{group:"topic",caption:"Environmental Sciences",value:12,count:5},{group:"topic",caption:"Immunology and Microbiology",value:13,count:8},{group:"topic",caption:"Materials Science",value:14,count:15},{group:"topic",caption:"Mathematics",value:15,count:9},{group:"topic",caption:"Medicine",value:16,count:64},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:2},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:7},{group:"topic",caption:"Physics",value:20,count:5},{group:"topic",caption:"Psychology",value:21,count:5},{group:"topic",caption:"Robotics",value:22,count:2},{group:"topic",caption:"Social Sciences",value:23,count:8},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:12,limit:12,total:9},popularBooks:{featuredBooks:[{type:"book",id:"7827",title:"Interpersonal Relationships",subtitle:null,isOpenForSubmission:!1,hash:"ebf41f4d17c75010eb3294cc8cac3d47",slug:"interpersonal-relationships",bookSignature:"Martha Peaslee Levine",coverURL:"https://cdn.intechopen.com/books/images_new/7827.jpg",editors:[{id:"186919",title:"Dr.",name:"Martha",middleName:null,surname:"Peaslee Levine",slug:"martha-peaslee-levine",fullName:"Martha Peaslee Levine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10808",title:"Current Concepts in Dental Implantology",subtitle:"From Science to Clinical Research",isOpenForSubmission:!1,hash:"4af8830e463f89c57515c2da2b9777b0",slug:"current-concepts-in-dental-implantology-from-science-to-clinical-research",bookSignature:"Dragana Gabrić and Marko Vuletić",coverURL:"https://cdn.intechopen.com/books/images_new/10808.jpg",editors:[{id:"26946",title:"Prof.",name:"Dragana",middleName:null,surname:"Gabrić",slug:"dragana-gabric",fullName:"Dragana Gabrić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10796",title:"Extracellular Vesicles",subtitle:"Role in Diseases, Pathogenesis and Therapy",isOpenForSubmission:!1,hash:"eb5407fcf93baff7bca3fae5640153a2",slug:"extracellular-vesicles-role-in-diseases-pathogenesis-and-therapy",bookSignature:"Manash K. Paul",coverURL:"https://cdn.intechopen.com/books/images_new/10796.jpg",editors:[{id:"319365",title:"Assistant Prof.",name:"Manash K.",middleName:null,surname:"Paul",slug:"manash-k.-paul",fullName:"Manash K. Paul"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10908",title:"Advances in Decision Making",subtitle:null,isOpenForSubmission:!1,hash:"126486f7f91e18e2e3539a32c38be7b1",slug:"advances-in-decision-making",bookSignature:"Fausto Pedro García Márquez",coverURL:"https://cdn.intechopen.com/books/images_new/10908.jpg",editors:[{id:"22844",title:"Prof.",name:"Fausto Pedro",middleName:null,surname:"García Márquez",slug:"fausto-pedro-garcia-marquez",fullName:"Fausto Pedro García Márquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"95",title:"Applications and Experiences of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"4bcb22b1eee68210a977a97d5a0f363a",slug:"applications-and-experiences-of-quality-control",bookSignature:"Ognyan Ivanov",coverURL:"https://cdn.intechopen.com/books/images_new/95.jpg",editors:[{id:"22230",title:"Prof.",name:"Ognyan",middleName:null,surname:"Ivanov",slug:"ognyan-ivanov",fullName:"Ognyan Ivanov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3560",title:"Advances in Landscape Architecture",subtitle:null,isOpenForSubmission:!1,hash:"a20614517ec5f7e91188fe8e42832138",slug:"advances-in-landscape-architecture",bookSignature:"Murat Özyavuz",coverURL:"https://cdn.intechopen.com/books/images_new/3560.jpg",editors:[{id:"93073",title:"Dr.",name:"Murat",middleName:null,surname:"Ozyavuz",slug:"murat-ozyavuz",fullName:"Murat Ozyavuz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10739",title:"Global Decline of Insects",subtitle:null,isOpenForSubmission:!1,hash:"543783652b9092962a8fa4bed38eeb17",slug:"global-decline-of-insects",bookSignature:"Hamadttu Abdel Farag El-Shafie",coverURL:"https://cdn.intechopen.com/books/images_new/10739.jpg",editors:[{id:"192142",title:"Dr.",name:"Hamadttu",middleName:null,surname:"Abdel Farag El-Shafie",slug:"hamadttu-abdel-farag-el-shafie",fullName:"Hamadttu Abdel Farag El-Shafie"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10911",title:"Higher Education",subtitle:"New Approaches to Accreditation, Digitalization, and Globalization in the Age of Covid",isOpenForSubmission:!1,hash:"223a02337498e535e967174c1f648fbc",slug:"higher-education-new-approaches-to-accreditation-digitalization-and-globalization-in-the-age-of-covid",bookSignature:"Lee Waller and Sharon Waller",coverURL:"https://cdn.intechopen.com/books/images_new/10911.jpg",editors:[{id:"263301",title:"Dr.",name:"Lee",middleName:null,surname:"Waller",slug:"lee-waller",fullName:"Lee Waller"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3568",title:"Recent Advances in Plant in vitro Culture",subtitle:null,isOpenForSubmission:!1,hash:"830bbb601742c85a3fb0eeafe1454c43",slug:"recent-advances-in-plant-in-vitro-culture",bookSignature:"Annarita Leva and Laura M. R. Rinaldi",coverURL:"https://cdn.intechopen.com/books/images_new/3568.jpg",editors:[{id:"142145",title:"Dr.",name:"Annarita",middleName:null,surname:"Leva",slug:"annarita-leva",fullName:"Annarita Leva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3737",title:"MATLAB",subtitle:"Modelling, Programming and Simulations",isOpenForSubmission:!1,hash:null,slug:"matlab-modelling-programming-and-simulations",bookSignature:"Emilson Pereira Leite",coverURL:"https://cdn.intechopen.com/books/images_new/3737.jpg",editors:[{id:"12051",title:"Prof.",name:"Emilson",middleName:null,surname:"Pereira Leite",slug:"emilson-pereira-leite",fullName:"Emilson Pereira Leite"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"1770",title:"Gel Electrophoresis",subtitle:"Principles and Basics",isOpenForSubmission:!1,hash:"279701f6c802cf02deef45103e0611ff",slug:"gel-electrophoresis-principles-and-basics",bookSignature:"Sameh Magdeldin",coverURL:"https://cdn.intechopen.com/books/images_new/1770.jpg",editors:[{id:"123648",title:"Dr.",name:"Sameh",middleName:null,surname:"Magdeldin",slug:"sameh-magdeldin",fullName:"Sameh Magdeldin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:4797},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"7827",title:"Interpersonal Relationships",subtitle:null,isOpenForSubmission:!1,hash:"ebf41f4d17c75010eb3294cc8cac3d47",slug:"interpersonal-relationships",bookSignature:"Martha Peaslee Levine",coverURL:"https://cdn.intechopen.com/books/images_new/7827.jpg",publishedDate:"July 27th 2022",numberOfDownloads:7175,editors:[{id:"186919",title:"Dr.",name:"Martha",middleName:null,surname:"Peaslee Levine",slug:"martha-peaslee-levine",fullName:"Martha Peaslee Levine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10808",title:"Current Concepts in Dental Implantology",subtitle:"From Science to Clinical Research",isOpenForSubmission:!1,hash:"4af8830e463f89c57515c2da2b9777b0",slug:"current-concepts-in-dental-implantology-from-science-to-clinical-research",bookSignature:"Dragana Gabrić and Marko Vuletić",coverURL:"https://cdn.intechopen.com/books/images_new/10808.jpg",publishedDate:"July 27th 2022",numberOfDownloads:1981,editors:[{id:"26946",title:"Prof.",name:"Dragana",middleName:null,surname:"Gabrić",slug:"dragana-gabric",fullName:"Dragana Gabrić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10796",title:"Extracellular Vesicles",subtitle:"Role in Diseases, Pathogenesis and Therapy",isOpenForSubmission:!1,hash:"eb5407fcf93baff7bca3fae5640153a2",slug:"extracellular-vesicles-role-in-diseases-pathogenesis-and-therapy",bookSignature:"Manash K. Paul",coverURL:"https://cdn.intechopen.com/books/images_new/10796.jpg",publishedDate:"July 20th 2022",numberOfDownloads:2308,editors:[{id:"319365",title:"Assistant Prof.",name:"Manash K.",middleName:null,surname:"Paul",slug:"manash-k.-paul",fullName:"Manash K. Paul"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10908",title:"Advances in Decision Making",subtitle:null,isOpenForSubmission:!1,hash:"126486f7f91e18e2e3539a32c38be7b1",slug:"advances-in-decision-making",bookSignature:"Fausto Pedro García Márquez",coverURL:"https://cdn.intechopen.com/books/images_new/10908.jpg",publishedDate:"July 27th 2022",numberOfDownloads:1473,editors:[{id:"22844",title:"Prof.",name:"Fausto Pedro",middleName:null,surname:"García Márquez",slug:"fausto-pedro-garcia-marquez",fullName:"Fausto Pedro García Márquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"95",title:"Applications and Experiences of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"4bcb22b1eee68210a977a97d5a0f363a",slug:"applications-and-experiences-of-quality-control",bookSignature:"Ognyan Ivanov",coverURL:"https://cdn.intechopen.com/books/images_new/95.jpg",publishedDate:"April 26th 2011",numberOfDownloads:318571,editors:[{id:"22230",title:"Prof.",name:"Ognyan",middleName:null,surname:"Ivanov",slug:"ognyan-ivanov",fullName:"Ognyan Ivanov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",publishedDate:"September 26th 2012",numberOfDownloads:271836,editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3560",title:"Advances in Landscape Architecture",subtitle:null,isOpenForSubmission:!1,hash:"a20614517ec5f7e91188fe8e42832138",slug:"advances-in-landscape-architecture",bookSignature:"Murat Özyavuz",coverURL:"https://cdn.intechopen.com/books/images_new/3560.jpg",publishedDate:"July 1st 2013",numberOfDownloads:243450,editors:[{id:"93073",title:"Dr.",name:"Murat",middleName:null,surname:"Ozyavuz",slug:"murat-ozyavuz",fullName:"Murat Ozyavuz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10739",title:"Global Decline of Insects",subtitle:null,isOpenForSubmission:!1,hash:"543783652b9092962a8fa4bed38eeb17",slug:"global-decline-of-insects",bookSignature:"Hamadttu Abdel Farag El-Shafie",coverURL:"https://cdn.intechopen.com/books/images_new/10739.jpg",publishedDate:"July 20th 2022",numberOfDownloads:1582,editors:[{id:"192142",title:"Dr.",name:"Hamadttu",middleName:null,surname:"Abdel Farag El-Shafie",slug:"hamadttu-abdel-farag-el-shafie",fullName:"Hamadttu Abdel Farag El-Shafie"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10911",title:"Higher Education",subtitle:"New Approaches to Accreditation, Digitalization, and Globalization in the Age of Covid",isOpenForSubmission:!1,hash:"223a02337498e535e967174c1f648fbc",slug:"higher-education-new-approaches-to-accreditation-digitalization-and-globalization-in-the-age-of-covid",bookSignature:"Lee Waller and Sharon Waller",coverURL:"https://cdn.intechopen.com/books/images_new/10911.jpg",publishedDate:"July 13th 2022",numberOfDownloads:2082,editors:[{id:"263301",title:"Dr.",name:"Lee",middleName:null,surname:"Waller",slug:"lee-waller",fullName:"Lee Waller"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3568",title:"Recent Advances in Plant in vitro Culture",subtitle:null,isOpenForSubmission:!1,hash:"830bbb601742c85a3fb0eeafe1454c43",slug:"recent-advances-in-plant-in-vitro-culture",bookSignature:"Annarita Leva and Laura M. R. Rinaldi",coverURL:"https://cdn.intechopen.com/books/images_new/3568.jpg",publishedDate:"October 17th 2012",numberOfDownloads:256294,editors:[{id:"142145",title:"Dr.",name:"Annarita",middleName:null,surname:"Leva",slug:"annarita-leva",fullName:"Annarita Leva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"10808",title:"Current Concepts in Dental Implantology",subtitle:"From Science to Clinical Research",isOpenForSubmission:!1,hash:"4af8830e463f89c57515c2da2b9777b0",slug:"current-concepts-in-dental-implantology-from-science-to-clinical-research",bookSignature:"Dragana Gabrić and Marko Vuletić",coverURL:"https://cdn.intechopen.com/books/images_new/10808.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"26946",title:"Prof.",name:"Dragana",middleName:null,surname:"Gabrić",slug:"dragana-gabric",fullName:"Dragana Gabrić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11328",title:"Botulinum Toxin",subtitle:"Recent Topics and Applications",isOpenForSubmission:!1,hash:"7dd05a316001cef143e209eda51387a7",slug:"botulinum-toxin-recent-topics-and-applications",bookSignature:"Suna Sabuncuoglu",coverURL:"https://cdn.intechopen.com/books/images_new/11328.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"270856",title:"Associate Prof.",name:"Suna",middleName:null,surname:"Sabuncuoglu",slug:"suna-sabuncuoglu",fullName:"Suna Sabuncuoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11085",title:"Polycystic Ovary Syndrome",subtitle:"Functional Investigation and Clinical Application",isOpenForSubmission:!1,hash:"3066dd3ff29e1fac072fd60b08d4d3e7",slug:"polycystic-ovary-syndrome-functional-investigation-and-clinical-application",bookSignature:"Zhengchao Wang",coverURL:"https://cdn.intechopen.com/books/images_new/11085.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"204883",title:"Dr.",name:"Zhengchao",middleName:null,surname:"Wang",slug:"zhengchao-wang",fullName:"Zhengchao Wang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10833",title:"Tumor Angiogenesis and Modulators",subtitle:null,isOpenForSubmission:!1,hash:"f29b575c46128b2da061ef7f9bd1070b",slug:"tumor-angiogenesis-and-modulators",bookSignature:"Ke Xu",coverURL:"https://cdn.intechopen.com/books/images_new/10833.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"59529",title:"Dr.",name:"Ke",middleName:null,surname:"Xu",slug:"ke-xu",fullName:"Ke Xu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11356",title:"Molecular Cloning",subtitle:null,isOpenForSubmission:!1,hash:"671c629dd86e97f0fb467b9e70e92296",slug:"molecular-cloning",bookSignature:"Sadık Dincer, Hatice Aysun Mercimek Takcı and Melis Sumengen Ozdenef",coverURL:"https://cdn.intechopen.com/books/images_new/11356.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"188141",title:"Prof.",name:"Sadik",middleName:null,surname:"Dincer",slug:"sadik-dincer",fullName:"Sadik Dincer"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7827",title:"Interpersonal Relationships",subtitle:null,isOpenForSubmission:!1,hash:"ebf41f4d17c75010eb3294cc8cac3d47",slug:"interpersonal-relationships",bookSignature:"Martha Peaslee Levine",coverURL:"https://cdn.intechopen.com/books/images_new/7827.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"186919",title:"Dr.",name:"Martha",middleName:null,surname:"Peaslee Levine",slug:"martha-peaslee-levine",fullName:"Martha Peaslee Levine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10908",title:"Advances in Decision Making",subtitle:null,isOpenForSubmission:!1,hash:"126486f7f91e18e2e3539a32c38be7b1",slug:"advances-in-decision-making",bookSignature:"Fausto Pedro García Márquez",coverURL:"https://cdn.intechopen.com/books/images_new/10908.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"22844",title:"Prof.",name:"Fausto Pedro",middleName:null,surname:"García Márquez",slug:"fausto-pedro-garcia-marquez",fullName:"Fausto Pedro García Márquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10669",title:"Corrosion",subtitle:"Fundamentals and Protection Mechanisms",isOpenForSubmission:!1,hash:"4a76d54f8a40fc2e7002a8d13fd617c1",slug:"corrosion-fundamentals-and-protection-mechanisms",bookSignature:"Fahmina Zafar, Anujit Ghosal and Eram Sharmin",coverURL:"https://cdn.intechopen.com/books/images_new/10669.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"89672",title:"Dr.",name:"Fahmina",middleName:null,surname:"Zafar",slug:"fahmina-zafar",fullName:"Fahmina Zafar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10677",title:"Advanced Topics of Topology",subtitle:null,isOpenForSubmission:!1,hash:"bf964c52f9e653fac20a7fcab58070e5",slug:"advanced-topics-of-topology",bookSignature:"Francisco Bulnes",coverURL:"https://cdn.intechopen.com/books/images_new/10677.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"92918",title:"Dr.",name:"Francisco",middleName:null,surname:"Bulnes",slug:"francisco-bulnes",fullName:"Francisco Bulnes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11195",title:"Recent Advances in Biometrics",subtitle:null,isOpenForSubmission:!1,hash:"2d32e33e0f499cb5241734bb75dd2a83",slug:"recent-advances-in-biometrics",bookSignature:"Muhammad Sarfraz",coverURL:"https://cdn.intechopen.com/books/images_new/11195.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"215610",title:"Prof.",name:"Muhammad",middleName:null,surname:"Sarfraz",slug:"muhammad-sarfraz",fullName:"Muhammad Sarfraz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"36",title:"Food Science",slug:"food-science",parent:{id:"5",title:"Agricultural and Biological Sciences",slug:"agricultural-and-biological-sciences"},numberOfBooks:17,numberOfSeries:0,numberOfAuthorsAndEditors:395,numberOfWosCitations:777,numberOfCrossrefCitations:501,numberOfDimensionsCitations:1304,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"36",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"10897",title:"Food Systems Resilience",subtitle:null,isOpenForSubmission:!1,hash:"ae9dd92f53433e4607f1db188dc649b4",slug:"food-systems-resilience",bookSignature:"Ana I. Ribeiro-Barros, Daniel S. Tevera, Luís F. Goulao and Lucas D. Tivana",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",editedByType:"Edited by",editors:[{id:"171036",title:"Dr.",name:"Ana I.",middleName:null,surname:"Ribeiro-Barros",slug:"ana-i.-ribeiro-barros",fullName:"Ana I. Ribeiro-Barros"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10237",title:"Innovation in the Food Sector Through the Valorization of Food and Agro-Food By-Products",subtitle:null,isOpenForSubmission:!1,hash:"c3a5a3c7f7999d68f04ae49ff0553f3d",slug:"innovation-in-the-food-sector-through-the-valorization-of-food-and-agro-food-by-products",bookSignature:"Ana Novo de Barros and Irene Gouvinhas",coverURL:"https://cdn.intechopen.com/books/images_new/10237.jpg",editedByType:"Edited by",editors:[{id:"260510",title:"Prof.",name:"Ana",middleName:null,surname:"Novo de Barros",slug:"ana-novo-de-barros",fullName:"Ana Novo de Barros"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6972",title:"Soybean for Human Consumption and Animal Feed",subtitle:null,isOpenForSubmission:!1,hash:"4bc6f95dc8630c9a8be84bb46286c445",slug:"soybean-for-human-consumption-and-animal-feed",bookSignature:"Aleksandra Sudarić",coverURL:"https://cdn.intechopen.com/books/images_new/6972.jpg",editedByType:"Edited by",editors:[{id:"21485",title:"Dr.",name:"Aleksandra",middleName:null,surname:"Sudarić",slug:"aleksandra-sudaric",fullName:"Aleksandra Sudarić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9020",title:"Food Processing",subtitle:null,isOpenForSubmission:!1,hash:"4ec2cdd3d6127695e24ca587a854e6a9",slug:"food-processing",bookSignature:"Romina Alina Marc, Antonio Valero Díaz and Guiomar Denisse Posada Izquierdo",coverURL:"https://cdn.intechopen.com/books/images_new/9020.jpg",editedByType:"Edited by",editors:[{id:"275077",title:"Dr.Ing.",name:"Romina Alina",middleName:null,surname:"Marc",slug:"romina-alina-marc",fullName:"Romina Alina Marc"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8544",title:"Food Preservation and Waste Exploitation",subtitle:null,isOpenForSubmission:!1,hash:"510c0be10ee47559ddfd296740e24517",slug:"food-preservation-and-waste-exploitation",bookSignature:"Sonia A. Socaci, Anca C. F?rca?, Thierry Aussenac and Jean-Claude Laguerre",coverURL:"https://cdn.intechopen.com/books/images_new/8544.jpg",editedByType:"Edited by",editors:[{id:"191241",title:"Ph.D.",name:"Sonia A.",middleName:null,surname:"Socaci",slug:"sonia-a.-socaci",fullName:"Sonia A. Socaci"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8504",title:"Pectins",subtitle:"Extraction, Purification, Characterization and Applications",isOpenForSubmission:!1,hash:"ff1acef627b277c575a10b3259dd331b",slug:"pectins-extraction-purification-characterization-and-applications",bookSignature:"Martin Masuelli",coverURL:"https://cdn.intechopen.com/books/images_new/8504.jpg",editedByType:"Edited by",editors:[{id:"99994",title:"Dr.",name:"Martin",middleName:"Alberto",surname:"Alberto Masuelli",slug:"martin-alberto-masuelli",fullName:"Martin Alberto Masuelli"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8311",title:"Nutraceuticals",subtitle:"Past, Present and Future",isOpenForSubmission:!1,hash:"51994c7d3887b9ecd6926b4967a4fdfb",slug:"nutraceuticals-past-present-and-future",bookSignature:"María Chávarri Hueda",coverURL:"https://cdn.intechopen.com/books/images_new/8311.jpg",editedByType:"Edited by",editors:[{id:"150285",title:"Dr.",name:"María",middleName:null,surname:"Chávarri Hueda",slug:"maria-chavarri-hueda",fullName:"María Chávarri Hueda"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8313",title:"Food Engineering",subtitle:null,isOpenForSubmission:!1,hash:"f34f0100db8038cd838a4a03fb56de6a",slug:"food-engineering",bookSignature:"Teodora Emilia Coldea",coverURL:"https://cdn.intechopen.com/books/images_new/8313.jpg",editedByType:"Edited by",editors:[{id:"220490",title:"Ph.D.",name:"Teodora Emilia",middleName:null,surname:"Coldea",slug:"teodora-emilia-coldea",fullName:"Teodora Emilia Coldea"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8625",title:"Whey",subtitle:"Biological Properties and Alternative Uses",isOpenForSubmission:!1,hash:"449a36f43c9a30ae4d43f9775599e8ac",slug:"whey-biological-properties-and-alternative-uses",bookSignature:"Isabel Gigli",coverURL:"https://cdn.intechopen.com/books/images_new/8625.jpg",editedByType:"Edited by",editors:[{id:"175679",title:"Dr.",name:"Isabel",middleName:null,surname:"Gigli",slug:"isabel-gigli",fullName:"Isabel Gigli"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7332",title:"Some New Aspects of Colloidal Systems in Foods",subtitle:null,isOpenForSubmission:!1,hash:"0dd822267e027684bd3ff53da4f2ef41",slug:"some-new-aspects-of-colloidal-systems-in-foods",bookSignature:"Jafar M. Milani",coverURL:"https://cdn.intechopen.com/books/images_new/7332.jpg",editedByType:"Edited by",editors:[{id:"91158",title:"Associate Prof.",name:"Jafar",middleName:"Mohammadzadeh",surname:"Milani",slug:"jafar-milani",fullName:"Jafar Milani"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6878",title:"Frontiers and New Trends in the Science of Fermented Food and Beverages",subtitle:null,isOpenForSubmission:!1,hash:"aaeaec7ab2b300434df9061448772e57",slug:"frontiers-and-new-trends-in-the-science-of-fermented-food-and-beverages",bookSignature:"Rosa Lidia Solís-Oviedo and Ángel de la Cruz Pech-Canul",coverURL:"https://cdn.intechopen.com/books/images_new/6878.jpg",editedByType:"Edited by",editors:[{id:"227052",title:"Dr.",name:"Rosa Lidia",middleName:null,surname:"Solís-Oviedo",slug:"rosa-lidia-solis-oviedo",fullName:"Rosa Lidia Solís-Oviedo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7337",title:"Legume Seed Nutraceutical Research",subtitle:null,isOpenForSubmission:!1,hash:"a01ad0ca780f39f3aefd09f00cd0b7a3",slug:"legume-seed-nutraceutical-research",bookSignature:"Jose C. Jimenez-Lopez and Alfonso Clemente",coverURL:"https://cdn.intechopen.com/books/images_new/7337.jpg",editedByType:"Edited by",editors:[{id:"33993",title:"Dr.",name:"Jose Carlos",middleName:null,surname:"Jimenez-Lopez",slug:"jose-carlos-jimenez-lopez",fullName:"Jose Carlos Jimenez-Lopez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:17,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"38355",doi:"10.5772/48167",title:"Protein-Based Edible Films: Characteristics and Improvement of Properties",slug:"protein-based-edible-films-characteristics-and-improvement-of-properties",totalDownloads:6024,totalCrossrefCites:33,totalDimensionsCites:89,abstract:null,book:{id:"1128",slug:"structure-and-function-of-food-engineering",title:"Structure and Function of Food Engineering",fullTitle:"Structure and Function of Food Engineering"},signatures:"Thawien Wittaya",authors:[{id:"139906",title:"Dr.",name:"Thawien",middleName:null,surname:"Wittaya",slug:"thawien-wittaya",fullName:"Thawien Wittaya"}]},{id:"38363",doi:"10.5772/48678",title:"Pulsed Electric Fields for Food Processing Technology",slug:"pulsed-electric-fields-for-food-processing-technology",totalDownloads:29535,totalCrossrefCites:16,totalDimensionsCites:77,abstract:null,book:{id:"1128",slug:"structure-and-function-of-food-engineering",title:"Structure and Function of Food Engineering",fullTitle:"Structure and Function of Food Engineering"},signatures:"Maged E.A. Mohamed and Ayman H. Amer Eissa",authors:[{id:"147638",title:"Dr.",name:"Maged",middleName:"E. A.",surname:"Mohammed",slug:"maged-mohammed",fullName:"Maged Mohammed"}]},{id:"56975",doi:"10.5772/intechopen.70653",title:"Metabolic Processes During Seed Germination",slug:"metabolic-processes-during-seed-germination",totalDownloads:6220,totalCrossrefCites:29,totalDimensionsCites:63,abstract:"Seed germination is crucial stage in plant development and can be considered as a determinant for plant productivity. Physiological and biochemical changes followed by morphological changes during germination are strongly related to seedling survival rate and vegetative growth which consequently affect yield and quality. This study is aimed to focus on proceeding of the most vital metabolic processes namely reserve mobilization, phytohormonal regulation, glyoxylate cycle and respiration process under either stressful or non-stressful conditions that may be led to suggest and conduct the more successful experimental improvements. Seed imbibition triggered the activation of various metabolic processes such as synthesis of hydrolytic enzymes which resulted in hydrolysis of reserve food into simple available form for embryo uptake. Abiotic stresses potentially affect seed germination and seedling establishment through various factors, such as a reduction in water availability, changes in the mobilization of stored reserves, hormonal balance alteration and affecting the structural organization of proteins. Recent strategies for improving seed quality involved classical genetic, molecular biology and invigoration treatments known as priming treatments. H2O2 accumulation and associated oxidative damages together with a decline in antioxidant mechanisms can be regarded as a source of stress that may suppress germination. Seed priming was aimed primarily to control seed hydration by lowering external water potential, or shortening the hydration period.",book:{id:"6096",slug:"advances-in-seed-biology",title:"Seed Biology",fullTitle:"Advances in Seed Biology"},signatures:"Awatif S. Ali and Alaaeldin A. Elozeiri",authors:[{id:"207241",title:"Dr.",name:"Awatif",middleName:null,surname:"Ali",slug:"awatif-ali",fullName:"Awatif Ali"}]},{id:"62738",doi:"10.5772/intechopen.79550",title:"The Role of UV-Visible Spectroscopy for Phenolic Compounds Quantification in Winemaking",slug:"the-role-of-uv-visible-spectroscopy-for-phenolic-compounds-quantification-in-winemaking",totalDownloads:2764,totalCrossrefCites:20,totalDimensionsCites:56,abstract:"Phenolic compounds are bioactive substances present in a large number of food products including wine. The importance of these compounds in wine is due to their large effect on the organoleptic attributes of wine. Phenolic compounds play a crucial role in the colour as well as mouthfeel properties of wines. UV-visible spectroscopy appears as a suitable technique for the evaluation of phenolic compounds’ properties and content. The ability of the phenolic ring to absorb UV light and the fact that some of the phenolic substances are coloured compounds, i.e. show absorption features in the visible region, make UV-visible spectroscopy a suitable technique to investigate and quantify grape and wine phenolic compounds. A number of analytical techniques are currently used for phenolic quantification. These include both simpler approaches (spectrophotometric determinations) as well as more complex methodologies such liquid chromatography analysis. Moreover, a number of spectroscopy applications have also been recently reported and are becoming popular within the wine industry. This chapter reviews information on the UV-visible spectral properties of phenolic compounds, changes occurring during wine ageing and also discusses the current UV-visible based analytical techniques used for the quantification of phenolic compounds in grapes and wine.",book:{id:"6878",slug:"frontiers-and-new-trends-in-the-science-of-fermented-food-and-beverages",title:"Frontiers and New Trends in the Science of Fermented Food and Beverages",fullTitle:"Frontiers and New Trends in the Science of Fermented Food and Beverages"},signatures:"Jose Luis Aleixandre-Tudo and Wessel du Toit",authors:[{id:"250919",title:"Dr.",name:"Jose Luis",middleName:null,surname:"Aleixandre-Tudo",slug:"jose-luis-aleixandre-tudo",fullName:"Jose Luis Aleixandre-Tudo"},{id:"261223",title:"Prof.",name:"Wessel",middleName:null,surname:"Du Toit",slug:"wessel-du-toit",fullName:"Wessel Du Toit"}]},{id:"38354",doi:"10.5772/48453",title:"Oxygen Scavengers: An Approach on Food Preservation",slug:"oxygen-scavengers-an-approach-on-food-preservation",totalDownloads:16184,totalCrossrefCites:8,totalDimensionsCites:48,abstract:null,book:{id:"1128",slug:"structure-and-function-of-food-engineering",title:"Structure and Function of Food Engineering",fullTitle:"Structure and Function of Food Engineering"},signatures:"Renato Souza Cruz, Geany Peruch Camilloto and Ana Clarissa dos Santos Pires",authors:[{id:"144206",title:"Dr.",name:"Renato",middleName:null,surname:"Cruz",slug:"renato-cruz",fullName:"Renato Cruz"},{id:"144215",title:"Dr.",name:"Ana Clarissa",middleName:null,surname:"Pires",slug:"ana-clarissa-pires",fullName:"Ana Clarissa Pires"},{id:"144219",title:"MSc.",name:"Geany",middleName:null,surname:"Camilloto",slug:"geany-camilloto",fullName:"Geany Camilloto"}]}],mostDownloadedChaptersLast30Days:[{id:"38363",title:"Pulsed Electric Fields for Food Processing Technology",slug:"pulsed-electric-fields-for-food-processing-technology",totalDownloads:29530,totalCrossrefCites:16,totalDimensionsCites:77,abstract:null,book:{id:"1128",slug:"structure-and-function-of-food-engineering",title:"Structure and Function of Food Engineering",fullTitle:"Structure and Function of Food Engineering"},signatures:"Maged E.A. Mohamed and Ayman H. Amer Eissa",authors:[{id:"147638",title:"Dr.",name:"Maged",middleName:"E. A.",surname:"Mohammed",slug:"maged-mohammed",fullName:"Maged Mohammed"}]},{id:"66671",title:"Extraction and Purification of Pectin from Agro-Industrial Wastes",slug:"extraction-and-purification-of-pectin-from-agro-industrial-wastes",totalDownloads:2765,totalCrossrefCites:1,totalDimensionsCites:9,abstract:"With the advent of science and technology, agro-industrial wastes are converted into various value-added products to meet the demands of increasing population. In recent years, natural polymers have evoked tremendous interest due to easy conversion into value-added products. Apart from various natural polymers, pectin occupied a prominent place due to diverse pharmaceutical and therapeutic applications. Excess utilisation of pectin, the gap between production and demand is widening. To fulfil this gap various techniques are adopted for obtaining high yield pectin from various agro-industrial wastes. This chapter will be focusing on extraction and purification of pectin from various agro-industrial wastes, considered as main environmental pollutants.",book:{id:"8504",slug:"pectins-extraction-purification-characterization-and-applications",title:"Pectins",fullTitle:"Pectins - Extraction, Purification, Characterization and Applications"},signatures:"Erumalla Venkatanagaraju, N. Bharathi, Rachiraju Hema Sindhuja, Rajshree Roy Chowdhury and Yarram Sreelekha",authors:null},{id:"69396",title:"Soybean Amino Acids in Health, Genetics, and Evaluation",slug:"soybean-amino-acids-in-health-genetics-and-evaluation",totalDownloads:1421,totalCrossrefCites:0,totalDimensionsCites:6,abstract:"Soybean is an important source of protein and amino acids for humans and livestock because of its well-balanced amino acid profile. This chapter outlines the strengths and weaknesses of soybean as a complete amino acid source as well as the relative importance of individual amino acids. Special attention is paid to the sulfur-containing amino acids, methionine and cysteine. Breeding and genetic engineering efforts are summarized to highlight previous accomplishments in amino acid improvement and potential avenues for future research. Agronomic properties and processing methods that affect amino acid levels in soybean food and feed are also explained. A brief introduction into current amino acid evaluation techniques is provided. By understanding the complexities of amino acids in soybean, protein quality for humans and livestock can be maximized.",book:{id:"6972",slug:"soybean-for-human-consumption-and-animal-feed",title:"Soybean for Human Consumption and Animal Feed",fullTitle:"Soybean for Human Consumption and Animal Feed"},signatures:"William Monte Singer, Bo Zhang, M.A. Rouf Mian and Haibo Huang",authors:[{id:"308970",title:"Mr.",name:"William",middleName:null,surname:"Singer",slug:"william-singer",fullName:"William Singer"},{id:"309005",title:"Dr.",name:"Bo",middleName:null,surname:"Zhang",slug:"bo-zhang",fullName:"Bo Zhang"},{id:"310776",title:"Dr.",name:"M.A. Rouf",middleName:null,surname:"Mian",slug:"m.a.-rouf-mian",fullName:"M.A. Rouf Mian"},{id:"310777",title:"Dr.",name:"Haibo",middleName:null,surname:"Huang",slug:"haibo-huang",fullName:"Haibo Huang"}]},{id:"56975",title:"Metabolic Processes During Seed Germination",slug:"metabolic-processes-during-seed-germination",totalDownloads:6220,totalCrossrefCites:29,totalDimensionsCites:63,abstract:"Seed germination is crucial stage in plant development and can be considered as a determinant for plant productivity. Physiological and biochemical changes followed by morphological changes during germination are strongly related to seedling survival rate and vegetative growth which consequently affect yield and quality. This study is aimed to focus on proceeding of the most vital metabolic processes namely reserve mobilization, phytohormonal regulation, glyoxylate cycle and respiration process under either stressful or non-stressful conditions that may be led to suggest and conduct the more successful experimental improvements. Seed imbibition triggered the activation of various metabolic processes such as synthesis of hydrolytic enzymes which resulted in hydrolysis of reserve food into simple available form for embryo uptake. Abiotic stresses potentially affect seed germination and seedling establishment through various factors, such as a reduction in water availability, changes in the mobilization of stored reserves, hormonal balance alteration and affecting the structural organization of proteins. Recent strategies for improving seed quality involved classical genetic, molecular biology and invigoration treatments known as priming treatments. H2O2 accumulation and associated oxidative damages together with a decline in antioxidant mechanisms can be regarded as a source of stress that may suppress germination. Seed priming was aimed primarily to control seed hydration by lowering external water potential, or shortening the hydration period.",book:{id:"6096",slug:"advances-in-seed-biology",title:"Seed Biology",fullTitle:"Advances in Seed Biology"},signatures:"Awatif S. Ali and Alaaeldin A. Elozeiri",authors:[{id:"207241",title:"Dr.",name:"Awatif",middleName:null,surname:"Ali",slug:"awatif-ali",fullName:"Awatif Ali"}]},{id:"51587",title:"Casein Proteins: Structural and Functional Aspects",slug:"casein-proteins-structural-and-functional-aspects",totalDownloads:4870,totalCrossrefCites:17,totalDimensionsCites:42,abstract:"Mammalian milk is a complex fluid mixture of various proteins, minerals, and lipids, which play an important role in providing nutrition and immunity to the newborn. Casein proteins, which form about 80% of the bovine milk proteins, form large colloidal particles with calcium phosphate to form casein micelles, which for many years have been an important subject of interest. Casein micelles are composed of four main types of proteins: αS1‐casein, αS2‐casein, β‐casein, and k‐casein. These constituent casein proteins lack well‐defined secondary and tertiary structure due to large amount of propyl residues. These micelles are being extensively studied because of their importance in functional behavior of milk and various milk products. However, the exact structure and nature of these casein micelles are still under debate. These different casein proteins possess different functional properties due to their primary amino acid sequence.",book:{id:"5060",slug:"milk-proteins-from-structure-to-biological-properties-and-health-aspects",title:"Milk Proteins",fullTitle:"Milk Proteins - From Structure to Biological Properties and Health Aspects"},signatures:"Mohd Younus Bhat, Tanveer Ali Dar and Laishram Rajendrakumar\nSingh",authors:[{id:"178323",title:"Dr.",name:"Laishram R",middleName:null,surname:"Singh",slug:"laishram-r-singh",fullName:"Laishram R Singh"},{id:"183444",title:"Mr.",name:"Md. Younus",middleName:null,surname:"Bhat",slug:"md.-younus-bhat",fullName:"Md. Younus Bhat"}]}],onlineFirstChaptersFilter:{topicId:"36",limit:6,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:8,limit:8,total:0},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:90,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:108,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:33,numberOfPublishedChapters:330,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:14,numberOfPublishedChapters:145,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:9,numberOfPublishedChapters:141,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!0},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:124,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:11,numberOfPublishedChapters:112,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:22,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2753-894X",doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:11,numberOfOpenTopics:1,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!0},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:5,numberOfUpcomingTopics:0,issn:"2753-6580",doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}},{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}}]},series:{item:{id:"11",title:"Biochemistry",doi:"10.5772/intechopen.72877",issn:"2632-0983",scope:"Biochemistry, the study of chemical transformations occurring within living organisms, impacts all areas of life sciences, from molecular crystallography and genetics to ecology, medicine, and population biology. Biochemistry examines macromolecules - proteins, nucleic acids, carbohydrates, and lipids – and their building blocks, structures, functions, and interactions. Much of biochemistry is devoted to enzymes, proteins that catalyze chemical reactions, enzyme structures, mechanisms of action and their roles within cells. Biochemistry also studies small signaling molecules, coenzymes, inhibitors, vitamins, and hormones, which play roles in life processes. Biochemical experimentation, besides coopting classical chemistry methods, e.g., chromatography, adopted new techniques, e.g., X-ray diffraction, electron microscopy, NMR, radioisotopes, and developed sophisticated microbial genetic tools, e.g., auxotroph mutants and their revertants, fermentation, etc. More recently, biochemistry embraced the ‘big data’ omics systems. Initial biochemical studies have been exclusively analytic: dissecting, purifying, and examining individual components of a biological system; in the apt words of Efraim Racker (1913 –1991), “Don’t waste clean thinking on dirty enzymes.” Today, however, biochemistry is becoming more agglomerative and comprehensive, setting out to integrate and describe entirely particular biological systems. The ‘big data’ metabolomics can define the complement of small molecules, e.g., in a soil or biofilm sample; proteomics can distinguish all the comprising proteins, e.g., serum; metagenomics can identify all the genes in a complex environment, e.g., the bovine rumen. This Biochemistry Series will address the current research on biomolecules and the emerging trends with great promise.",coverUrl:"https://cdn.intechopen.com/series/covers/11.jpg",latestPublicationDate:"August 2nd, 2022",hasOnlineFirst:!0,numberOfPublishedBooks:33,editor:{id:"31610",title:"Dr.",name:"Miroslav",middleName:null,surname:"Blumenberg",slug:"miroslav-blumenberg",fullName:"Miroslav Blumenberg",profilePictureURL:"https://mts.intechopen.com/storage/users/31610/images/system/31610.jpg",biography:"Miroslav Blumenberg, Ph.D., was born in Subotica and received his BSc in Belgrade, Yugoslavia. He completed his Ph.D. at MIT in Organic Chemistry; he followed up his Ph.D. with two postdoctoral study periods at Stanford University. Since 1983, he has been a faculty member of the RO Perelman Department of Dermatology, NYU School of Medicine, where he is codirector of a training grant in cutaneous biology. Dr. Blumenberg’s research is focused on the epidermis, expression of keratin genes, transcription profiling, keratinocyte differentiation, inflammatory diseases and cancers, and most recently the effects of the microbiome on the skin. He has published more than 100 peer-reviewed research articles and graduated numerous Ph.D. and postdoctoral students.",institutionString:null,institution:{name:"New York University Langone Medical Center",institutionURL:null,country:{name:"United States of America"}}},editorTwo:null,editorThree:null},subseries:{paginationCount:4,paginationItems:[{id:"14",title:"Cell and Molecular Biology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/14.jpg",isOpenForSubmission:!0,editor:{id:"165627",title:"Dr.",name:"Rosa María",middleName:null,surname:"Martínez-Espinosa",slug:"rosa-maria-martinez-espinosa",fullName:"Rosa María Martínez-Espinosa",profilePictureURL:"https://mts.intechopen.com/storage/users/165627/images/system/165627.jpeg",biography:"Dr. Rosa María Martínez-Espinosa has been a Spanish Full Professor since 2020 (Biochemistry and Molecular Biology) and is currently Vice-President of International Relations and Cooperation development and leader of the research group 'Applied Biochemistry” (University of Alicante, Spain). Other positions she has held at the university include Vice-Dean of Master Programs, Vice-Dean of the Degree in Biology and Vice-Dean for Mobility and Enterprise and Engagement at the Faculty of Science (University of Alicante). She received her Bachelor in Biology in 1998 (University of Alicante) and her PhD in 2003 (Biochemistry, University of Alicante). She undertook post-doctoral research at the University of East Anglia (Norwich, U.K. 2004-2005; 2007-2008).\nHer multidisciplinary research focuses on investigating archaea and their potential applications in biotechnology. She has an H-index of 21. She has authored one patent and has published more than 70 indexed papers and around 60 book chapters.\nShe has contributed to more than 150 national and international meetings during the last 15 years. Her research interests include archaea metabolism, enzymes purification and characterization, gene regulation, carotenoids and bioplastics production, antioxidant\ncompounds, waste water treatments, and brines bioremediation.\nRosa María’s other roles include editorial board member for several journals related\nto biochemistry, reviewer for more than 60 journals (biochemistry, molecular biology, biotechnology, chemistry and microbiology) and president of several organizing committees in international meetings related to the N-cycle or respiratory processes.",institutionString:null,institution:{name:"University of Alicante",institutionURL:null,country:{name:"Spain"}}},editorTwo:null,editorThree:null},{id:"15",title:"Chemical Biology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/15.jpg",isOpenForSubmission:!0,editor:{id:"441442",title:"Dr.",name:"Şükrü",middleName:null,surname:"Beydemir",slug:"sukru-beydemir",fullName:"Şükrü Beydemir",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00003GsUoIQAV/Profile_Picture_1634557147521",biography:"Dr. Şükrü Beydemir obtained a BSc in Chemistry in 1995 from Yüzüncü Yıl University, MSc in Biochemistry in 1998, and PhD in Biochemistry in 2002 from Atatürk University, Turkey. He performed post-doctoral studies at Max-Planck Institute, Germany, and University of Florence, Italy in addition to making several scientific visits abroad. He currently works as a Full Professor of Biochemistry in the Faculty of Pharmacy, Anadolu University, Turkey. Dr. Beydemir has published over a hundred scientific papers spanning protein biochemistry, enzymology and medicinal chemistry, reviews, book chapters and presented several conferences to scientists worldwide. He has received numerous publication awards from various international scientific councils. He serves in the Editorial Board of several international journals. Dr. Beydemir is also Rector of Bilecik Şeyh Edebali University, Turkey.",institutionString:null,institution:{name:"Anadolu University",institutionURL:null,country:{name:"Turkey"}}},editorTwo:{id:"13652",title:"Prof.",name:"Deniz",middleName:null,surname:"Ekinci",slug:"deniz-ekinci",fullName:"Deniz Ekinci",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYLT1QAO/Profile_Picture_1634557223079",biography:"Dr. Deniz Ekinci obtained a BSc in Chemistry in 2004, MSc in Biochemistry in 2006, and PhD in Biochemistry in 2009 from Atatürk University, Turkey. He studied at Stetson University, USA, in 2007-2008 and at the Max Planck Institute of Molecular Cell Biology and Genetics, Germany, in 2009-2010. Dr. Ekinci currently works as a Full Professor of Biochemistry in the Faculty of Agriculture and is the Head of the Enzyme and Microbial Biotechnology Division, Ondokuz Mayıs University, Turkey. He is a member of the Turkish Biochemical Society, American Chemical Society, and German Genetics society. Dr. Ekinci published around ninety scientific papers, reviews and book chapters, and presented several conferences to scientists. He has received numerous publication awards from several scientific councils. Dr. Ekinci serves as the Editor in Chief of four international books and is involved in the Editorial Board of several international journals.",institutionString:null,institution:{name:"Ondokuz Mayıs University",institutionURL:null,country:{name:"Turkey"}}},editorThree:null},{id:"17",title:"Metabolism",coverUrl:"https://cdn.intechopen.com/series_topics/covers/17.jpg",isOpenForSubmission:!0,editor:{id:"138626",title:"Dr.",name:"Yannis",middleName:null,surname:"Karamanos",slug:"yannis-karamanos",fullName:"Yannis Karamanos",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002g6Jv2QAE/Profile_Picture_1629356660984",biography:"Yannis Karamanos, born in Greece in 1953, completed his pre-graduate studies at the Université Pierre et Marie Curie, Paris, then his Masters and Doctoral degree at the Université de Lille (1983). He was associate professor at the University of Limoges (1987) before becoming full professor of biochemistry at the Université d’Artois (1996). He worked on the structure-function relationships of glycoconjugates and his main project was the investigations on the biological roles of the de-N-glycosylation enzymes (Endo-N-acetyl-β-D-glucosaminidase and peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidase). From 2002 he contributes to the understanding of the Blood-brain barrier functioning using proteomics approaches. He has published more than 70 papers. His teaching areas are energy metabolism and regulation, integration and organ specialization and metabolic adaptation.",institutionString:null,institution:{name:"Artois University",institutionURL:null,country:{name:"France"}}},editorTwo:null,editorThree:null},{id:"18",title:"Proteomics",coverUrl:"https://cdn.intechopen.com/series_topics/covers/18.jpg",isOpenForSubmission:!0,editor:{id:"200689",title:"Prof.",name:"Paolo",middleName:null,surname:"Iadarola",slug:"paolo-iadarola",fullName:"Paolo Iadarola",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSCl8QAG/Profile_Picture_1623568118342",biography:"Paolo Iadarola graduated with a degree in Chemistry from the University of Pavia (Italy) in July 1972. He then worked as an Assistant Professor at the Faculty of Science of the same University until 1984. In 1985, Prof. Iadarola became Associate Professor at the Department of Biology and Biotechnologies of the University of Pavia and retired in October 2017. Since then, he has been working as an Adjunct Professor in the same Department at the University of Pavia. His research activity during the first years was primarily focused on the purification and structural characterization of enzymes from animal and plant sources. During this period, Prof. Iadarola familiarized himself with the conventional techniques used in column chromatography, spectrophotometry, manual Edman degradation, and electrophoresis). Since 1995, he has been working on: i) the determination in biological fluids (serum, urine, bronchoalveolar lavage, sputum) of proteolytic activities involved in the degradation processes of connective tissue matrix, and ii) on the identification of biological markers of lung diseases. In this context, he has developed and validated new methodologies (e.g., Capillary Electrophoresis coupled to Laser-Induced Fluorescence, CE-LIF) whose application enabled him to determine both the amounts of biochemical markers (Desmosines) in urine/serum of patients affected by Chronic Obstructive Pulmonary Disease (COPD) and the activity of proteolytic enzymes (Human Neutrophil Elastase, Cathepsin G, Pseudomonas aeruginosa elastase) in sputa of these patients. More recently, Prof. Iadarola was involved in developing techniques such as two-dimensional electrophoresis coupled to liquid chromatography/mass spectrometry (2DE-LC/MS) for the proteomic analysis of biological fluids aimed at the identification of potential biomarkers of different lung diseases. He is the author of about 150 publications (According to Scopus: H-Index: 23; Total citations: 1568- According to WOS: H-Index: 20; Total Citations: 1296) of peer-reviewed international journals. He is a Consultant Reviewer for several journals, including the Journal of Chromatography A, Journal of Chromatography B, Plos ONE, Proteomes, International Journal of Molecular Science, Biotech, Electrophoresis, and others. He is also Associate Editor of Biotech.",institutionString:null,institution:{name:"University of Pavia",institutionURL:null,country:{name:"Italy"}}},editorTwo:{id:"201414",title:"Dr.",name:"Simona",middleName:null,surname:"Viglio",slug:"simona-viglio",fullName:"Simona Viglio",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRKDHQA4/Profile_Picture_1630402531487",biography:"Simona Viglio is an Associate Professor of Biochemistry at the Department of Molecular Medicine at the University of Pavia. She has been working since 1995 on the determination of proteolytic enzymes involved in the degradation process of connective tissue matrix and on the identification of biological markers of lung diseases. She gained considerable experience in developing and validating new methodologies whose applications allowed her to determine both the amount of biomarkers (Desmosine and Isodesmosine) in the urine of patients affected by COPD, and the activity of proteolytic enzymes (HNE, Cathepsin G, Pseudomonas aeruginosa elastase) in the sputa of these patients. Simona Viglio was also involved in research dealing with the supplementation of amino acids in patients with brain injury and chronic heart failure. She is presently engaged in the development of 2-DE and LC-MS techniques for the study of proteomics in biological fluids. The aim of this research is the identification of potential biomarkers of lung diseases. She is an author of about 90 publications (According to Scopus: H-Index: 23; According to WOS: H-Index: 20) on peer-reviewed journals, a member of the “Società Italiana di Biochimica e Biologia Molecolare,“ and a Consultant Reviewer for International Journal of Molecular Science, Journal of Chromatography A, COPD, Plos ONE and Nutritional Neuroscience.",institutionString:null,institution:{name:"University of Pavia",institutionURL:null,country:{name:"Italy"}}},editorThree:null}]},overviewPageOFChapters:{paginationCount:42,paginationItems:[{id:"82914",title:"Glance on the Critical Role of IL-23 Receptor Gene Variations in Inflammation-Induced Carcinogenesis",doi:"10.5772/intechopen.105049",signatures:"Mohammed El-Gedamy",slug:"glance-on-the-critical-role-of-il-23-receptor-gene-variations-in-inflammation-induced-carcinogenesis",totalDownloads:15,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Chemokines Updates",coverURL:"https://cdn.intechopen.com/books/images_new/11672.jpg",subseries:{id:"18",title:"Proteomics"}}},{id:"82875",title:"Lipidomics as a Tool in the Diagnosis and Clinical Therapy",doi:"10.5772/intechopen.105857",signatures:"María Elizbeth Alvarez Sánchez, Erick Nolasco Ontiveros, Rodrigo Arreola, Adriana Montserrat Espinosa González, Ana María García Bores, Roberto Eduardo López Urrutia, Ignacio Peñalosa Castro, María del Socorro Sánchez Correa and Edgar Antonio Estrella Parra",slug:"lipidomics-as-a-tool-in-the-diagnosis-and-clinical-therapy",totalDownloads:7,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Fatty Acids - Recent Advances",coverURL:"https://cdn.intechopen.com/books/images_new/11669.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"82440",title:"Lipid Metabolism and Associated Molecular Signaling Events in Autoimmune Disease",doi:"10.5772/intechopen.105746",signatures:"Mohan Vanditha, Sonu Das and Mathew John",slug:"lipid-metabolism-and-associated-molecular-signaling-events-in-autoimmune-disease",totalDownloads:17,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Fatty Acids - Recent Advances",coverURL:"https://cdn.intechopen.com/books/images_new/11669.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"82483",title:"Oxidative Stress in Cardiovascular Diseases",doi:"10.5772/intechopen.105891",signatures:"Laura Mourino-Alvarez, Tamara Sastre-Oliva, Nerea Corbacho-Alonso and Maria G. Barderas",slug:"oxidative-stress-in-cardiovascular-diseases",totalDownloads:10,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Importance of Oxidative Stress and Antioxidant System in Health and Disease",coverURL:"https://cdn.intechopen.com/books/images_new/11671.jpg",subseries:{id:"15",title:"Chemical Biology"}}}]},overviewPagePublishedBooks:{paginationCount:33,paginationItems:[{type:"book",id:"7006",title:"Biochemistry and Health Benefits of Fatty Acids",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7006.jpg",slug:"biochemistry-and-health-benefits-of-fatty-acids",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Viduranga Waisundara",hash:"c93a00abd68b5eba67e5e719f67fd20b",volumeInSeries:1,fullTitle:"Biochemistry and Health Benefits of Fatty Acids",editors:[{id:"194281",title:"Dr.",name:"Viduranga Y.",middleName:null,surname:"Waisundara",slug:"viduranga-y.-waisundara",fullName:"Viduranga Y. Waisundara",profilePictureURL:"https://mts.intechopen.com/storage/users/194281/images/system/194281.jpg",biography:"Dr. Viduranga Waisundara obtained her Ph.D. in Food Science\nand Technology from the Department of Chemistry, National\nUniversity of Singapore, in 2010. She was a lecturer at Temasek Polytechnic, Singapore from July 2009 to March 2013.\nShe relocated to her motherland of Sri Lanka and spearheaded the Functional Food Product Development Project at the\nNational Institute of Fundamental Studies from April 2013 to\nOctober 2016. She was a senior lecturer on a temporary basis at the Department of\nFood Technology, Faculty of Technology, Rajarata University of Sri Lanka. She is\ncurrently Deputy Principal of the Australian College of Business and Technology –\nKandy Campus, Sri Lanka. She is also the Global Harmonization Initiative (GHI)",institutionString:"Australian College of Business & Technology",institution:{name:"Kobe College",institutionURL:null,country:{name:"Japan"}}}]},{type:"book",id:"6820",title:"Keratin",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6820.jpg",slug:"keratin",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Miroslav Blumenberg",hash:"6def75cd4b6b5324a02b6dc0359896d0",volumeInSeries:2,fullTitle:"Keratin",editors:[{id:"31610",title:"Dr.",name:"Miroslav",middleName:null,surname:"Blumenberg",slug:"miroslav-blumenberg",fullName:"Miroslav Blumenberg",profilePictureURL:"https://mts.intechopen.com/storage/users/31610/images/system/31610.jpg",biography:"Miroslav Blumenberg, Ph.D., was born in Subotica and received his BSc in Belgrade, Yugoslavia. He completed his Ph.D. at MIT in Organic Chemistry; he followed up his Ph.D. with two postdoctoral study periods at Stanford University. Since 1983, he has been a faculty member of the RO Perelman Department of Dermatology, NYU School of Medicine, where he is codirector of a training grant in cutaneous biology. Dr. Blumenberg’s research is focused on the epidermis, expression of keratin genes, transcription profiling, keratinocyte differentiation, inflammatory diseases and cancers, and most recently the effects of the microbiome on the skin. He has published more than 100 peer-reviewed research articles and graduated numerous Ph.D. and postdoctoral students.",institutionString:null,institution:{name:"New York University Langone Medical Center",institutionURL:null,country:{name:"United States of America"}}}]},{type:"book",id:"7978",title:"Vitamin A",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7978.jpg",slug:"vitamin-a",publishedDate:"May 15th 2019",editedByType:"Edited by",bookSignature:"Leila Queiroz Zepka, Veridiana Vera de Rosso and Eduardo Jacob-Lopes",hash:"dad04a658ab9e3d851d23705980a688b",volumeInSeries:3,fullTitle:"Vitamin A",editors:[{id:"261969",title:"Dr.",name:"Leila",middleName:null,surname:"Queiroz Zepka",slug:"leila-queiroz-zepka",fullName:"Leila Queiroz Zepka",profilePictureURL:"https://mts.intechopen.com/storage/users/261969/images/system/261969.png",biography:"Prof. Dr. Leila Queiroz Zepka is currently an associate professor in the Department of Food Technology and Science, Federal University of Santa Maria, Brazil. She has more than fifteen years of teaching and research experience. She has published more than 550 scientific publications/communications, including 15 books, 50 book chapters, 100 original research papers, 380 research communications in national and international conferences, and 12 patents. She is a member of the editorial board of five journals and acts as a reviewer for several national and international journals. Her research interests include microalgal biotechnology with an emphasis on microalgae-based products.",institutionString:"Universidade Federal de Santa Maria",institution:{name:"Universidade Federal de Santa Maria",institutionURL:null,country:{name:"Brazil"}}}]},{type:"book",id:"7953",title:"Bioluminescence",subtitle:"Analytical Applications and Basic Biology",coverURL:"https://cdn.intechopen.com/books/images_new/7953.jpg",slug:"bioluminescence-analytical-applications-and-basic-biology",publishedDate:"September 25th 2019",editedByType:"Edited by",bookSignature:"Hirobumi Suzuki",hash:"3a8efa00b71abea11bf01973dc589979",volumeInSeries:4,fullTitle:"Bioluminescence - Analytical Applications and Basic Biology",editors:[{id:"185746",title:"Dr.",name:"Hirobumi",middleName:null,surname:"Suzuki",slug:"hirobumi-suzuki",fullName:"Hirobumi Suzuki",profilePictureURL:"https://mts.intechopen.com/storage/users/185746/images/system/185746.png",biography:"Dr. Hirobumi Suzuki received his Ph.D. in 1997 from Tokyo Metropolitan University, Japan, where he studied firefly phylogeny and the evolution of mating systems. He is especially interested in the genetic differentiation pattern and speciation process that correlate to the flashing pattern and mating behavior of some fireflies in Japan. He then worked for Olympus Corporation, a Japanese manufacturer of optics and imaging products, where he was involved in the development of luminescence technology and produced a bioluminescence microscope that is currently being used for gene expression analysis in chronobiology, neurobiology, and developmental biology. Dr. Suzuki currently serves as a visiting researcher at Kogakuin University, Japan, and also a vice president of the Japan Firefly Society.",institutionString:"Kogakuin University",institution:null}]}]},openForSubmissionBooks:{paginationCount:2,paginationItems:[{id:"11474",title:"Quality of Life Interventions - Magnitude of Effect and Transferability",coverURL:"https://cdn.intechopen.com/books/images_new/11474.jpg",hash:"5a6bcdaf5ee144d043bcdab893ff9e1c",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"July 7th 2022",isOpenForSubmission:!0,editors:[{id:"245319",title:"Ph.D.",name:"Sage",surname:"Arbor",slug:"sage-arbor",fullName:"Sage Arbor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11473",title:"Social Inequality - Structure and Social Processes",coverURL:"https://cdn.intechopen.com/books/images_new/11473.jpg",hash:"cefab077e403fd1695fb2946e7914942",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"July 13th 2022",isOpenForSubmission:!0,editors:[{id:"313341",title:"Ph.D.",name:"Yaroslava",surname:"Robles-Bykbaev",slug:"yaroslava-robles-bykbaev",fullName:"Yaroslava Robles-Bykbaev"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},onlineFirstChapters:{paginationCount:21,paginationItems:[{id:"83000",title:"Purine and Pyrimidine Pathways as Antimalarial Targets",doi:"10.5772/intechopen.106468",signatures:"Yacoba V.T. Minnow and Vern L. Schramm",slug:"purine-and-pyrimidine-pathways-as-antimalarial-targets",totalDownloads:0,totalCrossrefCites:null,totalDimensionsCites:null,authors:null,book:{title:"Malaria - Recent Advances, and New Perspectives",coverURL:"https://cdn.intechopen.com/books/images_new/11576.jpg",subseries:{id:"5",title:"Parasitic Infectious Diseases"}}},{id:"83065",title:"Interventions and Practical Approaches to Reduce the Burden of Malaria on School-Aged Children",doi:"10.5772/intechopen.106469",signatures:"Andrew Macnab",slug:"interventions-and-practical-approaches-to-reduce-the-burden-of-malaria-on-school-aged-children",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Andrew",surname:"Macnab"}],book:{title:"Malaria - Recent Advances, and New Perspectives",coverURL:"https://cdn.intechopen.com/books/images_new/11576.jpg",subseries:{id:"5",title:"Parasitic Infectious Diseases"}}},{id:"82804",title:"Psychiatric Problems in HIV Care",doi:"10.5772/intechopen.106077",signatures:"Seggane Musisi and Noeline Nakasujja",slug:"psychiatric-problems-in-hiv-care",totalDownloads:2,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Future Opportunities and Tools for Emerging Challenges for HIV/AIDS Control",coverURL:"https://cdn.intechopen.com/books/images_new/11575.jpg",subseries:{id:"6",title:"Viral Infectious Diseases"}}},{id:"82827",title:"Epidemiology and Control of Schistosomiasis",doi:"10.5772/intechopen.105170",signatures:"Célestin Kyambikwa Bisangamo",slug:"epidemiology-and-control-of-schistosomiasis",totalDownloads:6,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"New Horizons for Schistosomiasis Research",coverURL:"https://cdn.intechopen.com/books/images_new/10829.jpg",subseries:{id:"5",title:"Parasitic Infectious Diseases"}}},{id:"82817",title:"Perspective Chapter: Microfluidic Technologies for On-Site Detection and Quantification of Infectious Diseases - The Experience with SARS-CoV-2/COVID-19",doi:"10.5772/intechopen.105950",signatures:"Andres Escobar and Chang-qing Xu",slug:"perspective-chapter-microfluidic-technologies-for-on-site-detection-and-quantification-of-infectious",totalDownloads:3,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"SARS-CoV-2 Variants - Two Years After",coverURL:"https://cdn.intechopen.com/books/images_new/11573.jpg",subseries:{id:"6",title:"Viral Infectious Diseases"}}},{id:"82667",title:"Perspective Chapter: Analysis of SARS-CoV-2 Indirect Spreading Routes and Possible Countermeasures",doi:"10.5772/intechopen.105914",signatures:"Cesare Saccani, Marco Pellegrini and Alessandro Guzzini",slug:"perspective-chapter-analysis-of-sars-cov-2-indirect-spreading-routes-and-possible-countermeasures",totalDownloads:10,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"SARS-CoV-2 Variants - Two Years After",coverURL:"https://cdn.intechopen.com/books/images_new/11573.jpg",subseries:{id:"6",title:"Viral Infectious Diseases"}}},{id:"82559",title:"Perspective Chapter: Bioinformatics Study of the Evolution of SARS-CoV-2 Spike Protein",doi:"10.5772/intechopen.105915",signatures:"Črtomir Podlipnik, Radostina Alexandrova, Sebastian Pleško, Urban Bren and Marko Jukič",slug:"perspective-chapter-bioinformatics-study-of-the-evolution-of-sars-cov-2-spike-protein",totalDownloads:14,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"SARS-CoV-2 Variants - Two Years After",coverURL:"https://cdn.intechopen.com/books/images_new/11573.jpg",subseries:{id:"6",title:"Viral Infectious Diseases"}}},{id:"82521",title:"Challenges in Platelet Functions in HIV/AIDS Management",doi:"10.5772/intechopen.105731",signatures:"Gordon Ogweno",slug:"challenges-in-platelet-functions-in-hiv-aids-management",totalDownloads:16,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Future Opportunities and Tools for Emerging Challenges for HIV/AIDS Control",coverURL:"https://cdn.intechopen.com/books/images_new/11575.jpg",subseries:{id:"6",title:"Viral Infectious Diseases"}}},{id:"82701",title:"Pathology of Streptococcal Infections",doi:"10.5772/intechopen.105814",signatures:"Yutaka Tsutsumi",slug:"pathology-of-streptococcal-infections",totalDownloads:8,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Yutaka",surname:"Tsutsumi"}],book:{title:"Streptococcal Infections",coverURL:"https://cdn.intechopen.com/books/images_new/10828.jpg",subseries:{id:"3",title:"Bacterial Infectious Diseases"}}},{id:"82634",title:"Bacterial Sexually Transmitted Disease",doi:"10.5772/intechopen.105747",signatures:"Lebeza Alemu Tenaw",slug:"bacterial-sexually-transmitted-disease",totalDownloads:12,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Bacterial Sexually Transmitted Infections - New Findings, Diagnosis, Treatment, and Prevention",coverURL:"https://cdn.intechopen.com/books/images_new/11569.jpg",subseries:{id:"3",title:"Bacterial Infectious Diseases"}}}]},subseriesFiltersForOFChapters:[{caption:"Fungal Infectious Diseases",value:4,count:1,group:"subseries"},{caption:"Bacterial Infectious Diseases",value:3,count:5,group:"subseries"},{caption:"Parasitic Infectious Diseases",value:5,count:5,group:"subseries"},{caption:"Viral Infectious Diseases",value:6,count:10,group:"subseries"}],publishedBooks:{paginationCount:9,paginationItems:[{type:"book",id:"10654",title:"Brain-Computer Interface",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/10654.jpg",slug:"brain-computer-interface",publishedDate:"May 18th 2022",editedByType:"Edited by",bookSignature:"Vahid Asadpour",hash:"a5308884068cc53ed31c6baba756857f",volumeInSeries:9,fullTitle:"Brain-Computer Interface",editors:[{id:"165328",title:"Dr.",name:"Vahid",middleName:null,surname:"Asadpour",slug:"vahid-asadpour",fullName:"Vahid Asadpour",profilePictureURL:"https://mts.intechopen.com/storage/users/165328/images/system/165328.jpg",institutionString:"Kaiser Permanente Southern California",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10859",title:"Data Mining",subtitle:"Concepts and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/10859.jpg",slug:"data-mining-concepts-and-applications",publishedDate:"March 30th 2022",editedByType:"Edited by",bookSignature:"Ciza Thomas",hash:"63a4e514e537d3962cf53ef1c6b9d5eb",volumeInSeries:8,fullTitle:"Data Mining - Concepts and Applications",editors:[{id:"43680",title:"Prof.",name:"Ciza",middleName:null,surname:"Thomas",slug:"ciza-thomas",fullName:"Ciza Thomas",profilePictureURL:"https://mts.intechopen.com/storage/users/43680/images/system/43680.jpeg",institutionString:null,institution:{name:"Government of Kerala",institutionURL:null,country:{name:"India"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10651",title:"Machine Learning",subtitle:"Algorithms, Models and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/10651.jpg",slug:"machine-learning-algorithms-models-and-applications",publishedDate:"December 22nd 2021",editedByType:"Edited by",bookSignature:"Jaydip Sen",hash:"6208156401c496e0a4ca5ff4265324cc",volumeInSeries:7,fullTitle:"Machine Learning - Algorithms, Models and Applications",editors:[{id:"4519",title:"Prof.",name:"Jaydip",middleName:null,surname:"Sen",slug:"jaydip-sen",fullName:"Jaydip Sen",profilePictureURL:"https://mts.intechopen.com/storage/users/4519/images/system/4519.jpeg",institutionString:"Praxis Business School",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9869",title:"Self-Driving Vehicles and Enabling Technologies",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9869.jpg",slug:"self-driving-vehicles-and-enabling-technologies",publishedDate:"September 22nd 2021",editedByType:"Edited by",bookSignature:"Marian Găiceanu",hash:"fd451ca2e4785ef098e04b7d695a18d9",volumeInSeries:6,fullTitle:"Self-Driving Vehicles and Enabling Technologies",editors:[{id:"169608",title:"Prof.",name:"Marian",middleName:null,surname:"Găiceanu",slug:"marian-gaiceanu",fullName:"Marian Găiceanu",profilePictureURL:"https://mts.intechopen.com/storage/users/169608/images/system/169608.png",institutionString:'"Dunarea de Jos" University of Galati',institution:{name:'"Dunarea de Jos" University of Galati',institutionURL:null,country:{name:"Romania"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9958",title:"Artificial Intelligence",subtitle:"Latest Advances, New Paradigms and Novel Applications",coverURL:"https://cdn.intechopen.com/books/images_new/9958.jpg",slug:"artificial-intelligence-latest-advances-new-paradigms-and-novel-applications",publishedDate:"September 1st 2021",editedByType:"Edited by",bookSignature:"Eneko Osaba, Esther Villar, Jesús L. Lobo and Ibai Laña",hash:"39648fbfdaa11385097d62b1f13aad54",volumeInSeries:5,fullTitle:"Artificial Intelligence - Latest Advances, New Paradigms and Novel Applications",editors:[{id:"221364",title:"Dr.",name:"Eneko",middleName:null,surname:"Osaba",slug:"eneko-osaba",fullName:"Eneko Osaba",profilePictureURL:"https://mts.intechopen.com/storage/users/221364/images/system/221364.jpg",institutionString:"TECNALIA Research & Innovation",institution:{name:"Tecnalia",institutionURL:null,country:{name:"Spain"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9963",title:"Advances and Applications in Deep Learning",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9963.jpg",slug:"advances-and-applications-in-deep-learning",publishedDate:"December 9th 2020",editedByType:"Edited by",bookSignature:"Marco Antonio Aceves-Fernandez",hash:"0d51ba46f22e55cb89140f60d86a071e",volumeInSeries:4,fullTitle:"Advances and Applications in Deep Learning",editors:[{id:"24555",title:"Dr.",name:"Marco Antonio",middleName:null,surname:"Aceves Fernandez",slug:"marco-antonio-aceves-fernandez",fullName:"Marco Antonio Aceves Fernandez",profilePictureURL:"https://mts.intechopen.com/storage/users/24555/images/system/24555.jpg",institutionString:"Universidad Autonoma de Queretaro",institution:{name:"Autonomous University of Queretaro",institutionURL:null,country:{name:"Mexico"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7656",title:"Fuzzy Logic",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7656.jpg",slug:"fuzzy-logic",publishedDate:"February 5th 2020",editedByType:"Edited by",bookSignature:"Constantin Volosencu",hash:"54f092d4ffe0abf5e4172a80025019bc",volumeInSeries:3,fullTitle:"Fuzzy Logic",editors:[{id:"1063",title:"Prof.",name:"Constantin",middleName:null,surname:"Volosencu",slug:"constantin-volosencu",fullName:"Constantin Volosencu",profilePictureURL:"https://mts.intechopen.com/storage/users/1063/images/system/1063.png",institutionString:'"Politechnica" University Timişoara',institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7726",title:"Swarm Intelligence",subtitle:"Recent Advances, New Perspectives and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/7726.jpg",slug:"swarm-intelligence-recent-advances-new-perspectives-and-applications",publishedDate:"December 4th 2019",editedByType:"Edited by",bookSignature:"Javier Del Ser, Esther Villar and Eneko Osaba",hash:"e7ea7e74ce7a7a8e5359629e07c68d31",volumeInSeries:2,fullTitle:"Swarm Intelligence - Recent Advances, New Perspectives and Applications",editors:[{id:"49813",title:"Dr.",name:"Javier",middleName:null,surname:"Del Ser",slug:"javier-del-ser",fullName:"Javier Del Ser",profilePictureURL:"https://mts.intechopen.com/storage/users/49813/images/system/49813.png",institutionString:"Tecnalia Research & Innovation",institution:{name:"Tecnalia",institutionURL:null,country:{name:"Spain"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7723",title:"Artificial Intelligence",subtitle:"Applications in Medicine and Biology",coverURL:"https://cdn.intechopen.com/books/images_new/7723.jpg",slug:"artificial-intelligence-applications-in-medicine-and-biology",publishedDate:"July 31st 2019",editedByType:"Edited by",bookSignature:"Marco Antonio Aceves-Fernandez",hash:"a3852659e727f95c98c740ed98146011",volumeInSeries:1,fullTitle:"Artificial Intelligence - Applications in Medicine and Biology",editors:[{id:"24555",title:"Dr.",name:"Marco Antonio",middleName:null,surname:"Aceves Fernandez",slug:"marco-antonio-aceves-fernandez",fullName:"Marco Antonio Aceves Fernandez",profilePictureURL:"https://mts.intechopen.com/storage/users/24555/images/system/24555.jpg",institutionString:"Universidad Autonoma de Queretaro",institution:{name:"Autonomous University of Queretaro",institutionURL:null,country:{name:"Mexico"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},subseriesFiltersForPublishedBooks:[{group:"subseries",caption:"Computational Neuroscience",value:23,count:1},{group:"subseries",caption:"Evolutionary Computation",value:25,count:1},{group:"subseries",caption:"Machine Learning and Data Mining",value:26,count:3},{group:"subseries",caption:"Applied Intelligence",value:22,count:4}],publicationYearFilters:[{group:"publicationYear",caption:"2022",value:2022,count:2},{group:"publicationYear",caption:"2021",value:2021,count:3},{group:"publicationYear",caption:"2020",value:2020,count:2},{group:"publicationYear",caption:"2019",value:2019,count:2}],authors:{paginationCount:754,paginationItems:[{id:"310674",title:"Dr.",name:"Pravin",middleName:null,surname:"Kendrekar",slug:"pravin-kendrekar",fullName:"Pravin Kendrekar",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/310674/images/system/310674.jpg",biography:"Dr. Pravin Kendrekar, MSc, MBA, Ph.D., is currently a visiting scientist at the Lipid Nanostructure Laboratory, University of Central Lancashire, England. He previously worked as a post-doctoral fellow at the Ben-Gurion University of Negev, Israel; University of the Free State, South Africa; and Central University of Technology Bloemfontein, South Africa. He obtained his Ph.D. in Organic Chemistry from Nagaoka University of Technology, Japan. He has published more than seventy-four journal articles and attended several national and international conferences as speaker and chair. Dr. Kendrekar has received many international awards. He has several funded projects, namely, anti-malaria drug development, MRSA, and SARS-CoV-2 activity of curcumin and its formulations. He has filed four patents in collaboration with the University of Central Lancashire and Mayo Clinic Infectious Diseases. His present research includes organic synthesis, drug discovery and development, biochemistry, nanoscience, and nanotechnology.",institutionString:"Visiting Scientist at Lipid Nanostructures Laboratory, Centre for Smart Materials, School of Natural Sciences, University of Central Lancashire",institution:null},{id:"428125",title:"Dr.",name:"Vinayak",middleName:null,surname:"Adimule",slug:"vinayak-adimule",fullName:"Vinayak Adimule",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/428125/images/system/428125.jpg",biography:"Dr. Vinayak Adimule, MSc, Ph.D., is a professor and dean of R&D, Angadi Institute of Technology and Management, India. He has 15 years of research experience as a senior research scientist and associate research scientist in R&D organizations. He has published more than fifty research articles as well as several book chapters. He has two Indian patents and two international patents to his credit. Dr. Adimule has attended, chaired, and presented papers at national and international conferences. He is a guest editor for Topics in Catalysis and other journals. He is also an editorial board member, life member, and associate member for many international societies and research institutions. His research interests include nanoelectronics, material chemistry, artificial intelligence, sensors and actuators, bio-nanomaterials, and medicinal chemistry.",institutionString:"Angadi Institute of Technology and Management",institution:null},{id:"284317",title:"Prof.",name:"Kantharaju",middleName:null,surname:"Kamanna",slug:"kantharaju-kamanna",fullName:"Kantharaju Kamanna",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/284317/images/21050_n.jpg",biography:"Prof. K. Kantharaju has received Bachelor of science (PCM), master of science (Organic Chemistry) and Doctor of Philosophy in Chemistry from Bangalore University. He worked as a Executive Research & Development @ Cadila Pharmaceuticals Ltd, Ahmedabad. He received DBT-postdoc fellow @ Molecular Biophysics Unit, Indian Institute of Science, Bangalore under the supervision of Prof. P. Balaram, later he moved to NIH-postdoc researcher at Drexel University College of Medicine, Philadelphia, USA, after his return from postdoc joined NITK-Surthakal as a Adhoc faculty at department of chemistry. Since from August 2013 working as a Associate Professor, and in 2016 promoted to Profeesor in the School of Basic Sciences: Department of Chemistry and having 20 years of teaching and research experiences.",institutionString:null,institution:{name:"Rani Channamma University, Belagavi",country:{name:"India"}}},{id:"158492",title:"Prof.",name:"Yusuf",middleName:null,surname:"Tutar",slug:"yusuf-tutar",fullName:"Yusuf Tutar",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/158492/images/system/158492.jpeg",biography:"Prof. Dr. Yusuf Tutar conducts his research at the Hamidiye Faculty of Pharmacy, Department of Basic Pharmaceutical Sciences, Division of Biochemistry, University of Health Sciences, Turkey. He is also a faculty member in the Molecular Oncology Program. He obtained his MSc and Ph.D. at Oregon State University and Texas Tech University, respectively. He pursued his postdoctoral studies at Rutgers University Medical School and the National Institutes of Health (NIH/NIDDK), USA. His research focuses on biochemistry, biophysics, genetics, molecular biology, and molecular medicine with specialization in the fields of drug design, protein structure-function, protein folding, prions, microRNA, pseudogenes, molecular cancer, epigenetics, metabolites, proteomics, genomics, protein expression, and characterization by spectroscopic and calorimetric methods.",institutionString:"University of Health Sciences",institution:null},{id:"180528",title:"Dr.",name:"Hiroyuki",middleName:null,surname:"Kagechika",slug:"hiroyuki-kagechika",fullName:"Hiroyuki Kagechika",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/180528/images/system/180528.jpg",biography:"Hiroyuki Kagechika received his bachelor’s degree and Ph.D. in Pharmaceutical Sciences from the University of Tokyo, Japan, where he served as an associate professor until 2004. He is currently a professor at the Institute of Biomaterials and Bioengineering (IBB), Tokyo Medical and Dental University (TMDU). From 2010 to 2012, he was the dean of the Graduate School of Biomedical Science. Since 2012, he has served as the vice dean of the Graduate School of Medical and Dental Sciences. He has been the director of the IBB since 2020. Dr. Kagechika’s major research interests are the medicinal chemistry of retinoids, vitamins D/K, and nuclear receptors. He has developed various compounds including a drug for acute promyelocytic leukemia.",institutionString:"Tokyo Medical and Dental University",institution:{name:"Tokyo Medical and Dental University",country:{name:"Japan"}}},{id:"94311",title:"Prof.",name:"Martins",middleName:"Ochubiojo",surname:"Ochubiojo Emeje",slug:"martins-ochubiojo-emeje",fullName:"Martins Ochubiojo Emeje",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/94311/images/system/94311.jpeg",biography:"Martins Emeje obtained a BPharm with distinction from Ahmadu Bello University, Nigeria, and an MPharm and Ph.D. from the University of Nigeria (UNN), where he received the best Ph.D. award and was enlisted as UNN’s “Face of Research.” He established the first nanomedicine center in Nigeria and was the pioneer head of the intellectual property and technology transfer as well as the technology innovation and support center. Prof. Emeje’s several international fellowships include the prestigious Raman fellowship. He has published more than 150 articles and patents. He is also the head of R&D at NIPRD and holds a visiting professor position at Nnamdi Azikiwe University, Nigeria. He has a postgraduate certificate in Project Management from Walden University, Minnesota, as well as a professional teaching certificate and a World Bank certification in Public Procurement. Prof. Emeje was a national chairman of academic pharmacists in Nigeria and the 2021 winner of the May & Baker Nigeria Plc–sponsored prize for professional service in research and innovation.",institutionString:"National Institute for Pharmaceutical Research and Development",institution:{name:"National Institute for Pharmaceutical Research and Development",country:{name:"Nigeria"}}},{id:"436430",title:"Associate Prof.",name:"Mesut",middleName:null,surname:"Işık",slug:"mesut-isik",fullName:"Mesut Işık",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/436430/images/19686_n.jpg",biography:null,institutionString:null,institution:{name:"Bilecik University",country:{name:"Turkey"}}},{id:"268659",title:"Ms.",name:"Xianquan",middleName:null,surname:"Zhan",slug:"xianquan-zhan",fullName:"Xianquan Zhan",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/268659/images/8143_n.jpg",biography:"Dr. Zhan received his undergraduate and graduate training in the fields of preventive medicine and epidemiology and statistics at the West China University of Medical Sciences in China during 1989 to 1999. He received his post-doctoral training in oncology and cancer proteomics for two years at the Cancer Research Institute of Human Medical University in China. In 2001, he went to the University of Tennessee Health Science Center (UTHSC) in USA, where he was a post-doctoral researcher and focused on mass spectrometry and cancer proteomics. Then, he was appointed as an Assistant Professor of Neurology, UTHSC in 2005. He moved to the Cleveland Clinic in USA as a Project Scientist/Staff in 2006 where he focused on the studies of eye disease proteomics and biomarkers. He returned to UTHSC as an Assistant Professor of Neurology in the end of 2007, engaging in proteomics and biomarker studies of lung diseases and brain tumors, and initiating the studies of predictive, preventive, and personalized medicine (PPPM) in cancer. In 2010, he was promoted to Associate Professor of Neurology, UTHSC. Currently, he is a Professor at Xiangya Hospital of Central South University in China, Fellow of Royal Society of Medicine (FRSM), the European EPMA National Representative in China, Regular Member of American Association for the Advancement of Science (AAAS), European Cooperation of Science and Technology (e-COST) grant evaluator, Associate Editors of BMC Genomics, BMC Medical Genomics, EPMA Journal, and Frontiers in Endocrinology, Executive Editor-in-Chief of Med One. He has\npublished 116 peer-reviewed research articles, 16 book chapters, 2 books, and 2 US patents. His current main research interest focuses on the studies of cancer proteomics and biomarkers, and the use of modern omics techniques and systems biology for PPPM in cancer, and on the development and use of 2DE-LC/MS for the large-scale study of human proteoforms.",institutionString:null,institution:{name:"Xiangya Hospital Central South University",country:{name:"China"}}},{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/40482/images/system/40482.jpeg",biography:"Dr. Rizwan Ahmad is a University Professor and Coordinator, Quality and Development, College of Medicine, Imam Abdulrahman bin Faisal University, Saudi Arabia. Previously, he was Associate Professor of Human Function, Oman Medical College, Oman, and SBS University, Dehradun. Dr. Ahmad completed his education at Aligarh Muslim University, Aligarh. He has published several articles in peer-reviewed journals, chapters, and edited books. His area of specialization is free radical biochemistry and autoimmune diseases.",institutionString:"Imam Abdulrahman Bin Faisal University",institution:{name:"Imam Abdulrahman Bin Faisal University",country:{name:"Saudi Arabia"}}},{id:"41865",title:"Prof.",name:"Farid A.",middleName:null,surname:"Badria",slug:"farid-a.-badria",fullName:"Farid A. Badria",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/41865/images/system/41865.jpg",biography:"Farid A. Badria, Ph.D., is the recipient of several awards, including The World Academy of Sciences (TWAS) Prize for Public Understanding of Science; the World Intellectual Property Organization (WIPO) Gold Medal for best invention; Outstanding Arab Scholar, Kuwait; and the Khwarizmi International Award, Iran. He has 250 publications, 12 books, 20 patents, and several marketed pharmaceutical products to his credit. He continues to lead research projects on developing new therapies for liver, skin disorders, and cancer. Dr. Badria was listed among the world’s top 2% of scientists in medicinal and biomolecular chemistry in 2019 and 2020. He is a member of the Arab Development Fund, Kuwait; International Cell Research Organization–United Nations Educational, Scientific and Cultural Organization (ICRO–UNESCO), Chile; and UNESCO Biotechnology France",institutionString:"Mansoura University",institution:{name:"Mansoura University",country:{name:"Egypt"}}},{id:"329385",title:"Dr.",name:"Rajesh K.",middleName:"Kumar",surname:"Singh",slug:"rajesh-k.-singh",fullName:"Rajesh K. Singh",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/329385/images/system/329385.png",biography:"Dr. Singh received a BPharm (2003) and MPharm (2005) from Panjab University, Chandigarh, India, and a Ph.D. (2013) from Punjab Technical University (PTU), Jalandhar, India. He has more than sixteen years of teaching experience and has supervised numerous postgraduate and Ph.D. students. He has to his credit more than seventy papers in SCI- and SCOPUS-indexed journals, fifty-five conference proceedings, four books, six Best Paper Awards, and five projects from different government agencies. He is currently an editorial board member of eight international journals and a reviewer for more than fifty scientific journals. He received Top Reviewer and Excellent Peer Reviewer Awards from Publons in 2016 and 2017, respectively. He is also on the panel of The International Reviewer for reviewing research proposals for grants from the Royal Society. He also serves as a Publons Academy mentor and Bentham brand ambassador.",institutionString:"Punjab Technical University",institution:{name:"Punjab Technical University",country:{name:"India"}}},{id:"142388",title:"Dr.",name:"Thiago",middleName:"Gomes",surname:"Gomes Heck",slug:"thiago-gomes-heck",fullName:"Thiago Gomes Heck",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/142388/images/7259_n.jpg",biography:null,institutionString:null,institution:{name:"Universidade Regional do Noroeste do Estado do Rio Grande do Sul",country:{name:"Brazil"}}},{id:"336273",title:"Assistant Prof.",name:"Janja",middleName:null,surname:"Zupan",slug:"janja-zupan",fullName:"Janja Zupan",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/336273/images/14853_n.jpeg",biography:"Janja Zupan graduated in 2005 at the Department of Clinical Biochemistry (superviser prof. dr. Janja Marc) in the field of genetics of osteoporosis. Since November 2009 she is working as a Teaching Assistant at the Faculty of Pharmacy, Department of Clinical Biochemistry. In 2011 she completed part of her research and PhD work at Institute of Genetics and Molecular Medicine, University of Edinburgh. She finished her PhD entitled The influence of the proinflammatory cytokines on the RANK/RANKL/OPG in bone tissue of osteoporotic and osteoarthritic patients in 2012. From 2014-2016 she worked at the Institute of Biomedical Sciences, University of Aberdeen as a postdoctoral research fellow on UK Arthritis research project where she gained knowledge in mesenchymal stem cells and regenerative medicine. She returned back to University of Ljubljana, Faculty of Pharmacy in 2016. She is currently leading project entitled Mesenchymal stem cells-the keepers of tissue endogenous regenerative capacity facing up to aging of the musculoskeletal system funded by Slovenian Research Agency.",institutionString:null,institution:{name:"University of Ljubljana",country:{name:"Slovenia"}}},{id:"357453",title:"Dr.",name:"Radheshyam",middleName:null,surname:"Maurya",slug:"radheshyam-maurya",fullName:"Radheshyam Maurya",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/357453/images/16535_n.jpg",biography:null,institutionString:null,institution:{name:"University of Hyderabad",country:{name:"India"}}},{id:"418340",title:"Dr.",name:"Jyotirmoi",middleName:null,surname:"Aich",slug:"jyotirmoi-aich",fullName:"Jyotirmoi Aich",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000038Ugi5QAC/Profile_Picture_2022-04-15T07:48:28.png",biography:"Biotechnologist with 15 years of research including 6 years of teaching experience. Demonstrated record of scientific achievements through consistent publication record (H index = 13, with 874 citations) in high impact journals such as Nature Communications, Oncotarget, Annals of Oncology, PNAS, and AJRCCM, etc. Strong research professional with a post-doctorate from ACTREC where I gained experimental oncology experience in clinical settings and a doctorate from IGIB where I gained expertise in asthma pathophysiology. A well-trained biotechnologist with diverse experience on the bench across different research themes ranging from asthma to cancer and other infectious diseases. An individual with a strong commitment and innovative mindset. Have the ability to work on diverse projects such as regenerative and molecular medicine with an overall mindset of improving healthcare.",institutionString:"DY Patil Deemed to Be University",institution:null},{id:"349288",title:"Prof.",name:"Soumya",middleName:null,surname:"Basu",slug:"soumya-basu",fullName:"Soumya Basu",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000035QxIDQA0/Profile_Picture_2022-04-15T07:47:01.jpg",biography:"Soumya Basu, Ph.D., is currently working as an Associate Professor at Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pune, Maharashtra, India. With 16+ years of trans-disciplinary research experience in Drug Design, development, and pre-clinical validation; 20+ research article publications in journals of repute, 9+ years of teaching experience, trained with cross-disciplinary education, Dr. Basu is a life-long learner and always thrives for new challenges.\r\nHer research area is the design and synthesis of small molecule partial agonists of PPAR-γ in lung cancer. She is also using artificial intelligence and deep learning methods to understand the exosomal miRNA’s role in cancer metastasis. Dr. Basu is the recipient of many awards including the Early Career Research Award from the Department of Science and Technology, Govt. of India. She is a reviewer of many journals like Molecular Biology Reports, Frontiers in Oncology, RSC Advances, PLOS ONE, Journal of Biomolecular Structure & Dynamics, Journal of Molecular Graphics and Modelling, etc. She has edited and authored/co-authored 21 journal papers, 3 book chapters, and 15 abstracts. She is a Board of Studies member at her university. She is a life member of 'The Cytometry Society”-in India and 'All India Cell Biology Society”- in India.",institutionString:"Dr. D.Y. Patil Vidyapeeth, Pune",institution:{name:"Dr. D.Y. Patil Vidyapeeth, Pune",country:{name:"India"}}},{id:"354817",title:"Dr.",name:"Anubhab",middleName:null,surname:"Mukherjee",slug:"anubhab-mukherjee",fullName:"Anubhab Mukherjee",position:null,profilePictureURL:"https://intech-files.s3.amazonaws.com/0033Y0000365PbRQAU/ProfilePicture%202022-04-15%2005%3A11%3A18.480",biography:"A former member of Laboratory of Nanomedicine, Brigham and Women’s Hospital, Harvard University, Boston, USA, Dr. Anubhab Mukherjee is an ardent votary of science who strives to make an impact in the lives of those afflicted with cancer and other chronic/acute ailments. He completed his Ph.D. from CSIR-Indian Institute of Chemical Technology, Hyderabad, India, having been skilled with RNAi, liposomal drug delivery, preclinical cell and animal studies. He pursued post-doctoral research at College of Pharmacy, Health Science Center, Texas A & M University and was involved in another postdoctoral research at Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, Santa Monica, California. In 2015, he worked in Harvard-MIT Health Sciences & Technology as a visiting scientist. He has substantial experience in nanotechnology-based formulation development and successfully served various Indian organizations to develop pharmaceuticals and nutraceutical products. He is an inventor in many US patents and an author in many peer-reviewed articles, book chapters and books published in various media of international repute. Dr. Mukherjee is currently serving as Principal Scientist, R&D at Esperer Onco Nutrition (EON) Pvt. Ltd. and heads the Hyderabad R&D center of the organization.",institutionString:"Esperer Onco Nutrition Pvt Ltd.",institution:null},{id:"319365",title:"Assistant Prof.",name:"Manash K.",middleName:null,surname:"Paul",slug:"manash-k.-paul",fullName:"Manash K. Paul",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/319365/images/system/319365.png",biography:"Manash K. Paul is a Principal Investigator and Scientist at the University of California Los Angeles. He has contributed significantly to the fields of stem cell biology, regenerative medicine, and lung cancer. His research focuses on various signaling processes involved in maintaining stem cell homeostasis during the injury-repair process, deciphering lung stem cell niche, pulmonary disease modeling, immuno-oncology, and drug discovery. He is currently investigating the role of extracellular vesicles in premalignant lung cell migration and detecting the metastatic phenotype of lung cancer via machine-learning-based analyses of exosomal signatures. Dr. Paul has published in more than fifty peer-reviewed international journals and is highly cited. He is the recipient of many awards, including the UCLA Vice Chancellor’s award, a senior member of the Institute of Electrical and Electronics Engineers (IEEE), and an editorial board member for several international journals.",institutionString:"University of California Los Angeles",institution:{name:"University of California Los Angeles",country:{name:"United States of America"}}},{id:"311457",title:"Dr.",name:"Júlia",middleName:null,surname:"Scherer Santos",slug:"julia-scherer-santos",fullName:"Júlia Scherer Santos",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/311457/images/system/311457.jpg",biography:"Dr. Júlia Scherer Santos works in the areas of cosmetology, nanotechnology, pharmaceutical technology, beauty, and aesthetics. Dr. Santos also has experience as a professor of graduate courses. Graduated in Pharmacy, specialization in Cosmetology and Cosmeceuticals applied to aesthetics, specialization in Aesthetic and Cosmetic Health, and a doctorate in Pharmaceutical Nanotechnology. Teaching experience in Pharmacy and Aesthetics and Cosmetics courses. She works mainly on the following subjects: nanotechnology, cosmetology, pharmaceutical technology, aesthetics.",institutionString:"Universidade Federal de Juiz de Fora",institution:{name:"Universidade Federal de Juiz de Fora",country:{name:"Brazil"}}},{id:"219081",title:"Dr.",name:"Abdulsamed",middleName:null,surname:"Kükürt",slug:"abdulsamed-kukurt",fullName:"Abdulsamed Kükürt",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/219081/images/system/219081.png",biography:"Dr. Kükürt graduated from Uludağ University in Turkey. He started his academic career as a Research Assistant in the Department of Biochemistry at Kafkas University. In 2019, he completed his Ph.D. program in the Department of Biochemistry at the Institute of Health Sciences. He is currently working at the Department of Biochemistry, Kafkas University. He has 27 published research articles in academic journals, 11 book chapters, and 37 papers. He took part in 10 academic projects. He served as a reviewer for many articles. He still serves as a member of the review board in many academic journals. He is currently working on the protective activity of phenolic compounds in disorders associated with oxidative stress and inflammation.",institutionString:null,institution:{name:"Kafkas University",country:{name:"Turkey"}}},{id:"178366",title:"Dr.",name:"Volkan",middleName:null,surname:"Gelen",slug:"volkan-gelen",fullName:"Volkan Gelen",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/178366/images/system/178366.jpg",biography:"Volkan Gelen is a Physiology specialist who received his veterinary degree from Kafkas University in 2011. Between 2011-2015, he worked as an assistant at Atatürk University, Faculty of Veterinary Medicine, Department of Physiology. In 2016, he joined Kafkas University, Faculty of Veterinary Medicine, Department of Physiology as an assistant professor. Dr. Gelen has been engaged in various academic activities at Kafkas University since 2016. There he completed 5 projects and has 3 ongoing projects. He has 60 articles published in scientific journals and 20 poster presentations in scientific congresses. His research interests include physiology, endocrine system, cancer, diabetes, cardiovascular system diseases, and isolated organ bath system studies.",institutionString:"Kafkas University",institution:{name:"Kafkas University",country:{name:"Turkey"}}},{id:"418963",title:"Dr.",name:"Augustine Ododo",middleName:"Augustine",surname:"Osagie",slug:"augustine-ododo-osagie",fullName:"Augustine Ododo Osagie",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/418963/images/16900_n.jpg",biography:"Born into the family of Osagie, a prince of the Benin Kingdom. I am currently an academic in the Department of Medical Biochemistry, University of Benin. Part of the duties are to teach undergraduate students and conduct academic research.",institutionString:null,institution:{name:"University of Benin",country:{name:"Nigeria"}}},{id:"192992",title:"Prof.",name:"Shagufta",middleName:null,surname:"Perveen",slug:"shagufta-perveen",fullName:"Shagufta Perveen",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/192992/images/system/192992.png",biography:"Prof. Shagufta Perveen is a Distinguish Professor in the Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. Dr. Perveen has acted as the principal investigator of major research projects funded by the research unit of King Saud University. She has more than ninety original research papers in peer-reviewed journals of international repute to her credit. She is a fellow member of the Royal Society of Chemistry UK and the American Chemical Society of the United States.",institutionString:"King Saud University",institution:{name:"King Saud University",country:{name:"Saudi Arabia"}}},{id:"49848",title:"Dr.",name:"Wen-Long",middleName:null,surname:"Hu",slug:"wen-long-hu",fullName:"Wen-Long Hu",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/49848/images/system/49848.jpg",biography:"Wen-Long Hu is Chief of the Division of Acupuncture, Department of Chinese Medicine at Kaohsiung Chang Gung Memorial Hospital, as well as an adjunct associate professor at Fooyin University and Kaohsiung Medical University. Wen-Long is President of Taiwan Traditional Chinese Medicine Medical Association. He has 28 years of experience in clinical practice in laser acupuncture therapy and 34 years in acupuncture. He is an invited speaker for lectures and workshops in laser acupuncture at many symposiums held by medical associations. He owns the patent for herbal preparation and producing, and for the supercritical fluid-treated needle. Dr. Hu has published three books, 12 book chapters, and more than 30 papers in reputed journals, besides serving as an editorial board member of repute.",institutionString:"Kaohsiung Chang Gung Memorial Hospital",institution:{name:"Kaohsiung Chang Gung Memorial Hospital",country:{name:"Taiwan"}}},{id:"298472",title:"Prof.",name:"Andrey V.",middleName:null,surname:"Grechko",slug:"andrey-v.-grechko",fullName:"Andrey V. Grechko",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/298472/images/system/298472.png",biography:"Andrey Vyacheslavovich Grechko, Ph.D., Professor, is a Corresponding Member of the Russian Academy of Sciences. He graduated from the Semashko Moscow Medical Institute (Semashko National Research Institute of Public Health) with a degree in Medicine (1998), the Clinical Department of Dermatovenerology (2000), and received a second higher education in Psychology (2009). Professor A.V. Grechko held the position of Сhief Physician of the Central Clinical Hospital in Moscow. He worked as a professor at the faculty and was engaged in scientific research at the Medical University. Starting in 2013, he has been the initiator of the creation of the Federal Scientific and Clinical Center for Intensive Care and Rehabilitology, Moscow, Russian Federation, where he also serves as Director since 2015. He has many years of experience in research and teaching in various fields of medicine, is an author/co-author of more than 200 scientific publications, 13 patents, 15 medical books/chapters, including Chapter in Book «Metabolomics», IntechOpen, 2020 «Metabolomic Discovery of Microbiota Dysfunction as the Cause of Pathology».",institutionString:"Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology",institution:null},{id:"199461",title:"Prof.",name:"Natalia V.",middleName:null,surname:"Beloborodova",slug:"natalia-v.-beloborodova",fullName:"Natalia V. Beloborodova",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/199461/images/system/199461.jpg",biography:'Natalia Vladimirovna Beloborodova was educated at the Pirogov Russian National Research Medical University, with a degree in pediatrics in 1980, a Ph.D. in 1987, and a specialization in Clinical Microbiology from First Moscow State Medical University in 2004. She has been a Professor since 1996. Currently, she is the Head of the Laboratory of Metabolism, a division of the Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russian Federation. N.V. Beloborodova has many years of clinical experience in the field of intensive care and surgery. She studies infectious complications and sepsis. She initiated a series of interdisciplinary clinical and experimental studies based on the concept of integrating human metabolism and its microbiota. Her scientific achievements are widely known: she is the recipient of the Marie E. Coates Award \\"Best lecturer-scientist\\" Gustafsson Fund, Karolinska Institutes, Stockholm, Sweden, and the International Sepsis Forum Award, Pasteur Institute, Paris, France (2014), etc. Professor N.V. Beloborodova wrote 210 papers, five books, 10 chapters and has edited four books.',institutionString:"Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology",institution:null},{id:"354260",title:"Ph.D.",name:"Tércio Elyan",middleName:"Azevedo",surname:"Azevedo Martins",slug:"tercio-elyan-azevedo-martins",fullName:"Tércio Elyan Azevedo Martins",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/354260/images/16241_n.jpg",biography:"Graduated in Pharmacy from the Federal University of Ceará with the modality in Industrial Pharmacy, Specialist in Production and Control of Medicines from the University of São Paulo (USP), Master in Pharmaceuticals and Medicines from the University of São Paulo (USP) and Doctor of Science in the program of Pharmaceuticals and Medicines by the University of São Paulo. Professor at Universidade Paulista (UNIP) in the areas of chemistry, cosmetology and trichology. Assistant Coordinator of the Higher Course in Aesthetic and Cosmetic Technology at Universidade Paulista Campus Chácara Santo Antônio. Experience in the Pharmacy area, with emphasis on Pharmacotechnics, Pharmaceutical Technology, Research and Development of Cosmetics, acting mainly on topics such as cosmetology, antioxidant activity, aesthetics, photoprotection, cyclodextrin and thermal analysis.",institutionString:null,institution:{name:"University of Sao Paulo",country:{name:"Brazil"}}},{id:"334285",title:"Ph.D. Student",name:"Sameer",middleName:"Kumar",surname:"Jagirdar",slug:"sameer-jagirdar",fullName:"Sameer Jagirdar",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/334285/images/14691_n.jpg",biography:"I\\'m a graduate student at the center for biosystems science and engineering at the Indian Institute of Science, Bangalore, India. I am interested in studying host-pathogen interactions at the biomaterial interface.",institutionString:null,institution:{name:"Indian Institute of Science Bangalore",country:{name:"India"}}},{id:"329248",title:"Dr.",name:"Md. Faheem",middleName:null,surname:"Haider",slug:"md.-faheem-haider",fullName:"Md. Faheem Haider",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/329248/images/system/329248.jpg",biography:"Dr. Md. Faheem Haider completed his BPharm in 2012 at Integral University, Lucknow, India. In 2014, he completed his MPharm with specialization in Pharmaceutics at Babasaheb Bhimrao Ambedkar University, Lucknow, India. He received his Ph.D. degree from Jamia Hamdard University, New Delhi, India, in 2018. He was selected for the GPAT six times and his best All India Rank was 34. Currently, he is an assistant professor at Integral University. Previously he was an assistant professor at IIMT University, Meerut, India. He has experience teaching DPharm, Pharm.D, BPharm, and MPharm students. He has more than five publications in reputed journals to his credit. Dr. Faheem’s research area is the development and characterization of nanoformulation for the delivery of drugs to various organs.",institutionString:"Integral University",institution:{name:"Integral University",country:{name:"India"}}},{id:"329795",title:"Dr.",name:"Mohd Aftab",middleName:"Aftab",surname:"Siddiqui",slug:"mohd-aftab-siddiqui",fullName:"Mohd Aftab Siddiqui",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/329795/images/system/329795.png",biography:"Dr. Mohd Aftab Siddiqui is an assistant professor in the Faculty of Pharmacy, Integral University, Lucknow, India, where he obtained a Ph.D. in Pharmacology in 2020. He also obtained a BPharm and MPharm from the same university in 2013 and 2015, respectively. His area of research is the pharmacological screening of herbal drugs/natural products in liver cancer and cardiac diseases. He is a member of many professional bodies and has guided many MPharm and PharmD research projects. Dr. Siddiqui has many national and international publications and one German patent to his credit.",institutionString:"Integral University",institution:null}]}},subseries:{item:{id:"10",type:"subseries",title:"Animal Physiology",keywords:"Physiology, Comparative, Evolution, Biomolecules, Organ, Homeostasis, Anatomy, Pathology, Medical, Cell Division, Cell Signaling, Cell Growth, Cell Metabolism, Endocrine, Neuroscience, Cardiovascular, Development, Aging, Development",scope:"Physiology, the scientific study of functions and mechanisms of living systems, is an essential area of research in its own right, but also in relation to medicine and health sciences. The scope of this topic will range from molecular, biochemical, cellular, and physiological processes in all animal species. Work pertaining to the whole organism, organ systems, individual organs and tissues, cells, and biomolecules will be included. Medical, animal, cell, and comparative physiology and allied fields such as anatomy, histology, and pathology with physiology links will be covered in this topic. Physiology research may be linked to development, aging, environment, regular and pathological processes, adaptation and evolution, exercise, or several other factors affecting, or involved with, animal physiology.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/10.jpg",hasOnlineFirst:!1,hasPublishedBooks:!1,annualVolume:11406,editor:{id:"202192",title:"Dr.",name:"Catrin",middleName:null,surname:"Rutland",slug:"catrin-rutland",fullName:"Catrin Rutland",profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",biography:"Catrin Rutland is an Associate Professor of Anatomy and Developmental Genetics at the University of Nottingham, UK. She obtained a BSc from the University of Derby, England, a master’s degree from Technische Universität München, Germany, and a Ph.D. from the University of Nottingham. She undertook a post-doctoral research fellowship in the School of Medicine before accepting tenure in Veterinary Medicine and Science. Dr. Rutland also obtained an MMedSci (Medical Education) and a Postgraduate Certificate in Higher Education (PGCHE). She is the author of more than sixty peer-reviewed journal articles, twelve books/book chapters, and more than 100 research abstracts in cardiovascular biology and oncology. She is a board member of the European Association of Veterinary Anatomists, Fellow of the Anatomical Society, and Senior Fellow of the Higher Education Academy. Dr. Rutland has also written popular science books for the public. https://orcid.org/0000-0002-2009-4898. www.nottingham.ac.uk/vet/people/catrin.rutland",institutionString:null,institution:{name:"University of Nottingham",institutionURL:null,country:{name:"United Kingdom"}}},editorTwo:null,editorThree:null,series:{id:"10",title:"Physiology",doi:"10.5772/intechopen.72796",issn:"2631-8261"},editorialBoard:[{id:"306970",title:"Mr.",name:"Amin",middleName:null,surname:"Tamadon",slug:"amin-tamadon",fullName:"Amin Tamadon",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002oHR5wQAG/Profile_Picture_1623910304139",institutionString:null,institution:{name:"Bushehr University of Medical Sciences",institutionURL:null,country:{name:"Iran"}}},{id:"251314",title:"Dr.",name:"Juan Carlos",middleName:null,surname:"Gardón Poggi",slug:"juan-carlos-gardon-poggi",fullName:"Juan Carlos Gardón Poggi",profilePictureURL:"https://mts.intechopen.com/storage/users/251314/images/system/251314.jpeg",institutionString:null,institution:{name:"Valencia Catholic University Saint Vincent Martyr",institutionURL:null,country:{name:"Spain"}}},{id:"245306",title:"Dr.",name:"María Luz",middleName:null,surname:"Garcia Pardo",slug:"maria-luz-garcia-pardo",fullName:"María Luz Garcia Pardo",profilePictureURL:"https://mts.intechopen.com/storage/users/245306/images/system/245306.png",institutionString:null,institution:{name:"Miguel Hernandez University",institutionURL:null,country:{name:"Spain"}}},{id:"283315",title:"Prof.",name:"Samir",middleName:null,surname:"El-Gendy",slug:"samir-el-gendy",fullName:"Samir El-Gendy",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRduYQAS/Profile_Picture_1606215849748",institutionString:null,institution:{name:"Alexandria University",institutionURL:null,country:{name:"Egypt"}}},{id:"178366",title:"Dr.",name:"Volkan",middleName:null,surname:"Gelen",slug:"volkan-gelen",fullName:"Volkan Gelen",profilePictureURL:"https://mts.intechopen.com/storage/users/178366/images/system/178366.jpg",institutionString:"Kafkas University",institution:{name:"Kafkas University",institutionURL:null,country:{name:"Turkey"}}}]},onlineFirstChapters:{paginationCount:26,paginationItems:[{id:"83087",title:"Role of Cellular Responses in Periodontal Tissue Destruction",doi:"10.5772/intechopen.106645",signatures:"Nam Cong-Nhat Huynh",slug:"role-of-cellular-responses-in-periodontal-tissue-destruction",totalDownloads:1,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Periodontology - New Insights",coverURL:"https://cdn.intechopen.com/books/images_new/11566.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"82654",title:"Atraumatic Restorative Treatment: More than a Minimally Invasive Approach?",doi:"10.5772/intechopen.105623",signatures:"Manal A. Ablal",slug:"atraumatic-restorative-treatment-more-than-a-minimally-invasive-approach",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Dental Caries - The Selection of Restoration Methods and Restorative Materials",coverURL:"https://cdn.intechopen.com/books/images_new/11565.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"82735",title:"The Influence of Salivary pH on the Prevalence of Dental Caries",doi:"10.5772/intechopen.106154",signatures:"Laura-Cristina Rusu, Alexandra Roi, Ciprian-Ioan Roi, Codruta Victoria Tigmeanu and Lavinia Cosmina Ardelean",slug:"the-influence-of-salivary-ph-on-the-prevalence-of-dental-caries",totalDownloads:12,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Dental Caries - The Selection of Restoration Methods and Restorative Materials",coverURL:"https://cdn.intechopen.com/books/images_new/11565.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"82357",title:"Caries Management Aided by Fluorescence-Based Devices",doi:"10.5772/intechopen.105567",signatures:"Atena Galuscan, Daniela Jumanca and Aurora Doris Fratila",slug:"caries-management-aided-by-fluorescence-based-devices",totalDownloads:6,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Dental Caries - The Selection of Restoration Methods and Restorative Materials",coverURL:"https://cdn.intechopen.com/books/images_new/11565.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"81894",title:"Diet and Nutrition and Their Relationship with Early Childhood Dental Caries",doi:"10.5772/intechopen.105123",signatures:"Luanna Gonçalves Ferreira, Giuliana de Campos Chaves Lamarque and Francisco Wanderley Garcia Paula-Silva",slug:"diet-and-nutrition-and-their-relationship-with-early-childhood-dental-caries",totalDownloads:20,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Dental Caries - The Selection of Restoration Methods and Restorative Materials",coverURL:"https://cdn.intechopen.com/books/images_new/11565.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"80964",title:"Upper Airway Expansion in Disabled Children",doi:"10.5772/intechopen.102830",signatures:"David Andrade, Joana Andrade, Maria-João Palha, Cristina Areias, Paula Macedo, Ana Norton, Miguel Palha, Lurdes Morais, Dóris Rocha Ruiz and Sônia Groisman",slug:"upper-airway-expansion-in-disabled-children",totalDownloads:44,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Oral Health Care - An Important Issue of the Modern Society",coverURL:"https://cdn.intechopen.com/books/images_new/10827.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"80839",title:"Herbs and Oral Health",doi:"10.5772/intechopen.103715",signatures:"Zuhair S. Natto",slug:"herbs-and-oral-health",totalDownloads:70,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Oral Health Care - An Important Issue of the Modern Society",coverURL:"https://cdn.intechopen.com/books/images_new/10827.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"80441",title:"Periodontitis and Heart Disease: Current Perspectives on the Associative Relationships and Preventive Impact",doi:"10.5772/intechopen.102669",signatures:"Alexandra Roman, Andrada Soancă, Bogdan Caloian, Alexandru Bucur, Gabriela Valentina Caracostea, Andreia Paraschiva Preda, Dora Maria Popescu, Iulia Cristina Micu, Petra Șurlin, Andreea Ciurea, Diana Oneț, Mircea Viorel Ciurea, Dragoș Alexandru Țermure and Marius Negucioiu",slug:"periodontitis-and-heart-disease-current-perspectives-on-the-associative-relationships-and-preventive",totalDownloads:66,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Oral Health Care - An Important Issue of the Modern Society",coverURL:"https://cdn.intechopen.com/books/images_new/10827.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"79498",title:"Oral Aspects and Dental Management of Special Needs Patient",doi:"10.5772/intechopen.101067",signatures:"Pinar Kiymet Karataban",slug:"oral-aspects-and-dental-management-of-special-needs-patient",totalDownloads:114,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Pinar",surname:"Karataban"}],book:{title:"Oral Health Care - An Important Issue of the Modern Society",coverURL:"https://cdn.intechopen.com/books/images_new/10827.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"79699",title:"Metabolomics Distinction of Cigarette Smokers from Non-Smokers Using Non-Stationary Benchtop Nuclear Magnetic Resonance (NMR) Analysis of Human Saliva",doi:"10.5772/intechopen.101414",signatures:"Benita C. Percival, Angela Wann, Sophie Taylor, Mark Edgar, Miles Gibson and Martin Grootveld",slug:"metabolomics-distinction-of-cigarette-smokers-from-non-smokers-using-non-stationary-benchtop-nuclear",totalDownloads:56,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Oral Health Care - An Important Issue of the Modern Society",coverURL:"https://cdn.intechopen.com/books/images_new/10827.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"80295",title:"Preventive Methods and Treatments of White Spot Lesions in Orthodontics",doi:"10.5772/intechopen.102064",signatures:"Elif Nadide Akay",slug:"preventive-methods-and-treatments-of-white-spot-lesions-in-orthodontics",totalDownloads:89,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Oral Health Care - An Important Issue of the Modern Society",coverURL:"https://cdn.intechopen.com/books/images_new/10827.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"79876",title:"Management and Prevention Strategies for Treating Dentine Hypersensitivity",doi:"10.5772/intechopen.101495",signatures:"David G. Gillam",slug:"management-and-prevention-strategies-for-treating-dentine-hypersensitivity",totalDownloads:94,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Oral Health Care - An Important Issue of the Modern Society",coverURL:"https://cdn.intechopen.com/books/images_new/10827.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"80020",title:"Alternative Denture Base Materials for Allergic Patients",doi:"10.5772/intechopen.101956",signatures:"Lavinia Cosmina Ardelean, Laura-Cristina Rusu and Codruta Victoria Tigmeanu",slug:"alternative-denture-base-materials-for-allergic-patients",totalDownloads:198,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Oral Health Care - An Important Issue of the Modern Society",coverURL:"https://cdn.intechopen.com/books/images_new/10827.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"79297",title:"Oral Health and Prevention in Older Adults",doi:"10.5772/intechopen.101043",signatures:"Irma Fabiola Díaz-García, Dinorah Munira Hernández-Santos, Julio Alberto Díaz-Ramos and Neyda Ma. Mendoza-Ruvalcaba",slug:"oral-health-and-prevention-in-older-adults",totalDownloads:113,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Oral Health Care - An Important Issue of the Modern Society",coverURL:"https://cdn.intechopen.com/books/images_new/10827.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"79903",title:"Molecular Docking of Phytochemicals against Streptococcus mutans Virulence Targets: A Proteomic Insight into Drug Planning",doi:"10.5772/intechopen.101506",signatures:"Diego Romário da Silva, Tahyná Duda Deps, Otavio Akira Souza Sakaguchi, Edja Maria Melo de Brito Costa, Carlus Alberto Oliveira dos Santos, Joanilda Paolla Raimundo e Silva, Bruna Dantas da Silva, Frederico Favaro Ribeiro, Francisco Jaime Bezerra Mendonça-Júnior and Andréa Cristina Barbosa da Silva",slug:"molecular-docking-of-phytochemicals-against-em-streptococcus-mutans-em-virulence-targets-a-proteomic",totalDownloads:114,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Oral Health Care - An Important Issue of the Modern Society",coverURL:"https://cdn.intechopen.com/books/images_new/10827.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"79754",title:"Evaluation of Trans-Resveratrol as a Treatment for Periodontitis",doi:"10.5772/intechopen.101477",signatures:"Tracey Lynn Harney",slug:"evaluation-of-trans-resveratrol-as-a-treatment-for-periodontitis",totalDownloads:112,totalCrossrefCites:1,totalDimensionsCites:1,authors:null,book:{title:"Oral Health Care - An Important Issue of the Modern Society",coverURL:"https://cdn.intechopen.com/books/images_new/10827.jpg",subseries:{id:"1",title:"Oral Health"}}}]},publishedBooks:{paginationCount:4,paginationItems:[{type:"book",id:"9528",title:"Current Topics and Emerging Issues in Malaria Elimination",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9528.jpg",slug:"current-topics-and-emerging-issues-in-malaria-elimination",publishedDate:"July 21st 2021",editedByType:"Edited by",bookSignature:"Alfonso J. Rodriguez-Morales",hash:"7f178329cc42e691efe226b32f14e2ea",volumeInSeries:8,fullTitle:"Current Topics and Emerging Issues in Malaria Elimination",editors:[{id:"131400",title:"Prof.",name:"Alfonso J.",middleName:null,surname:"Rodriguez-Morales",slug:"alfonso-j.-rodriguez-morales",fullName:"Alfonso J. Rodriguez-Morales",profilePictureURL:"https://mts.intechopen.com/storage/users/131400/images/system/131400.png",institutionString:"Institución Universitaria Visión de las Américas, Colombia",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7981",title:"Overview on Echinococcosis",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7981.jpg",slug:"overview-on-echinococcosis",publishedDate:"April 22nd 2020",editedByType:"Edited by",bookSignature:"Fethi Derbel and Meriem Braiki",hash:"24dee9209f3fd6b7cd28f042da0076f0",volumeInSeries:6,fullTitle:"Overview on Echinococcosis",editors:[{id:"62900",title:"Prof.",name:"Fethi",middleName:null,surname:"Derbel",slug:"fethi-derbel",fullName:"Fethi Derbel",profilePictureURL:"https://mts.intechopen.com/storage/users/62900/images/system/62900.jpeg",institutionString:"Clinique les Oliviers",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7839",title:"Malaria",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7839.jpg",slug:"malaria",publishedDate:"December 11th 2019",editedByType:"Edited by",bookSignature:"Fyson H. Kasenga",hash:"91cde4582ead884cb0f355a19b67cd56",volumeInSeries:4,fullTitle:"Malaria",editors:[{id:"86725",title:"Dr.",name:"Fyson",middleName:"Hanania",surname:"Kasenga",slug:"fyson-kasenga",fullName:"Fyson Kasenga",profilePictureURL:"https://mts.intechopen.com/storage/users/86725/images/system/86725.jpg",institutionString:"Malawi Adventist University",institution:{name:"Malawi Adventist University",institutionURL:null,country:{name:"Malawi"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7123",title:"Current Topics in Neglected Tropical Diseases",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7123.jpg",slug:"current-topics-in-neglected-tropical-diseases",publishedDate:"December 4th 2019",editedByType:"Edited by",bookSignature:"Alfonso J. Rodriguez-Morales",hash:"61c627da05b2ace83056d11357bdf361",volumeInSeries:3,fullTitle:"Current Topics in Neglected Tropical Diseases",editors:[{id:"131400",title:"Prof.",name:"Alfonso J.",middleName:null,surname:"Rodriguez-Morales",slug:"alfonso-j.-rodriguez-morales",fullName:"Alfonso J. Rodriguez-Morales",profilePictureURL:"https://mts.intechopen.com/storage/users/131400/images/system/131400.png",institutionString:"Institución Universitaria Visión de las Américas, Colombia",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},testimonialsList:[{id:"8",text:"I work with IntechOpen for a number of reasons: their professionalism, their mission in support of Open Access publishing, and the quality of their peer-reviewed publications, but also because they believe in equality.",author:{id:"202192",name:"Catrin",surname:"Rutland",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",slug:"catrin-rutland",institution:{id:"134",name:"University of Nottingham",country:{id:null,name:"United Kingdom"}}}},{id:"18",text:"It was great publishing with IntechOpen, the process was straightforward and I had support all along.",author:{id:"71579",name:"Berend",surname:"Olivier",institutionString:"Utrecht University",profilePictureURL:"https://mts.intechopen.com/storage/users/71579/images/system/71579.png",slug:"berend-olivier",institution:{id:"253",name:"Utrecht University",country:{id:null,name:"Netherlands"}}}},{id:"27",text:"The opportunity to work with a prestigious publisher allows for the possibility to collaborate with more research groups interested in animal nutrition, leading to the development of new feeding strategies and food valuation while being more sustainable with the environment, allowing more readers to learn about the subject.",author:{id:"175967",name:"Manuel",surname:"Gonzalez Ronquillo",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/175967/images/system/175967.png",slug:"manuel-gonzalez-ronquillo",institution:{id:"6221",name:"Universidad Autónoma del Estado de México",country:{id:null,name:"Mexico"}}}}]},submityourwork:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:90,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:108,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:33,numberOfPublishedChapters:330,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:14,numberOfPublishedChapters:145,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:9,numberOfPublishedChapters:141,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!0},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:124,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:11,numberOfPublishedChapters:112,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:22,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2753-894X",doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:11,numberOfOpenTopics:1,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!0},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:5,numberOfUpcomingTopics:0,issn:"2753-6580",doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],subseriesList:[],annualVolumeBook:{},thematicCollection:[],selectedSeries:null,selectedSubseries:null},seriesLanding:{item:null},libraryRecommendation:{success:null,errors:{},institutions:[]},route:{name:"chapter.detail",path:"/chapters/75427",hash:"",query:{},params:{id:"75427"},fullPath:"/chapters/75427",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()